QUARTERLY REPORT
Q1 2022 — Form 10-Q
Q1 2022PDF · 139 pages1.6 MB
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2022
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number 001-33708
Philip Morris International Inc.
(Exact name of registrant as specified in its charter)
Virginia 13-3435103
(State or other jurisdiction of
incorporation or organization) (I.R.S. Employer
Identification No.)
120 Park Avenue New York New York 10017
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code (917) 663-2000
Former name, former address and former fiscal year, if changed since last report
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, no par value PM New York Stock Exchange
2.375% Notes due 2022 PM22B New York Stock Exchange
2.500% Notes due 2022 PM22 New York Stock Exchange
2.500% Notes due 2022 PM22C New York Stock Exchange
2.625% Notes due 2023 PM23 New York Stock Exchange
2.125% Notes due 2023 PM23B New York Stock Exchange
3.600% Notes due 2023 PM23A New York Stock Exchange
2.875% Notes due 2024 PM24 New York Stock Exchange
2.875% Notes due 2024 PM24C New York Stock Exchange
0.625% Notes due 2024 PM24B New York Stock Exchange
3.250% Notes due 2024 PM24A New York Stock Exchange
2.750% Notes due 2025 PM25 New York Stock Exchange
3.375% Notes due 2025 PM25A New York Stock Exchange
2.750% Notes due 2026 PM26A New York Stock Exchange
-- 1 of 139 --
Title of each class Trading Symbol(s) Name of each exchange on which registered
2.875% Notes due 2026 PM26 New York Stock Exchange
0.125% Notes due 2026 PM26B New York Stock Exchange
3.125% Notes due 2027 PM27 New York Stock Exchange
3.125% Notes due 2028 PM28 New York Stock Exchange
2.875% Notes due 2029 PM29 New York Stock Exchange
3.375% Notes due 2029 PM29A New York Stock Exchange
0.800% Notes due 2031 PM31 New York Stock Exchange
3.125% Notes due 2033 PM33 New York Stock Exchange
2.000% Notes due 2036 PM36 New York Stock Exchange
1.875% Notes due 2037 PM37A New York Stock Exchange
6.375% Notes due 2038 PM38 New York Stock Exchange
1.450% Notes due 2039 PM39 New York Stock Exchange
4.375% Notes due 2041 PM41 New York Stock Exchange
4.500% Notes due 2042 PM42 New York Stock Exchange
3.875% Notes due 2042 PM42A New York Stock Exchange
4.125% Notes due 2043 PM43 New York Stock Exchange
4.875% Notes due 2043 PM43A New York Stock Exchange
4.250% Notes due 2044 PM44 New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes ☑ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405
of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such
files). Yes ☑ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or
an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth
company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☑ Accelerated filer ☐
Non-accelerated filer ☐ Smaller reporting company ☐
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑
At April 22, 2022, there were 1,550,110,316 shares outstanding of the registrant’s common stock, no par value per share.
1
-- 2 of 139 --
Table of Contents
PHILIP MORRIS INTERNATIONAL INC.
TABLE OF CONTENTS
Page No.
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements (Unaudited)
Condensed Consolidated Statements of Earnings for the
Three Months Ended March 31, 2022 and 2021 3
Condensed Consolidated Statements of Comprehensive Earnings for the
Three Months Ended March 31, 2022 and 2021 4
Condensed Consolidated Balance Sheets at
March 31, 2022 and December 31, 2021 5 – 6
Condensed Consolidated Statements of Cash Flows for the
Three Months Ended March 31, 2022 and 2021 7 – 8
Condensed Consolidated Statements of Stockholders’ (Deficit) Equity for the
Three Months Ended March 31, 2022 and 2021 9
Notes to Condensed Consolidated Financial Statements 10 – 43
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 44 – 92
Item 4. Controls and Procedures 93
PART II - OTHER INFORMATION
Item 1. Legal Proceedings 94
Item 1A. Risk Factors 94
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 95
Item 6. Exhibits 96
Signature 97
In this report, “PMI,” “we,” “us” and “our” refer to Philip Morris International Inc. and its subsidiaries.
Trademarks and service marks in this report are the registered property of, or licensed by, the subsidiaries of Philip Morris International Inc. and are
italicized.
2
-- 3 of 139 --
Table of Contents
PART I – FINANCIAL INFORMATION
Item 1. Financial Statements.
Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Statements of Earnings
(in millions of dollars, except per share data)
(Unaudited)
For the Three Months Ended March
31,
2022 2021
Revenues including excise taxes $ 19,341 $ 19,355
Excise taxes on products 11,595 11,770
Net revenues 7,746 7,585
Cost of sales (Note 18) 2,608 2,274
Gross profit 5,138 5,311
Marketing, administration and research costs (Notes 16 & 18) 1,802 1,849
Amortization of intangibles 38 18
Operating income 3,298 3,444
Interest expense, net 154 167
Pension and other employee benefit costs (Note 3) 4 28
Earnings before income taxes 3,140 3,249
Provision for income taxes 619 697
Equity investments and securities (income)/loss, net 56 (43)
Net earnings 2,465 2,595
Net earnings attributable to noncontrolling interests 134 177
Net earnings attributable to PMI $ 2,331 $ 2,418
Per share data (Note 6):
Basic earnings per share $ 1.50 $ 1.55
Diluted earnings per share $ 1.50 $ 1.55
See notes to condensed consolidated financial statements.
3
-- 4 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Statements of Comprehensive Earnings
(in millions of dollars)
(Unaudited)
For the Three Months Ended March 31,
2022 2021
Net earnings $ 2,465 $ 2,595
Other comprehensive earnings (losses), net of income taxes:
Change in currency translation adjustments:
Unrealized gains (losses), net of income taxes of $(31) in 2022 and $(85) in 2021 (194) 223
Change in net loss and prior service cost:
Amortization of net losses, prior service costs and net transition costs, net of income taxes of
$(13) in 2022 and $(18) in 2021 55 81
Change in fair value of derivatives accounted for as hedges:
Gains (losses) recognized, net of income taxes of $(20) in 2022 and $(14) in 2021 110 76
(Gains) losses transferred to earnings, net of income taxes of $2 in 2022 and $0 in 2021 (9) 21
Total other comprehensive earnings (losses) (38) 401
Total comprehensive earnings 2,427 2,996
Less comprehensive earnings attributable to:
Noncontrolling interests 279 143
Comprehensive earnings attributable to PMI $ 2,148 $ 2,853
See notes to condensed consolidated financial statements.
4
-- 5 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(in millions of dollars)
(Unaudited)
March 31,
2022 December 31,
2021
ASSETS
Cash and cash equivalents $ 4,622 $ 4,496
Trade receivables (less allowances of $32 in 2022 and $70 in 2021) 3,650 3,123
Other receivables (less allowances of $36 in 2022 and $36 in 2021) 768 817
Inventories:
Leaf tobacco 1,691 1,642
Other raw materials 2,297 1,652
Finished product 4,696 5,426
8,684 8,720
Other current assets 1,000 561
Total current assets 18,724 17,717
Property, plant and equipment, at cost 14,563 14,732
Less: accumulated depreciation 8,559 8,564
6,004 6,168
Goodwill (Note 4) 6,632 6,680
Other intangible assets, net (Note 4) 2,786 2,818
Equity investments (Note 12) 4,312 4,463
Deferred income taxes 694 895
Other assets (less allowances of $21 in 2022 and $21 in 2021) 2,581 2,549
TOTAL ASSETS $ 41,733 $ 41,290
See notes to condensed consolidated financial statements.
Continued
5
-- 6 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Balance Sheets (Continued)
(in millions of dollars, except share data)
(Unaudited)
March 31,
2022 December 31,
2021
LIABILITIES
Short-term borrowings (Note 10) $ 2,441 $ 225
Current portion of long-term debt (Note 10) 2,897 2,798
Accounts payable 3,203 3,331
Accrued liabilities:
Marketing and selling 678 811
Taxes, except income taxes 5,618 6,324
Employment costs 864 1,146
Dividends payable 1,958 1,958
Other 1,854 1,637
Income taxes 904 1,025
Total current liabilities 20,417 19,255
Long-term debt (Note 10) 24,019 24,783
Deferred income taxes 751 726
Employment costs 2,880 2,968
Income taxes and other liabilities 1,869 1,766
Total liabilities 49,936 49,498
Contingencies (Note 8)
STOCKHOLDERS’ (DEFICIT) EQUITY
Common stock, no par value
(2,109,316,331 shares issued in 2022 and 2021) — —
Additional paid-in capital 2,118 2,225
Earnings reinvested in the business 33,468 33,082
Accumulated other comprehensive losses (9,760) (9,577)
25,826 25,730
Less: cost of repurchased stock
(559,231,389 and 559,146,338 shares in 2022 and 2021, respectively) 35,924 35,836
Total PMI stockholders’ deficit (10,098) (10,106)
Noncontrolling interests 1,895 1,898
Total stockholders’ deficit (8,203) (8,208)
TOTAL LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY $ 41,733 $ 41,290
See notes to condensed consolidated financial statements.
6
-- 7 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(in millions of dollars)
(Unaudited)
For the Three Months Ended March
31,
2022 2021
CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES
Net earnings $ 2,465 $ 2,595
Adjustments to reconcile net earnings to operating cash flows:
Depreciation and amortization 253 245
Deferred income tax (benefit) provision (1) 33
Asset impairment and exit costs, net of cash paid (Note 16) (28) (36)
Cash effects of changes, net of the effects from acquired companies:
Receivables, net (553) (427)
Inventories (232) 305
Accounts payable 14 (67)
Accrued liabilities and other current assets (835) (2,108)
Income taxes (93) (91)
Pension plan contributions (34) (30)
Other 162 16
Net cash provided by operating activities 1,118 435
CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES
Capital expenditures (229) (179)
Equity investments (20) —
Net investment hedges 121 199
Other (68) 35
Net cash provided by (used in) investing activities (196) 55
See notes to condensed consolidated financial statements.
Continued
7
-- 8 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows (Continued)
(in millions of dollars)
(Unaudited)
For the Three Months Ended March
31,
2022 2021
CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES
Short-term borrowing activity by original maturity:
Net issuances (repayments) - maturities of 90 days or less $ 1,916 $ (49)
Issuances - maturities longer than 90 days 305 —
Long-term debt repaid (496) (1,632)
Repurchases of common stock (209) —
Dividends paid (1,952) (1,879)
Payments to noncontrolling interests and Other (Note 17) (265) (89)
Net cash used in financing activities (701) (3,649)
Effect of exchange rate changes on cash, cash equivalents and restricted cash (95) (220)
Cash, cash equivalents and restricted cash :
Increase (Decrease) 126 (3,379)
Balance at beginning of period 4,500 7,285
Balance at end of period $ 4,626 $ 3,906
The amounts for cash, cash equivalents and restricted cash shown above include restricted cash of $4 million and $4 million as of March 31, 2022 and 2021, respectively,
and $4 million and $5 million as of December 31, 2021 and 2020, respectively, which were included in other current assets in the condensed consolidated balance sheets.
See notes to condensed consolidated financial statements.
(1)
(1)
8
-- 9 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Statements of Stockholders’ (Deficit) Equity
For the Three Months Ended March 31, 2022 and 2021
(in millions of dollars, except per share amounts)
(Unaudited)
PMI Stockholders’ (Deficit) Equity
Common
Stock
Additional
Paid-in
Capital
Earnings
Reinvested in
the
Business
Accumulated
Other
Comprehensive Losses
Cost of
Repurchased
Stock Noncontrolling
Interests Total
Balances, January 1, 2021 $ — $ 2,105 $ 31,638 $ (11,181) $ (35,129) $ 1,936 $ (10,631)
Net earnings 2,418 177 2,595
Other comprehensive earnings
(losses), net of income taxes 435 (34) 401
Issuance of stock awards (25) 69 44
Dividends declared ($1.20 per
share) (1,878) (1,878)
Payments to noncontrolling
interests (105) (105)
Balances, March 31, 2021 $ — $ 2,080 $ 32,178 $ (10,746) $ (35,060) $ 1,974 $ (9,574)
Balances, January 1, 2022 $ — $ 2,225 $ 33,082 $ (9,577) $ (35,836) $ 1,898 $ (8,208)
Net earnings 2,331 134 2,465
Other comprehensive earnings
(losses), net of income taxes (12) (26) (38)
Issuance of stock awards (77) 111 34
Dividends declared ($1.25 per
share) (1,945) (1,945)
Payments to noncontrolling
interests (101) (101)
Common stock repurchased (199) (199)
Other (Note 17) (30) (171) (10) (211)
Balances, March 31, 2022 $ — $ 2,118 $ 33,468 $ (9,760) $ (35,924) $ 1,895 $ (8,203)
See notes to condensed consolidated financial statements.
9
-- 10 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note 1. Background and Basis of Presentation:
Background
Philip Morris International Inc. is a holding company incorporated in Virginia, U.S.A. (also referred to herein as the U.S., the United States or the United
States of America), whose subsidiaries and affiliates and their licensees are primarily engaged in the manufacture and sale of cigarettes and reduced-risk
products including heat-not-burn, vapor and oral nicotine products, in markets outside of the United States of America. Throughout these financial
statements, the term "PMI" refers to Philip Morris International Inc. and its subsidiaries.
Reduced-risk products ("RRPs") is the term PMI uses to refer to products that present, are likely to present, or have the potential to present less risk of
harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific
assessment and commercialization.
"Platform 1" is the term PMI uses to refer to PMI’s reduced-risk product that uses a precisely controlled heating device into which a specially designed and
proprietary tobacco unit is inserted and heated to generate an aerosol.
Basis of Presentation
The interim condensed consolidated financial statements of PMI are unaudited. These interim condensed consolidated financial statements have been
prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP") and such principles are applied on a
consistent basis. It is the opinion of PMI’s management that all adjustments necessary for a fair statement of the interim results presented have been
reflected therein. All such adjustments were of a normal recurring nature. Net revenues and net earnings attributable to PMI for any interim period are not
necessarily indicative of results that may be expected for the entire year.
In the third quarter of 2021, PMI acquired Fertin Pharma A/S, Vectura Group plc. and OtiTopic, Inc. On March 31, 2022, PMI launched a new Wellness
and Healthcare business consolidating these entities, Vectura Fertin Pharma. The operating results of this new business is reported in an Other category. For
further details, see Note 7. Segment Reporting and Note 17. Acquisitions.
Certain prior years' amounts have been reclassified to conform with the current year's presentation. During the first quarter of 2022, one of Fertin Pharma's
product lines was moved from the Other category to the European Union segment (reduced-risk product category). For further details, see Note 4. Goodwill
and Other Intangible Assets, net. The change did not have a material impact on PMI's consolidated financial position, results of operations or cash flows in
any of the periods presented.
These statements should be read in conjunction with the audited consolidated financial statements and related notes, which appear in PMI’s Annual Report
on Form 10-K for the year ended December 31, 2021.
10
-- 11 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note 2. Stock Plans:
In May 2017, PMI’s shareholders approved the Philip Morris International Inc. 2017 Performance Incentive Plan (the “2017 Plan”). Under the 2017 Plan,
PMI may grant to eligible employees restricted shares and restricted share units, performance-based cash incentive awards and performance-based equity
awards. Up to 25 million shares of PMI’s common stock may be issued under the 2017 Plan. At March 31, 2022, shares available for grant under the 2017
Plan were 12,644,751.
In May 2017, PMI’s shareholders also approved the Philip Morris International Inc. 2017 Stock Compensation Plan for Non-Employee Directors (the
“2017 Non-Employee Directors Plan”). A non-employee director is defined as a member of the PMI Board of Directors who is not a full-time employee of
PMI or of any corporation in which PMI owns, directly or indirectly, stock possessing at least 50% of the total combined voting power of all classes of
stock entitled to vote in the election of directors in such corporation. Up to 1 million shares of PMI common stock may be awarded under the 2017 Non-
Employee Directors Plan. At March 31, 2022, shares available for grant under the plan were 914,413.
Restricted share unit (RSU) awards
During the three months ended March 31, 2022 and 2021, shares granted to eligible employees, the weighted-average grant date fair value per share and the
recorded compensation expense related to RSU awards were as follows:
Number of
Shares
Granted
Weighted-Average Grant
Date Fair Value Per RSU
Award Granted
Compensation Expense
Related to RSU Awards
(in millions)
2022 1,551,050 $ 105.04 $ 39
2021 1,972,770 $ 81.86 $ 40
As of March 31, 2022, PMI had $259 million of total unrecognized compensation cost related to non-vested RSU awards. The cost is recognized over the
original restriction period of the awards, which is typically three years after the date of the award, or upon death, disability or reaching the age of 58.
During the three months ended March 31, 2022, 1,447,664 RSU awards vested. The grant date fair value of all the vested awards was approximately $112
million. The total fair value of RSU awards that vested during the three months ended March 31, 2022 was approximately $159 million.
Performance share unit (PSU) awards
During the three months ended March 31, 2022 and 2021, PMI granted PSU awards to certain executives. The PSU awards require the achievement of
certain performance metrics, which are predetermined at the time of grant, typically over a three-year performance cycle. The performance metrics for such
PSU's granted during the three months ended March 31, 2022 consisted of PMI's Total Shareholder Return ("TSR") relative to a predetermined peer group
and on an absolute basis (40% weight), PMI’s currency-neutral compound annual adjusted diluted earnings per share growth rate (30% weight), and a
Sustainability Index, which consists of two drivers:
• Product Sustainability (20% weight) measuring progress on PMI's efforts to maximize the benefits of smoke-free products, purposefully phase out
cigarettes, seek net positive impact in wellness and healthcare, and reduce post-consumer waste; and
• Operational Sustainability (10% weight) measuring progress on PMI's efforts to tackle climate change, preserve nature, improve the quality of life
of people in its supply chain, and foster an empowered, and inclusive workplace.
The performance metrics for such PSU's granted during the three months ended March 31, 2021 consisted of PMI's TSR relative to a predetermined peer
group and on an absolute basis (40% weight), PMI’s currency-neutral compound annual adjusted diluted earnings per share growth rate (30% weight), and
PMI’s performance against specific measures of PMI’s transformation, defined as net revenues from PMI's RRPs and any other non-combustible products
as a percentage of PMI's total net revenues in the last year of the performance cycle (30% weight).
11
-- 12 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The aggregate of the weighted performance factors for the three metrics in each such PSU award determines the percentage of PSUs that will vest at the
end of the three-year performance cycle. The minimum percentage of such PSUs that can vest is zero, with a target percentage of 100 and a maximum
percentage of 200. Each such vested PSU entitles the participant to one share of common stock. An aggregate weighted PSU performance factor of 100 will
result in the targeted number of PSUs being vested. At the end of the performance cycle, participants are entitled to an amount equivalent to the
accumulated dividends paid on common stock during the performance cycle for the number of shares earned.
During the three months ended March 31, 2022 and 2021, shares granted to eligible employee, the grant date fair value per share and the recorded
compensation expense related to PSU awards were as follows:
Number of Shares
Granted
Grant Date
Fair Value Subject to Other
Performance Metrics
Grant Date
Fair Value Subject to TSR
Performance Metric Compensation Expense
Related to PSU Awards
(in millions) (Per Share) (Per Share)
2022 451,790 $ 105.07 $ 143.94 $ 21
2021 574,410 $ 81.86 $ 106.93 $ 12
The grant date fair value of the PSU awards subject to the other performance metrics was determined by using the market price of PMI’s stock on the date
of the grant. The grant date fair value of the PSU market based awards subject to the TSR performance metric was determined by using the Monte Carlo
simulation model. The following assumptions were used to determine the grant date fair value of the PSU awards subject to the TSR performance metric:
2022 2021
Risk-free interest rate 1.6 % 0.2 %
Expected volatility 28.6 % 31.7 %
Based on the U.S. Treasury yield curve.
Determined using the observed historical volatility.
As of March 31, 2022, PMI had $76 million of total unrecognized compensation cost related to non-vested PSU awards. The cost is recognized over the
performance cycle of the awards, or upon death, disability or reaching the age of 58.
During the three months ended March 31, 2022, 669,960 PSU awards vested. The grant date fair value of all the vested awards was approximately $54
million. The total fair value of PSU awards that vested during the three months ended March 31, 2022 was approximately $74 million.
Note 3. Benefit Plans:
Pension coverage for employees of PMI’s subsidiaries is provided, to the extent deemed appropriate, through separate plans, many of which are governed
by local statutory requirements. In addition, PMI provides health care and other benefits to substantially all U.S. retired employees and certain non-U.S.
retired employees. In general, health care benefits for non-U.S. retired employees are covered through local government plans.
Pension and other employee benefit costs per the condensed consolidated statements of earnings consisted of the following:
For the Three Months Ended March
31,
(in millions) 2022 2021
Net pension costs (income) $ (25) $ (1)
Net postemployment costs 27 28
Net postretirement costs 2 1
Total pension and other employee benefit costs $ 4 $ 28
(a)
(b)
(a)
(b)
12
-- 13 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Pension Plans
Components of Net Periodic Benefit Cost
Net periodic pension cost consisted of the following:
Pension
For the Three Months Ended March
31,
(in millions) 2022 2021
Service cost $ 60 $ 75
Interest cost 20 13
Expected return on plan assets (92) (95)
Amortization:
Net loss 48 80
Prior service cost (1) 1
Net periodic pension cost $ 35 $ 74
Primarily non-U.S. based defined benefit retirement plans.
Employer Contributions
PMI makes, and plans to make, contributions, to the extent that they are tax deductible and meet specific funding requirements of its funded pension plans.
Employer contributions of $34 million were made to the pension plans during the three months ended March 31, 2022. Currently, PMI anticipates making
additional contributions during the remainder of 2022 of approximately $73 million to its pension plans, based on current tax and benefit laws. However,
this estimate is subject to change as a result of changes in tax and other benefit laws, as well as asset performance significantly above or below the assumed
long-term rate of return on pension assets, or changes in interest and currency rates.
Note 4. Goodwill and Other Intangible Assets, net:
The movements in goodwill were as follows:
(in millions) European
Union Eastern
Europe Middle East &
Africa South &
Southeast Asia East Asia &
Australia Americas Other Total
Balances, December 31, 2021 $ 1,397 $ 295 $ 79 $ 2,828 $ 539 $ 611 $ 931 $ 6,680
Changes due to:
Currency (19) (8) 8 (29) (7) 27 (20) (48)
Balances, March 31, 2022 $ 1,378 $ 287 $ 87 $ 2,799 $ 532 $ 638 $ 911 $ 6,632
At March 31, 2022, goodwill primarily reflects PMI’s business combinations in Colombia, Greece, Indonesia, Mexico, Pakistan, the Philippines and Serbia,
as well as the preliminary purchase price allocation of Fertin Pharma A/S and Vectura Group plc., which were acquired in September 2021.
As discussed in Note 1. Background and Basis of Presentation, during the first quarter of 2022, one of Fertin Pharma's product lines was moved from the
Other category to the European Union segment. As a result, the December 31, 2021 opening goodwill balance in the table above included a reclassification
of $24 million from the Other category to the European Union segment.
(1)
(1)
13
-- 14 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Details of other intangible assets were as follows:
March 31, 2022 December 31, 2021
(in millions)
Weighted-Average
Remaining Useful
Life Gross Carrying
Amount Accumulated
Amortization Net Gross Carrying
Amount Accumulated
Amortization Net
Non-amortizable intangible assets $ 1,321 $ 1,321 $ 1,312 $ 1,312
Amortizable intangible assets:
Trademarks 11 years 1,205 $ 656 549 1,201 $ 639 562
Developed technology, including
patents 12 years 855 82 773 859 63 796
Other 11 years 238 95 143 238 90 148
Total other intangible assets $ 3,619 $ 833 $ 2,786 $ 3,610 $ 792 $ 2,818
Primarily includes distribution networks and customer relationships.
Non-amortizable intangible assets substantially consist of trademarks from PMI’s acquisitions in Indonesia and Mexico, as well as the preliminary purchase
price allocation associated with PMI's business combinations in 2021 (primarily in-process research and development). The increase since December 31,
2021 was due to currency movements of $9 million.
The change in the accumulated amortization from December 31, 2021, was mainly due to the 2022 amortization of $38 million, and currency movements
of $3 million.
Amortization expense for each of the next five years is estimated to be $150 million or less, assuming no additional transactions occur that require the
amortization of intangible assets.
Note 5. Financial Instruments:
Overview
PMI operates in markets outside of the United States of America, with manufacturing and sales facilities in various locations around the world. PMI utilizes
certain financial instruments to manage foreign currency and interest rate exposures. Derivative financial instruments are used by PMI principally to reduce
exposures to market risks resulting from fluctuations in foreign currency exchange and interest rates by creating offsetting exposures. PMI is not a party to
leveraged derivatives and, by policy, does not use derivative financial instruments for speculative purposes. Substantially all of PMI's derivative financial
instruments are subject to master netting arrangements, whereby the right to offset occurs in the event of default by a participating party. While these
contracts contain the enforceable right to offset through close-out netting rights, PMI elects to present them on a gross basis in the consolidated balance
sheets. Collateral associated with these arrangements is in the form of cash and is unrestricted. Financial instruments qualifying for hedge accounting must
maintain a specified level of effectiveness between the hedging instrument and the item being hedged, both at inception and throughout the hedged period.
PMI formally documents the nature and relationships between the hedging instruments and hedged items, as well as its risk-management objectives,
strategies for undertaking the various hedge transactions and method of assessing hedge effectiveness. Additionally, for hedges of forecasted transactions,
the significant characteristics and expected terms of the forecasted transaction must be specifically identified, and it must be probable that each forecasted
transaction will occur. If it were deemed probable that the forecasted transaction would not occur, the gain or loss would be recognized in earnings.
PMI uses deliverable and non-deliverable forward foreign exchange contracts, foreign currency swaps and foreign currency options, collectively referred to
as foreign exchange contracts ("foreign exchange contracts"), and interest rate contracts to
(1)
(1)
14
-- 15 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
mitigate its exposure to changes in exchange and interest rates from third-party and intercompany actual and forecasted transactions. Both foreign exchange
contracts and interest rate contracts are collectively referred to as derivative contracts ("derivative contracts"). The primary currencies to which PMI is
exposed include the Euro, Indonesian rupiah, Japanese yen, Mexican peso, Philippine peso, Russian ruble and Swiss franc. At March 31, 2022, PMI had
contracts with aggregate notional amounts of $25.8 billion of which $4.9 billion related to cash flow hedges, $7.9 billion related to hedges of net
investments in foreign operations, $1.0 billion related to fair value hedges and $12.0 billion related to other derivatives that primarily offset currency
exposures on intercompany financing.
The fair value of PMI’s derivative contracts included in the condensed consolidated balance sheets as of March 31, 2022 and December 31, 2021, were as
follows:
Derivative Assets Derivative Liabilities
Fair Value Fair Value
At At At At
(in millions) Balance Sheet
Classification March 31, 2022 December 31,
2021 Balance Sheet
Classification March 31, 2022 December 31,
2021
Derivative contracts
designated as hedging
instruments Other current
assets $ 291 $ 173 Other accrued
liabilities $ 46 $ 34
Other assets 63 22 Income taxes and
other liabilities 182 190
Derivative contracts not
designated as hedging
instruments Other current
assets 55 37 Other accrued
liabilities 83 75
Other assets — — Income taxes and
other liabilities 14 —
Total gross amount
derivatives contracts
presented in the condensed
consolidated balance sheets $ 409 $ 232 $ 325 $ 299
Gross amounts not offset in
the condensed consolidated
balance sheets
Financial instruments (199) (126) (199) (126)
Cash collateral
received/pledged (200) (93) (87) (151)
Net amount $ 10 $ 13 $ 39 $ 22
PMI assesses the fair value of its foreign exchange contracts and interest rate contracts using standard valuation models that use, as their basis, readily
observable market inputs. The fair value of PMI’s foreign exchange forward contracts, foreign currency swaps and interest rate contracts is determined by
using the prevailing foreign exchange spot rates and interest rate differentials, and the respective maturity dates of the instruments. The fair value of PMI’s
currency options is determined by using a Black-Scholes methodology based on foreign exchange spot rates and interest rate differentials, currency
volatilities and maturity dates. PMI’s derivative contracts have been classified within Level 2 at March 31, 2022 and December 31, 2021.
15
-- 16 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
For the three months ended March 31, 2022 and 2021, PMI's derivative contracts impacted the condensed consolidated statements of earnings and
comprehensive earnings as follows:
(pre-tax, in millions) For the Three Months Ended March 31,
Amount of Gain/(Loss)
Recognized in Other
Comprehensive
Earnings/(Losses) on
Derivatives
Statement of Earnings
Classification of
Gain/(Loss)
on Derivatives
Amount of Gain/(Loss)
Reclassified from Other
Comprehensive
Earnings/(Losses) into
Earnings Amount of Gain/(Loss)
Recognized in Earnings
2022 2021 2022 2021 2022 2021
Derivative contracts designated as
hedging instruments:
Cash flow hedges $ 130 $ 90
Net revenues $ 17 $ —
Cost of sales — —
Marketing,
administration and
research costs (3) (18)
Interest expense, net (3) (3)
Fair value hedges Interest expense, net $ (37) $ —
Net investment hedges 105 318 Interest expense, net 33 42
Derivative contracts not designated as
hedging instruments: Interest expense, net 8 11
Marketing,
administration and
research costs (1) 287
Total $ 235 $ 408 $ 11 $ (21) $ 3 $ 340
Amount of gains (losses) on hedges of net investments principally related to changes in exchange and interest rates between the Euro and U.S. dollar
Represent the gains for amounts excluded from the effectiveness testing
The gains (losses) from these contracts attributable to changes in foreign currency exchange rates substantially offset the (losses) and gains generated by the underlying
intercompany and third-party loans being hedged
Cash Flow Hedges
PMI has entered into derivative contracts to hedge the foreign currency exchange and interest rate risks related to certain forecasted transactions. Gains and
losses associated with qualifying cash flow hedge contracts are deferred as components of accumulated other comprehensive losses until the underlying
hedged transactions are reported in PMI’s condensed consolidated statements of earnings. As of March 31, 2022, PMI has hedged forecasted transactions
for periods not exceeding the next twenty-one months with the exception of one derivative contract that expires in May 2024. The impact of these hedges is
primarily included in operating cash flows on PMI’s condensed consolidated statements of cash flows.
(a) (b)
(c)
(a)
(b)
(c)
16
-- 17 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Fair Value Hedges
PMI has entered into fixed-to-floating interest rate contracts, designated as fair value hedges to minimize exposure to changes in the fair value of fixed rate
U.S. dollar-denominated debt that results from fluctuations in benchmark interest rates. For derivative contracts that are designated and qualify as fair value
hedges the gain or loss on the derivative, as well as the offsetting gain or loss on the hedged items attributable to the hedged risk, is recognized in current
earnings. The carrying amount of the debt hedged, which includes the cumulative adjustment for fair value gains/losses, as of March 31, 2022 was $957
million, and is recorded in long-term debt in the condensed consolidated balance sheets. The cumulative amount of fair value gains/(losses) included in the
carrying amount of the debt hedged was $(36) million as of March 31, 2022.
Hedges of Net Investments in Foreign Operations
PMI designates derivative contracts and certain foreign currency denominated debt instruments as net investment hedges, primarily of its Euro net assets.
For the three months ended March 31, 2022 and 2021, the amount of pre-tax gain/(loss) related to these debt instruments, that was reported as a component
of accumulated other comprehensive losses within currency translation adjustments, was $66 million and $181 million, respectively. The premiums paid
for, and settlements of, net investment hedges are included in investing cash flows on PMI’s condensed consolidated statements of cash flows.
Other Derivatives
PMI has entered into derivative contracts to hedge the foreign currency exchange and interest rate risks related to intercompany loans between certain
subsidiaries, and third-party loans. While effective as economic hedges, no hedge accounting is applied for these contracts; therefore, the gains (losses)
relating to these contracts are reported in PMI’s condensed consolidated statements of earnings.
Qualifying Hedging Activities Reported in Accumulated Other Comprehensive Losses
Derivative gains or losses reported in accumulated other comprehensive losses are a result of qualifying hedging activity. Transfers of these gains or losses
to earnings are offset by the corresponding gains or losses on the underlying hedged item. Hedging activity affected accumulated other comprehensive
losses, net of income taxes, as follows:
(in millions) For the Three Months Ended March
31,
2022 2021
Gain/(loss) as of January 1, $ 4 $ (85)
Derivative (gains)/losses transferred to earnings (9) 21
Change in fair value 110 76
Gain/(loss) as of March 31, $ 105 $ 12
At March 31, 2022, PMI expects $76 million of derivative gains that are included in accumulated other comprehensive losses to be reclassified to the
condensed consolidated statement of earnings within the next 12 months. These gains are expected to be substantially offset by the statement of earnings
impact of the respective hedged transactions.
Contingent Features
PMI’s derivative instruments do not contain contingent features.
Credit Exposure and Credit Risk
PMI is exposed to credit loss in the event of non-performance by counterparties. While PMI does not anticipate non-performance, its risk is limited to the
fair value of the financial instruments less any cash collateral received or pledged. PMI actively monitors its exposure to credit risk through the use of
credit approvals and credit limits and by selecting and continuously monitoring a diverse group of major international banks and financial institutions as
counterparties.
17
-- 18 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Other Investments
A PMI investment, which is comprised primarily of money market funds, has been classified within Level 1 and had a fair value of $82 million at
March 31, 2022. For the three months ended March 31, 2022 the unrealized pre-tax gains on these investments were immaterial.
Note 6. Earnings Per Share:
Basic and diluted earnings per share (“EPS”) were calculated using the following:
(in millions) For the Three Months Ended March
31,
2022 2021
Net earnings attributable to PMI $ 2,331 $ 2,418
Less distributed and undistributed earnings attributable to share-based payment awards 7 7
Net earnings for basic and diluted EPS $ 2,324 $ 2,411
Weighted-average shares for basic EPS 1,550 1,558
Plus contingently issuable performance stock units (PSUs) 2 2
Weighted-average shares for diluted EPS 1,552 1,560
Unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents are participating securities and therefore are
included in PMI’s earnings per share calculation pursuant to the two-class method.
For the 2022 and 2021 computations, there were no antidilutive stock awards.
Note 7. Segment Reporting:
PMI’s subsidiaries and affiliates are primarily engaged in the manufacture and sale of cigarettes and RRPs, including heat-not-burn, vapor and oral nicotine
products, in markets outside of the United States of America. PMI's segments are generally organized by geographic region and managed by segment
managers who are responsible for the operating and financial results of the regions inclusive of combustible and reduced-risk product categories sold in the
region. PMI currently has six geographical segments: the European Union; Eastern Europe; Middle East & Africa; South & Southeast Asia; East Asia &
Australia; and Americas; as well as an Other category. Other consists of the operating results of PMI's new Wellness and Healthcare business, Vectura
Fertin Pharma. For further details on these acquisitions, see Note 17. Acquisitions. PMI records net revenues and operating income to its geographical
segments based upon the geographic area in which the customer resides.
PMI’s chief operating decision maker evaluates geographical segment performance and allocates resources based on regional operating income, which
includes results from all product categories sold in each region. Business operations in the Other category are managed and evaluated separately.
PMI disaggregates its net revenue from contracts with customers by both geographic location and product category for each of PMI's six geographical
segments. For the new Wellness and Healthcare business discussed above, net revenues from contracts with customers are included in the Other category.
PMI believes this best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors.
18
-- 19 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Segment data were as follows:
(in millions) For the Three Months Ended March
31,
2022 2021
Net revenues:
European Union $ 3,012 $ 2,909
Eastern Europe 726 796
Middle East & Africa 991 801
South & Southeast Asia 1,123 1,173
East Asia & Australia 1,404 1,472
Americas 424 434
Other 66 —
Net revenues $ 7,746 $ 7,585
Operating income (loss):
European Union $ 1,527 $ 1,490
Eastern Europe 144 261
Middle East & Africa 521 335
South & Southeast Asia 445 529
East Asia & Australia 571 695
Americas 121 134
Other (31) —
Operating income $ 3,298 $ 3,444
Items affecting the comparability of results from operations were as follows:
• Asset impairment and exit costs - See Note 16. Asset Impairment and Exit Costs for details of the $48 million pre-tax charge and a breakdown of
these costs by segment for the three months ended March 31, 2021.
• Charges related to the war in Ukraine - See Note 18. War in Ukraine for details of the $42 million pre-tax charges in the Eastern Europe segment for
the three months ended March 31, 2022.
19
-- 20 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
PMI's net revenues by product category were as follows:
(in millions) For the Three Months Ended March
31,
2022 2021
Net revenues:
Combustible products:
European Union $ 1,810 $ 1,950
Eastern Europe 456 492
Middle East & Africa 929 780
South & Southeast Asia 1,118 1,171
East Asia & Australia 601 648
Americas 416 422
Total combustible products $ 5,330 $ 5,463
Reduced-risk products:
European Union $ 1,202 $ 959
Eastern Europe 270 304
Middle East & Africa 62 21
South & Southeast Asia 5 2
East Asia & Australia 803 824
Americas 8 12
Total reduced-risk products $ 2,350 $ 2,122
Other:
Other $ 66 $ —
Total PMI net revenues $ 7,746 $ 7,585
Note: Sum of product categories or Regions might not foot to total PMI due to roundings.
Net revenues related to combustible products refer to the operating revenues generated from the sale of these products, including shipping and handling
charges billed to customers, net of sales and promotion incentives, and excise taxes. These net revenue amounts consist of the sale of PMI's cigarettes and
other tobacco products combined. Other tobacco products primarily include roll-your-own and make-your-own cigarettes, pipe tobacco, cigars and
cigarillos, and do not include reduced-risk products.
Net revenues related to reduced-risk products refer to the operating revenues generated from the sale of these products, including shipping and handling
charges billed to customers, net of sales and promotion incentives, and excise taxes. These net revenue amounts consist of the sale of PMI's heated tobacco
units, heat-not-burn devices and related accessories, and other nicotine-containing products, which primarily include PMI's e-vapor and oral nicotine
products.
Net revenues in the Other category primarily consist of operating revenues generated from the sale of inhaled therapeutics, and oral and intra-oral delivery
systems that are included in the operating results of PMI's new Wellness and Healthcare business, Vectura Fertin Pharma.
20
-- 21 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note 8. Contingencies:
Tobacco-Related Litigation
Legal proceedings covering a wide range of matters are pending or threatened against us, and/or our subsidiaries, and/or our indemnitees in various
jurisdictions. Our indemnitees include distributors, licensees, and others that have been named as parties in certain cases and that we have agreed to defend,
as well as to pay costs and some or all of judgments, if any, that may be entered against them. Pursuant to the terms of the Distribution Agreement between
Altria Group, Inc. (“Altria”) and PMI, PMI will indemnify Altria and Philip Morris USA Inc. (“PM USA”), a U.S. tobacco subsidiary of Altria, for tobacco
product claims based in substantial part on products manufactured by PMI or contract manufactured for PMI by PM USA, and PM USA will indemnify
PMI for tobacco product claims based in substantial part on products manufactured by PM USA, excluding tobacco products contract manufactured for
PMI.
It is possible that there could be adverse developments in pending cases against us and our subsidiaries. An unfavorable outcome or settlement of pending
tobacco-related litigation could encourage the commencement of additional litigation.
Damages claimed in some of the tobacco-related litigation are significant and, in certain cases in Brazil, Canada and Nigeria, range into the billions of U.S.
dollars. The variability in pleadings in multiple jurisdictions, together with the actual experience of management in litigating claims, demonstrate that the
monetary relief that may be specified in a lawsuit bears little relevance to the ultimate outcome. Much of the tobacco-related litigation is in its early stages,
and litigation is subject to uncertainty. However, as discussed below, we have to date been largely successful in defending tobacco-related litigation.
We and our subsidiaries record provisions in the consolidated financial statements for pending litigation when we determine that an unfavorable outcome is
probable and the amount of the loss can be reasonably estimated. At the present time, except as stated otherwise in this Note 8. Contingencies, while it is
reasonably possible that an unfavorable outcome in a case may occur, after assessing the information available to it (i) management has not concluded that
it is probable that a loss has been incurred in any of the pending tobacco-related cases; (ii) management is unable to estimate the possible loss or range of
loss for any of the pending tobacco-related cases; and (iii) accordingly, no estimated loss has been accrued in the consolidated financial statements for
unfavorable outcomes in these cases, if any. Legal defense costs are expensed as incurred.
It is possible that our consolidated results of operations, cash flows or financial position could be materially affected in a particular fiscal quarter or fiscal
year by an unfavorable outcome or settlement of certain pending litigation. Nevertheless, although litigation is subject to uncertainty, we and each of our
subsidiaries named as a defendant believe, and each has been so advised by counsel handling the respective cases, that we have valid defenses to the
litigation pending against us, as well as valid bases for appeal of adverse verdicts. All such cases are, and will continue to be, vigorously defended.
However, we and our subsidiaries may enter into settlement discussions in particular cases if we believe it is in our best interests to do so.
CCAA Proceedings and Stay of Tobacco-Related Cases Pending in Canada
As a result of the Court of Appeal of Quebec’s decision in both the Létourneau and Blais cases described below, our subsidiary, Rothmans, Benson &
Hedges Inc. (“RBH”), and the other defendants, JTI Macdonald Corp., and Imperial Tobacco Canada Limited, sought protection in the Ontario Superior
Court of Justice under the Companies’ Creditors Arrangement Act (“CCAA”) on March 22, March 8, and March 12, 2019, respectively. CCAA is a
Canadian federal law that permits a Canadian business to restructure its affairs while carrying on its business in the ordinary course. The initial CCAA
order made by the Ontario Superior Court on March 22, 2019 authorizes RBH to pay all expenses incurred in carrying on its business in the ordinary course
after the CCAA filing, including obligations to employees, vendors, and suppliers. As further described in Item 8, Note 20. Deconsolidation of RBH of
PMI's Annual Report on Form 10-K for the year ended December 31, 2021, RBH's financial results have been deconsolidated from our consolidated
financial statements since March 22, 2019. As part of the CCAA proceedings, there is currently a comprehensive stay up to and including September 30,
2022 of all tobacco-related litigation pending in Canada against RBH and the other defendants, including PMI and our indemnitees (PM USA and Altria),
namely, the smoking and health class actions filed in various Canadian provinces and health care cost recovery actions. These proceedings are presented
below under the caption “Stayed Litigation — Canada.” Ernst & Young Inc. has been appointed as monitor of RBH in the CCAA proceedings. In
accordance with the CCAA process, as the parties work towards a plan of arrangement or compromise in a confidential mediation, it is anticipated that the
court will set additional hearings and further extend the stay of proceedings. On April 17, 2019, the Ontario Superior Court ruled that RBH and the other
defendants will not be allowed to file an application to the Supreme Court of Canada for leave to appeal the Court of Appeal’s decision in the Létourneau
and the Blais cases so long as the comprehensive stay of all tobacco-related litigation in Canada remains in effect and that the time period to file the
application would be extended by the stay period. While RBH believes that the findings of liability and damages in both Létourneau and the Blais cases
were incorrect, the CCAA proceedings will provide a forum for
21
-- 22 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
RBH to seek resolution through a plan of arrangement or compromise of all tobacco-related litigation pending in Canada. It is not possible to predict the
resolution of the underlying legal proceedings or the length of the CCAA process.
Stayed Litigation — Canada
Smoking and Health Litigation — Canada
In the first class action pending in Canada, Conseil Québécois Sur Le Tabac Et La Santé and Jean-Yves Blais v. Imperial Tobacco Ltd., Rothmans,
Benson & Hedges Inc. and JTI-Macdonald Corp., Quebec Superior Court, Canada, filed in November 1998, RBH and other Canadian cigarette
manufacturers (Imperial Tobacco Canada Ltd. and JTI-Macdonald Corp.) are defendants. The plaintiffs, an anti-smoking organization and an individual
smoker, sought compensatory and punitive damages for each member of the class who suffers allegedly from certain smoking-related diseases. The class
was certified in 2005. The trial court issued its judgment on May 27, 2015. The trial court found RBH and two other Canadian manufacturers liable and
found that the class members’ compensatory damages totaled approximately CAD 15.5 billion, including pre-judgment interest (approximately $12.2
billion). The trial court awarded compensatory damages on a joint and several liability basis, allocating 20% to our subsidiary (approximately CAD 3.1
billion, including pre-judgment interest (approximately $2.4 billion)). In addition, the trial court awarded CAD 90,000 (approximately $70,800) in punitive
damages, allocating CAD 30,000 (approximately $23,600) to RBH. The trial court estimated the disease class at 99,957 members. RBH appealed to the
Court of Appeal of Quebec. In October 2015, the Court of Appeal ordered RBH to furnish security totaling CAD 226 million (approximately $178 million)
to cover both the Létourneau and Blais cases, which RBH has paid in installments through March 2017. The Court of Appeal ordered Imperial Tobacco
Canada Ltd. to furnish security totaling CAD 758 million (approximately $596 million) in installments through June 2017. JTI Macdonald Corp. was not
required to furnish security in accordance with plaintiffs’ motion. The Court of Appeal ordered that the security is payable upon a final judgment of the
Court of Appeal affirming the trial court’s judgment or upon further order of the Court of Appeal.
On March 1, 2019, the Court of Appeal issued a decision largely affirming the trial court’s findings of liability and the compensatory and punitive damages
award while reducing the total amount of compensatory damages to approximately CAD 13.5 billion including interest (approximately $10.6 billion) due to
the trial court’s error in the calculation of interest. The compensatory damages award is on a joint and several basis with an allocation of 20% to RBH
(approximately CAD 2.7 billion, including pre-judgment interest (approximately $2.1 billion)). The Court of Appeal upheld the trial court’s findings that
defendants violated the Civil Code of Quebec, the Quebec Charter of Human Rights and Freedoms, and the Quebec Consumer Protection Act by failing to
warn adequately of the dangers of smoking and by conspiring to prevent consumers from learning of the dangers of smoking. The Court of Appeal further
held that the plaintiffs either need not prove, or had adequately proven, that these faults were a cause of the class members’ injuries. In accordance with the
judgment, defendants were required to deposit their respective portions of the damages awarded in both the Létourneau case described below and the Blais
case, approximately CAD 1.1 billion (approximately $865 million), into trust accounts within 60 days. RBH’s share of the deposit was approximately CAD
257 million (approximately $194 million). PMI recorded a pre-tax charge of $194 million in its consolidated results, representing $142 million net of tax,
as tobacco litigation-related expense, in the first quarter of 2019. The charge reflects PMI’s assessment of the portion of the judgment that represents
probable and estimable loss prior to the deconsolidation of RBH and corresponds to the trust account deposit required by the judgment.
In the second class action pending in Canada, Cecilia Létourneau v. Imperial Tobacco Ltd., Rothmans, Benson & Hedges Inc. and JTI-Macdonald Corp.,
Quebec Superior Court, Canada, filed in September 1998, RBH and other Canadian cigarette manufacturers (Imperial Tobacco Canada Ltd. and JTI-
Macdonald Corp.) are defendants. The plaintiff, an individual smoker, sought compensatory and punitive damages for each member of the class who is
deemed addicted to smoking. The class was certified in 2005. The trial court issued its judgment on May 27, 2015. The trial court found RBH and two
other Canadian manufacturers liable and awarded a total of CAD 131 million (approximately $103 million) in punitive damages, allocating CAD 46
million (approximately $36 million) to RBH. The trial court estimated the size of the addiction class at 918,000 members but declined to award
compensatory damages to the addiction class because the evidence did not establish the claims with sufficient accuracy. The trial court found that a claims
process to allocate the awarded punitive damages to individual class members would be too expensive and difficult to administer. On March 1, 2019, the
Court of Appeal issued a decision largely affirming the trial court’s findings of liability and the total amount of punitive damages awarded allocating CAD
57 million including interest (approximately $45 million) to RBH. See the Blais description above and Item 8, Note 20. Deconsolidation of RBH in PMI's
Annual Report on Form 10-K for the year ended December 31, 2021 for further detail concerning the security order pertaining to both Létourneau and
Blais cases and the impact of the decision on PMI’s financial statements.
22
-- 23 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
RBH and PMI believe the findings of liability and damages in both Létourneau and the Blais cases were incorrect and in contravention of applicable law on
several grounds including the following: (i) defendants had no obligation to warn class members who knew, or should have known, of the risks of smoking;
(ii) defendants cannot be liable to class members who would have smoked regardless of what warnings were given; and (iii) defendants cannot be liable to
all class members given the individual differences between class members.
In the third class action pending in Canada, Kunta v. Canadian Tobacco Manufacturers' Council, et al., The Queen's Bench, Winnipeg, Canada, filed
June 12, 2009, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker,
alleges her own addiction to tobacco products and chronic obstructive pulmonary disease (“COPD”), severe asthma, and mild reversible lung disease
resulting from the use of tobacco products. She is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers,
their estates, dependents and family members, as well as restitution of profits, and reimbursement of government health care costs allegedly caused by
tobacco products.
In the fourth class action pending in Canada, Adams v. Canadian Tobacco Manufacturers' Council, et al., The Queen's Bench, Saskatchewan, Canada, filed
July 10, 2009, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker,
alleges her own addiction to tobacco products and COPD resulting from the use of tobacco products. She is seeking compensatory and punitive damages on
behalf of a proposed class comprised of all smokers who have smoked a minimum of 25,000 cigarettes and have allegedly suffered, or suffer, from COPD,
emphysema, heart disease, or cancer, as well as restitution of profits.
In the fifth class action pending in Canada, Semple v. Canadian Tobacco Manufacturers' Council, et al., The Supreme Court (trial court), Nova Scotia,
Canada, filed June 18, 2009, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an
individual smoker, alleges his own addiction to tobacco products and COPD resulting from the use of tobacco products. He is seeking compensatory and
punitive damages on behalf of a proposed class comprised of all smokers, their estates, dependents and family members, as well as restitution of profits,
and reimbursement of government health care costs allegedly caused by tobacco products.
In the sixth class action pending in Canada, Dorion v. Canadian Tobacco Manufacturers' Council, et al., The Queen's Bench, Alberta, Canada, filed
June 15, 2009, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker,
alleges her own addiction to tobacco products and chronic bronchitis and severe sinus infections resulting from the use of tobacco products. She is seeking
compensatory and punitive damages on behalf of a proposed class comprised of all smokers, their estates, dependents and family members, restitution of
profits, and reimbursement of government health care costs allegedly caused by tobacco products. To date, we, our subsidiaries, and our indemnitees have
not been properly served with the complaint.
In the seventh class action pending in Canada, McDermid v. Imperial Tobacco Canada Limited, et al., Supreme Court, British Columbia, Canada, filed
June 25, 2010, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker,
alleges his own addiction to tobacco products and heart disease resulting from the use of tobacco products. He is seeking compensatory and punitive
damages on behalf of a proposed class comprised of all smokers who were alive on June 12, 2007, and who suffered from heart disease allegedly caused by
smoking, their estates, dependents and family members, plus disgorgement of revenues earned by the defendants from January 1, 1954, to the date the
claim was filed.
In the eighth class action pending in Canada, Bourassa v. Imperial Tobacco Canada Limited, et al., Supreme Court, British Columbia, Canada, filed
June 25, 2010, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, the heir to a deceased
smoker, alleges that the decedent was addicted to tobacco products and suffered from emphysema resulting from the use of tobacco products. She is
seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers who were alive on June 12, 2007, and who suffered
from chronic respiratory diseases allegedly caused by smoking, their estates, dependents and family members, plus disgorgement of revenues earned by the
defendants from January 1, 1954, to the date the claim was filed. In December 2014, plaintiff filed an amended statement of claim.
In the ninth class action pending in Canada, Suzanne Jacklin v. Canadian Tobacco Manufacturers' Council, et al., Ontario Superior Court of Justice, filed
June 20, 2012, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker,
alleges her own addiction to tobacco products and COPD resulting from the use of tobacco products. She is seeking compensatory and punitive damages on
behalf of a proposed class comprised
23
-- 24 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
of all smokers who have smoked a minimum of 25,000 cigarettes and have allegedly suffered, or suffer, from COPD, heart disease, or cancer, as well as
restitution of profits.
Health Care Cost Recovery Litigation — Canada
In the first health care cost recovery case pending in Canada, Her Majesty the Queen in Right of British Columbia v. Imperial Tobacco Limited, et al.,
Supreme Court, British Columbia, Vancouver Registry, Canada, filed January 24, 2001, we, RBH, our indemnitee (PM USA), and other members of the
industry are defendants. The plaintiff, the government of the province of British Columbia, brought a claim based upon legislation enacted by the province
authorizing the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, resulting
from a “tobacco related wrong.”
In the second health care cost recovery case filed in Canada, Her Majesty the Queen in Right of New Brunswick v. Rothmans Inc., et al., Court of Queen's
Bench of New Brunswick, Trial Court, New Brunswick, Fredericton, Canada, filed March 13, 2008, we, RBH, our indemnitees (PM USA and Altria), and
other members of the industry are defendants. The claim was filed by the government of the province of New Brunswick based on legislation enacted in the
province. This legislation is similar to the law introduced in British Columbia that authorizes the government to file a direct action against cigarette
manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
In the third health care cost recovery case filed in Canada, Her Majesty the Queen in Right of Ontario v. Rothmans Inc., et al., Ontario Superior Court of
Justice, Toronto, Canada, filed September 29, 2009, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants.
The claim was filed by the government of the province of Ontario based on legislation enacted in the province. This legislation is similar to the laws
introduced in British Columbia and New Brunswick that authorize the government to file a direct action against cigarette manufacturers to recover the
health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
In the fourth health care cost recovery case filed in Canada, Attorney General of Newfoundland and Labrador v. Rothmans Inc., et al., Supreme Court of
Newfoundland and Labrador, St. Johns, Canada, filed February 8, 2011, we, RBH, our indemnitees (PM USA and Altria), and other members of the
industry are defendants. The claim was filed by the government of the province of Newfoundland and Labrador based on legislation enacted in the province
that is similar to the laws introduced in British Columbia, New Brunswick and Ontario. The legislation authorizes the government to file a direct action
against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
In the fifth health care cost recovery case filed in Canada, Attorney General of Quebec v. Imperial Tobacco Limited, et al., Superior Court of Quebec,
Canada, filed June 8, 2012, we, RBH, our indemnitee (PM USA), and other members of the industry are defendants. The claim was filed by the
government of the province of Quebec based on legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces.
The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will
incur, as a result of a “tobacco related wrong.”
In the sixth health care cost recovery case filed in Canada, Her Majesty in Right of Alberta v. Altria Group, Inc., et al., Supreme Court of Queen's Bench
Alberta, Canada, filed June 8, 2012, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was
filed by the government of the province of Alberta based on legislation enacted in the province that is similar to the laws enacted in several other Canadian
provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred,
and will incur, as a result of a “tobacco related wrong.”
In the seventh health care cost recovery case filed in Canada, Her Majesty the Queen in Right of the Province of Manitoba v. Rothmans, Benson & Hedges,
Inc., et al., The Queen's Bench, Winnipeg Judicial Centre, Canada, filed May 31, 2012, we, RBH, our indemnitees (PM USA and Altria), and other
members of the industry are defendants. The claim was filed by the government of the province of Manitoba based on legislation enacted in the province
that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette
manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
In the eighth health care cost recovery case filed in Canada, The Government of Saskatchewan v. Rothmans, Benson & Hedges Inc., et al., Queen's Bench,
Judicial Centre of Saskatchewan, Canada, filed June 8, 2012, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are
defendants. The claim was filed by the government of the province of Saskatchewan based on legislation enacted in the province that is similar to the laws
enacted in several other Canadian
24
-- 25 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred,
and will incur, as a result of a “tobacco related wrong.”
In the ninth health care cost recovery case filed in Canada, Her Majesty the Queen in Right of the Province of Prince Edward Island v. Rothmans, Benson &
Hedges Inc., et al., Supreme Court of Prince Edward Island (General Section), Canada, filed September 10, 2012, we, RBH, our indemnitees (PM USA
and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Prince Edward Island based on
legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file
a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
In the tenth health care cost recovery case filed in Canada, Her Majesty the Queen in Right of the Province of Nova Scotia v. Rothmans, Benson & Hedges
Inc., et al., Supreme Court of Nova Scotia, Canada, filed January 2, 2015, we, RBH, our indemnitees (PM USA and Altria), and other members of the
industry are defendants. The claim was filed by the government of the province of Nova Scotia based on legislation enacted in the province that is similar
to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to
recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
__________
The table below lists the number of tobacco-related cases pertaining to combustible products pending against us and/or our subsidiaries or indemnitees as
of March 31, 2022, and March 31, 2021:¹
Type of Case
Number of Cases
Pending as of March
31, 2022
Number of Cases
Pending as of March
31, 2021
Individual Smoking and Health Cases 41 43
Smoking and Health Class Actions 9 9
Health Care Cost Recovery Actions 17 17
Label-Related Class Actions — —
Individual Label-Related Cases 5 5
Public Civil Actions 1 2
Since 1995, when the first tobacco-related litigation was filed against a PMI entity, 524 Smoking and Health, Label-Related, Health Care Cost Recovery,
and Public Civil Actions in which we and/or one of our subsidiaries and/or indemnitees were a defendant have been terminated in our favor. Fourteen cases
have had decisions in favor of plaintiffs. Ten of these cases have subsequently reached final resolution in our favor and four remain on appeal.
______
¹ Includes cases pending in Canada.
25
-- 26 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The table below lists the verdict and significant post-trial developments in the four pending cases where a verdict was returned in favor of the plaintiff:
Date
Location of
Court/Name of
Plaintiff Type of
Case Verdict Post-Trial
Developments
May 27, 2015 Canada/Conseil Québécois Sur
Le Tabac Et La Santé and Jean-
Yves Blais
Class Action On May 27, 2015, the Superior
Court of the District of
Montreal, Province of Quebec
ruled in favor of the Blais class
on liability and found the class
members’ compensatory
damages totaled approximately
CAD 15.5 billion
(approximately $12.2 billion),
including pre-judgment interest.
The trial court awarded
compensatory damages on a
joint and several liability basis,
allocating 20% to our subsidiary
(approximately CAD 3.1 billion
including pre-judgment interest
(approximately $2.4 billion)).
The trial court awarded CAD
90,000 (approximately $70,800)
in punitive damages, allocating
CAD 30,000 (approximately
$23,600) to our subsidiary. The
trial court ordered defendants to
pay CAD 1 billion
(approximately $786 million) of
the compensatory damage
award, CAD 200 million
(approximately $157 million) of
which is our subsidiary’s
portion, into a trust within 60
days.
In June 2015, RBH commenced the
appellate process with the Court of
Appeal of Quebec. On March 1, 2019,
the Court of Appeal issued a decision
largely affirming the trial court's
decision. (See “Stayed Litigation —
Canada” for further detail.)
26
-- 27 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Date
Location of
Court/Name of
Plaintiff Type of
Case Verdict Post-Trial
Developments
May 27, 2015 Canada/Cecilia Létourneau Class Action On May 27, 2015, the Superior
Court of the District of
Montreal, Province of Quebec
ruled in favor of the Létourneau
class on liability and awarded a
total of CAD 131 million
(approximately $103 million) in
punitive damages, allocating
CAD 46 million (approximately
$36 million) to RBH. The trial
court ordered defendants to pay
the full punitive damage award
into a trust within 60 days. The
court did not order the payment
of compensatory damages.
In June 2015, RBH commenced the
appellate process with the Court of
Appeal of Quebec. On March 1, 2019,
the Court of Appeal issued a decision
largely affirming the trial court's
decision. (See “Stayed Litigation —
Canada” for further detail.)
Date
Location of
Court/Name of
Plaintiff Type of
Case Verdict Post-Trial
Developments
August 5, 2016 Argentina/Hugo Lespada Individual
Action On August 5, 2016, the Civil
Court No. 14 - Mar del Plata,
issued a verdict in favor of
plaintiff, an individual smoker,
and awarded him ARS 110,000
(approximately $963), plus
interest, in compensatory and
moral damages. The trial court
found that our subsidiary failed
to warn plaintiff of the risk of
becoming addicted to cigarettes.
On August 23, 2016, our subsidiary filed
its notice of appeal. On October 31,
2017, the Civil and Commercial Court of
Appeals of Mar del Plata ruled that
plaintiff's claim was barred by the statute
of limitations and it reversed the trial
court's decision. On May 17, 2021
plaintiff filed a federal extraordinary
appeal. On November 1, 2021, the
Supreme Court of the Province of
Buenos Aires dismissed plaintiff's
federal extraordinary appeal. On
November 10, 2021, plaintiff filed a
direct appeal before the Federal Supreme
Court.
27
-- 28 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Date
Location of
Court/Name of
Plaintiff Type of
Case Verdict Post-Trial
Developments
June 17, 2021 Argentina/Claudia Milano Individual
Action On June 17, 2021, the Civil
Court No. 9 - Mar del Plata,
issued a verdict in favor of
plaintiff, an individual smoker,
and awarded her smoking
cessation treatments, ARS
150,000 (approximately
$1,314), in compensatory and
moral damages, and ARS
4,000,000 (approximately
$35,028) in punitive damages,
plus interest and costs. The trial
court found that our subsidiary
failed to warn plaintiff of the
risk of becoming addicted to
cigarettes.
On July 2, 2021, our subsidiary filed its
notice of appeal. In addition, plaintiff
filed an appeal challenging the dismissal
of the claim for psychological damages.
As required by local law, our subsidiary
deposited the damages awarded, plus
interest and costs, in total ARS 6,114,428
(approximately $53,544), into a court
escrow account. Our subsidiary
challenged the amount determined by the
court. The Mar del Plata Court of
Appeals granted our subsidiary's
challenge to the escrow amount
determined by the trial court. As a result,
on December 16, 2021, ARS 893,428
(approximately $7,823) was returned to
our subsidiary. If our subsidiary
ultimately prevails on appeal, the
remaining deposited amounts will be
returned to our subsidiary.
Pending claims related to tobacco products generally fall within the following categories:
Smoking and Health Litigation: These cases primarily allege personal injury and are brought by individual plaintiffs or on behalf of a class or purported
class of individual plaintiffs. Plaintiffs' allegations of liability in these cases are based on various theories of recovery, including negligence, gross
negligence, strict liability, fraud, misrepresentation, design defect, failure to warn, breach of express and implied warranties, violations of deceptive trade
practice laws and consumer protection statutes. Plaintiffs in these cases seek various forms of relief, including compensatory and other damages, and
injunctive and equitable relief. Defenses raised in these cases include licit activity, failure to state a claim, lack of defect, lack of proximate cause,
assumption of the risk, contributory negligence, and statute of limitations.
As of March 31, 2022, there were a number of smoking and health cases pending against us, our subsidiaries or indemnitees, as follows:
• 41 cases brought by individual plaintiffs in Argentina (30), Brazil (2), Canada (2), Chile (3), the Philippines (1), Turkey (1) and Scotland (1), as
well as 1 case brought by an individual plaintiff in the United States District Court for the District of Oregon in May 2021 (See information
regarding the provisions of the 2008 Share Distribution Agreement between PMI and Altria that provide for indemnities to PMI for certain
liabilities concerning tobacco products under the caption "Tobacco-Related Litigation" described above), compared with 43 such cases on
March 31, 2021; and
• 9 cases brought on behalf of classes of individual plaintiffs, compared with 9 such cases on March 31, 2021.
The class actions pending in Canada are described above under the caption “Smoking and Health Litigation — Canada.”
Health Care Cost Recovery Litigation: These cases, brought by governmental and non-governmental plaintiffs, seek reimbursement of health care cost
expenditures allegedly caused by tobacco products. Plaintiffs' allegations of liability in these cases are based on various theories of recovery including
unjust enrichment, negligence, negligent design, strict liability, breach of express and implied warranties, violation of a voluntary undertaking or special
duty, fraud, negligent misrepresentation, conspiracy, public nuisance, defective product, failure to warn, sale of cigarettes to minors, and claims under
statutes governing
28
-- 29 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
competition and deceptive trade practices. Plaintiffs in these cases seek various forms of relief including compensatory and other damages, and injunctive
and equitable relief. Defenses raised in these cases include lack of proximate cause, remoteness of injury, failure to state a claim, adequate remedy at law,
“unclean hands” (namely, that plaintiffs cannot obtain equitable relief because they participated in, and benefited from, the sale of cigarettes), and statute of
limitations.
As of March 31, 2022, there were 17 health care cost recovery cases pending against us, our subsidiaries or indemnitees in Brazil (1), Canada (10), Korea
(1) and Nigeria (5), compared with 17 such cases on March 31, 2021.
The health care cost recovery actions pending in Canada are described above under the caption “Health Care Cost Recovery Litigation — Canada.”
In the health care cost recovery case in Brazil, The Attorney General of Brazil v. Souza Cruz Ltda., et al., Federal Trial Court, Porto Alegre, Rio Grande do
Sul, Brazil, filed May 21, 2019, we, our subsidiaries, and other members of the industry are defendants. Plaintiff seeks reimbursement for the cost of
treating alleged smoking-related diseases in certain prior years, payment of anticipated costs of treating future alleged smoking-related diseases, and moral
damages. Defendants filed answers to the complaint in May 2020.
In the first health care cost recovery case in Nigeria, The Attorney General of Lagos State v. British American Tobacco (Nigeria) Limited, et al., High Court
of Lagos State, Lagos, Nigeria, filed March 13, 2008, we and other members of the industry are defendants. Plaintiff seeks reimbursement for the cost of
treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next 20
years, various forms of injunctive relief, plus punitive damages. We are in the process of making challenges to service and the court's jurisdiction.
Currently, the case is stayed in the trial court pending the appeals of certain co-defendants relating to service objections.
In the second health care cost recovery case in Nigeria, The Attorney General of Kano State v. British American Tobacco (Nigeria) Limited, et al., High
Court of Kano State, Kano, Nigeria, filed May 9, 2007, we and other members of the industry are defendants. Plaintiff seeks reimbursement for the cost of
treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next 20
years, various forms of injunctive relief, plus punitive damages. We are in the process of challenging the court's jurisdiction. Currently, the case is stayed in
the trial court pending the appeals of certain co-defendants relating to service objections.
In the third health care cost recovery case in Nigeria, The Attorney General of Gombe State v. British American Tobacco (Nigeria) Limited, et al., High
Court of Gombe State, Gombe, Nigeria, filed October 17, 2008, we and other members of the industry are defendants. Plaintiff seeks reimbursement for the
cost of treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next
20 years, various forms of injunctive relief, plus punitive damages. In February 2011, the court ruled that the plaintiff had not complied with the procedural
steps necessary to serve us. As a result of this ruling, plaintiff must re-serve its claim. We have not yet been re-served.
In the fourth health care cost recovery case in Nigeria, The Attorney General of Oyo State, et al., v. British American Tobacco (Nigeria) Limited, et al.,
High Court of Oyo State, Ibadan, Nigeria, filed May 25, 2007, we and other members of the industry are defendants. Plaintiffs seek reimbursement for the
cost of treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next
20 years, various forms of injunctive relief, plus punitive damages. We challenged service as improper. In June 2010, the court ruled that plaintiffs did not
have leave to serve the writ of summons on the defendants and that they must re-serve the writ. We have not yet been re-served.
In the fifth health care cost recovery case in Nigeria, The Attorney General of Ogun State v. British American Tobacco (Nigeria) Limited, et al., High Court
of Ogun State, Abeokuta, Nigeria, filed February 26, 2008, we and other members of the industry are defendants. Plaintiff seeks reimbursement for the cost
of treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next 20
years, various forms of injunctive relief, plus punitive damages. In May 2010, the trial court rejected our objections to the court's jurisdiction. We have
appealed. Currently, the case is stayed in the trial court pending the appeals of certain co-defendants relating to service objections.
In the health care cost recovery case in Korea, the National Health Insurance Service v. KT&G, et. al., filed April 14, 2014, our subsidiary and other
Korean manufacturers are defendants. Plaintiff alleges that defendants concealed the health hazards of smoking, marketed to youth, added ingredients to
make their products more harmful and addictive, and misled consumers into believing that Lights cigarettes are safer than regular cigarettes. The National
Health Insurance Service seeks to recover
29
-- 30 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
damages allegedly incurred in treating 3,484 patients with small cell lung cancer, squamous cell lung cancer, and squamous cell laryngeal cancer from 2003
to 2012. The trial court dismissed the case in its entirety on November 20, 2020. Plaintiff appealed.
Label-Related Cases: These cases, now brought only by individual plaintiffs, allege that the use of the descriptor “Lights” or other alleged
misrepresentations or omissions of labeling information constitute fraudulent and misleading conduct. Plaintiffs' allegations of liability in these cases are
based on various theories of recovery including misrepresentation, deception, and breach of consumer protection laws. Plaintiffs seek various forms of
relief including restitution, injunctive relief, and compensatory and other damages. Defenses raised include lack of causation, lack of reliance, assumption
of the risk, and statute of limitations.
As of March 31, 2022, there were 5 label-related cases brought by individual plaintiffs in Italy (1) and Chile (4) pending against our subsidiaries, compared
with 5 such cases on March 31, 2021.
Public Civil Actions: Claims have been filed either by an individual, or a public or private entity, seeking to protect collective or individual rights, such as
the right to health, the right to information or the right to safety. Plaintiffs' allegations of liability in these cases are based on various theories of recovery
including product defect, concealment, and misrepresentation. Plaintiffs in these cases seek various forms of relief including injunctive relief such as
banning cigarettes, descriptors, smoking in certain places and advertising, as well as implementing communication campaigns and reimbursement of
medical expenses incurred by public or private institutions.
As of March 31, 2022, there was 1 public civil action pending against our subsidiary in Venezuela (1), compared with 2 such cases on March 31, 2021.
In a public civil action in Venezuela, Federation of Consumers and Users Associations (“FEVACU”), et al. v. National Assembly of Venezuela and the
Venezuelan Ministry of Health, Constitutional Chamber of the Venezuelan Supreme Court, filed April 29, 2008, we were not named as a defendant, but the
plaintiffs published a notice pursuant to court order, notifying all interested parties to appear in the case. In January 2009, our subsidiary appeared in the
case in response to this notice. The plaintiffs purport to represent the right to health of the citizens of Venezuela and claim that the government failed to
protect adequately its citizens' right to health. The claim asks the court to order the government to enact stricter regulations on the manufacture and sale of
tobacco products. In addition, the plaintiffs ask the court to order companies involved in the tobacco industry to allocate a percentage of their “sales or
benefits” to establish a fund to pay for the health care costs of treating smoking-related diseases. In October 2008, the court ruled that plaintiffs have
standing to file the claim and that the claim meets the threshold admissibility requirements. In December 2012, the court admitted our subsidiary and BAT's
subsidiary as interested third parties. In February 2013, our subsidiary answered the complaint.
Reduced-Risk Products
In Colombia, an individual filed a purported class action, Ana Ferrero Rebolledo v. Philip Morris Colombia S.A., et al., in April 2019 against our
subsidiaries with the Civil Court of Bogota related to the marketing of our Platform 1 product. Plaintiff alleged that our subsidiaries advertise the product in
contravention of law and in a manner that misleads consumers by portraying the product in a positive light, and further asserts that the Platform 1 vapor
contains many toxic compounds, creates a high level of dependence, and has damaging second-hand effects. Plaintiff sought injunctive relief and damages
on her behalf and on a behalf of two classes (class 1 - all Platform 1 consumers in Colombia who seek damages for the purchase price of the product and
personal injuries related to the alleged addiction, and class 2 - all residents of the neighborhood where the advertising allegedly took place who seek
damages for exposure to the alleged illegal advertising). Our subsidiaries answered the complaint in January 2020, and in February 2020, plaintiff filed an
amended complaint. The amended complaint modifies the relief sought on behalf of the named plaintiff and on behalf of a single class (all consumers of
Platform 1 products in Colombia who seek damages for the product purchase price and personal injuries related to the use of an allegedly harmful product).
In June 2021, our subsidiaries answered the amended complaint.
30
-- 31 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Other Litigation
The Department of Special Investigations of the government of Thailand ("DSI") conducted an investigation into alleged underpayment by our subsidiary,
Philip Morris (Thailand) Limited ("PM Thailand"), of customs duties and excise taxes relating to imports from the Philippines covering the period 2003-
2007. On January 18, 2016, the Public Prosecutor filed charges against our subsidiary and seven former and current employees in the Bangkok Criminal
Court alleging that PM Thailand and the individual defendants jointly and with the intention to defraud the Thai government, under-declared import prices
of cigarettes to avoid full payment of taxes and duties in connection with import entries of cigarettes from the Philippines during the period of July 2003 to
June 2006. The government is seeking a fine of approximately THB 80.8 billion (approximately $2.4 billion). In May 2017, Thailand enacted a new
customs act. The new act, which took effect in November 2017, substantially limits the amount of fines that Thailand could seek in these proceedings. PM
Thailand believes that its declared import prices are in compliance with the Customs Valuation Agreement of the World Trade Organization and Thai law
and that the allegations of the Public Prosecutor are inconsistent with several decisions already taken by Thai Customs and other Thai governmental
agencies. Trial in the case began in November 2017 and concluded in September 2019. In November 2019, the trial court found our subsidiary guilty of
under-declaration of the prices and imposed a fine of approximately THB 1.2 billion (approximately $35 million). The trial court dismissed all charges
against the individual defendants. In December 2019, as required by the Thai law, our subsidiary paid the fine. This payment is included in other assets on
the condensed consolidated balance sheets and negatively impacted net cash provided by operating activities in the condensed consolidated statements of
cash flows in the period of payment. Our subsidiary filed an appeal of the trial court's decision. In addition, the Public Prosecutor filed an appeal of the trial
court's decision challenging the dismissal of charges against the individual defendants and the amount of the fine imposed. If our subsidiary ultimately
prevails on appeal, then Thailand will be required to return this payment to our subsidiary. The appellate court is scheduled to issue its decision on the
appeals on June 1, 2022.
The DSI also conducted an investigation into alleged underpayment by PM Thailand of customs duties and excise taxes relating to imports from Indonesia
covering the period 2000-2003. On January 26, 2017, the Public Prosecutor filed charges against PM Thailand and its former Thai employee in the
Bangkok Criminal Court alleging that PM Thailand and its former employee jointly and with the intention to defraud the Thai government under-declared
import prices of cigarettes to avoid full payment of taxes and duties in connection with import entries during the period from January 2002 to July 2003.
The government is seeking a fine of approximately THB 19.8 billion (approximately $582 million). In May 2017, Thailand enacted a new customs act. The
new act, which took effect in November 2017, substantially limits the amount of fines that Thailand could seek in these proceedings. PM Thailand believes
that its declared import prices are in compliance with the Customs Valuation Agreement of the World Trade Organization and Thai law, and that the
allegations of the Public Prosecutor are inconsistent with several decisions already taken by Thai Customs and a Thai court. Trial in the case began in
November 2018 and concluded in December 2019. In March 2020, the trial court found our subsidiary guilty of under-declaration of the prices and
imposed a fine of approximately THB 130 million (approximately $4 million). The trial court dismissed all charges against the individual defendant. In
April 2020, as required by Thai law, our subsidiary paid the fine. This payment is included in other assets on the condensed consolidated balance sheets and
negatively impacted net cash provided by operating activities in the condensed consolidated statements of cash flows in the period of payment. Our
subsidiary filed an appeal of the trial court's decision. In addition, the Public Prosecutor filed an appeal of the trial court's decision challenging the dismissal
of charges against the individual defendant and the amount of the fine imposed. If our subsidiary ultimately prevails on appeal, then Thailand will be
required to return this payment to our subsidiary. The appellate court is scheduled to issue its decision on the appeals on August 30, 2022.
The South Korean Board of Audit and Inspection (“BAI”) conducted an audit of certain Korean government agencies and the tobacco industry into whether
inventory movements ahead of the January 1, 2015 increase of cigarette-related taxes by tobacco companies, including Philip Morris Korea Inc. ("PM
Korea"), our South Korean subsidiary, were in compliance with South Korean tax laws. In November 2016, the tax authorities completed their audit and
assessed allegedly underpaid taxes and penalties. In order to avoid nonpayment financial costs, PM Korea paid approximately KRW 272 billion
(approximately $219 million), of which KRW 100 billion (approximately $80 million) was paid in 2016 and KRW 172 billion (approximately $138
million) was paid in the first quarter of 2017. These paid amounts are included in other assets in the condensed consolidated balance sheets and negatively
impacted net cash provided by operating activities in the condensed consolidated statements of cash flows in the period of payment. PM Korea appealed
the assessments. In January 2020, a trial court ruled that PM Korea did not underpay taxes in the amount of approximately KRW 218 billion
(approximately $175 million). The tax authorities appealed this decision to the appellate court. In September 2020, the appellate court upheld the trial
court's decision. The tax authorities have appealed to the Supreme Court of South Korea. In June 2020, another trial court ruled that PM Korea did not
underpay approximately KRW 54 billion (approximately $43 million) of alleged underpayments. The government agencies appealed this decision. In
January 2021, the appellate court upheld the trial court's decision. The government agencies appealed to the Supreme Court of South Korea. If the tax
authorities and government agencies ultimately lose, then they would be required to return the paid amounts to PM Korea.
31
-- 32 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The Saudi Arabia Customs General Authority issued its assessments requiring our distributors to pay additional customs duties in the amount of
approximately 1.5 billion Saudi Riyal, or approximately $396 million, in relation to the fees paid by these distributors under their agreements with our
subsidiary for exclusive rights to distribute our products in Saudi Arabia. In order to challenge these assessments, the distributors posted bank guarantees.
To enable the distributors' challenge, our subsidiary agreed with the banks to bear a portion of the amount the authority may draw on the bank guarantees.
In September and October 2020, respectively, the distributors lost their challenges of the assessments. Both distributors appealed, and in June 2021, the
Customs Appeal Committee in Riyadh notified the distributors of its decisions to largely reject their appeals. On the basis of the above-mentioned
decisions, in June 2021, PMI recorded a pre-tax charge of $246 million in relation to the period of 2014 through 2020 in line with existing and
contemplated arrangements with the distributors. The estimated amounts for 2021 and 2022 are immaterial. In accordance with U.S. GAAP, the charge was
recorded as a reduction in net revenues on the consolidated statements of earnings for the three months and six months ended June 30, 2021. Despite the
unfavorable decisions, our subsidiary believes that customs duties paid in Saudi Arabia were in compliance with the applicable law and the WTO Customs
Valuation Agreement.
A putative shareholder class action lawsuit, In re Philip Morris International Inc. Securities Litigation, is pending in the United States District Court for the
Southern District of New York, purportedly on behalf of purchasers of Philip Morris International Inc. stock between July 26, 2016 and April 18, 2018.
The lawsuit names Philip Morris International Inc. and certain officers and employees as defendants and includes allegations that the defendants made
false and/or misleading statements and/or failed to disclose information about PMI’s business, operations, financial condition, and prospects, related to
product sales of, and alleged irregularities in clinical studies of, PMI’s Platform 1 product. The lawsuit seeks various forms of relief, including damages. In
November 2018, the court consolidated three putative shareholder class action lawsuits with similar allegations previously filed in the Southern District of
New York (namely, City of Westland Police and Fire Retirement System v. Philip Morris International Inc., et al., Greater Pennsylvania Carpenters’
Pension Fund v. Philip Morris International Inc., et al., and Gilchrist v. Philip Morris International Inc., et al.) into these proceedings. A putative
shareholder class action lawsuit, Rubenstahl v. Philip Morris International Inc., et al., that had been previously filed in December 2017 in the United States
District Court for the District of New Jersey, was voluntarily dismissed by the plaintiff due to similar allegations in these proceedings. On February 4,
2020, the court granted defendants’ motion in its entirety, dismissing all but one of the plaintiffs’ claims with prejudice. The court noted that one of
plaintiffs’ claims (allegations relating to four non-clinical studies of PMI’s Platform 1 product) did not state a viable claim but allowed plaintiffs to replead
that claim by March 3, 2020. On February 18, 2020, the plaintiffs filed a motion for reconsideration of the court's February 4th decision; this motion was
denied on September 21, 2020. On September 28, 2020, plaintiffs filed an amended complaint seeking to replead allegations relating to four non-clinical
studies of PMI's Platform 1 product. On September 10, 2021, the court granted defendant's motion to dismiss plaintiffs' amended complaint in its entirety.
Plaintiffs have filed an appeal with the U.S. Court of Appeal for the Second Circuit. We believe that this lawsuit is without merit and will continue to
defend it vigorously.
In April 2020, affiliates of British American Tobacco plc (“BAT”) commenced patent infringement proceedings, RAI Strategic Holdings, Inc., et al. v.
Altria Client Services LLC, et al., in the federal court in the Eastern District of Virginia, where PMI's subsidiary, Philip Morris Products S.A., as well as
Altria Group, Inc.'s subsidiaries, are defendants. Plaintiffs seek damages and injunctive relief against the commercialization of the Platform 1 blade
products in the United States. In April 2020, BAT affiliates filed a complaint against PMI, Philip Morris Products S.A., Altria Group, Inc., and its
subsidiaries before the International Trade Commission ("ITC"). Plaintiffs seek an order to prevent the importation of Platform 1 products into the United
States. The ITC evidentiary hearing closed on February 1, 2021. On May 14, 2021, the administrative law judge issued an Initial and Recommended
Determination ("ID/RD") finding that the Platform 1 blade products infringe two of the three patents asserted by Plaintiffs, recommending that the ITC
issue a Limited Exclusion order against infringing products, and recommending against a cease-and-desist, as well as recommending against a bond
pending Presidential review of the ITC's Final Determination ("FD"). Defendants and Plaintiffs filed separate Petitions for Review with the ITC of the ID
on May 28, 2021; on July 27, 2021, the ITC granted each of the petitions in part, deciding to review certain issues in the ID. Plaintiffs and Defendants also
submitted brief statements of the public interest factors in issue to the ITC on June 15, 2021. On September 29, 2021, the ITC issued its FD finding a
violation of section 337 of the U.S. Tariff Act and issued (a) a limited exclusion order against Philip Morris Products S.A., prohibiting, inter alia, the
importation of Platform 1 product and infringing components; and (b) a cease-and-desist order against Altria Client Services, LLC and its affiliate
prohibiting, inter alia, sales of imported Platform 1 products. The ITC predicated the orders on its finding that Platform 1 blade products infringe two
patents owned by a BAT affiliate. The ITC also found that Platform 1 blade products do not infringe a third patent owned by a BAT affiliate. The ITC
further held that there were insufficient concerns over public interest to prevent the issuance of remedial orders. Following the Presidential Review period,
the orders became effective and Defendants filed a petition for review of the FD with the U.S. Court of Appeals for the Federal Circuit. Defendants also
filed motions in the ITC and Federal Circuit for a stay of the orders
32
-- 33 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
pending disposition of the appeal; the ITC denied the motion on January 20, 2022 and the Federal Circuit denied the motion on January 25, 2022. We
estimate that an adverse ruling is probable due to our inability to import the products and components impacted by the ITC's FD with immaterial financial
impact. In the Eastern District of Virginia case, the defendants also counterclaimed that BAT infringed their patents relating to certain e-vapor products,
seeking damages for, and injunctive relief against, the commercialization of these products by BAT; defendants' claims against BAT are set for trial
beginning the week of June 6, 2022. Upon petition of Philip Morris Products S.A., the Patent Trial and Appeal Board ("PTAB") of the United States Patent
and Trademark Office has instituted review of certain claims pertaining to four of the six patents asserted by BAT affiliates in both proceedings. On January
11, 2022, PTAB issued its final decision on one of the two patents underlying the ITC's FD, invalidating all challenged claims of BAT's patent. On March
30, 2022, PTAB issued its final decision on the second of the two patents underlying the ITC's FD, finding the challenged claims patentable. The parties
may appeal PTAB results to the U.S. Court of Appeals for the Federal Circuit.
In April 2020, BAT’s affiliate commenced patent infringement proceedings, Nicoventures Trading Limited v. PM GmbH, et al., against PMI’s German
subsidiary, Philip Morris GmbH, and Philip Morris Products S.A., in the Regional Court in Munich, Germany. Plaintiffs seek damages and injunctive relief
against the commercialization of the Platform 1 blade products in Germany. In June 2021, the court stayed the proceeding in respect of one of the two
patents asserted by BAT’s Affiliate.
In September 2020, BAT’s affiliates commenced patent infringement and unfair competition proceedings, RAI Strategic Holdings, Inc., et al. v. Philip
Morris Products S.A., et al., against Philip Morris Products S.A. and PMI’s Italian subsidiaries, Philip Morris Manufacturing & Technology Bologna S.p.A.
and Philip Morris Italia S.r.l., in the Court of Milan, Italy. Plaintiffs seek damages, as well as injunctive relief against the manufacture in Italy of the
Platform 1 blade heated tobacco units allegedly infringing the asserted patents and the commercialization of the Platform 1 blade products in Italy. As part
of this proceeding, in October 2020, BAT’s affiliates filed a request based on one of the two asserted patents seeking preliminary injunctive relief against
the manufacture and commercialization of the Platform 1 blade products in Italy.
In October 2020, BAT’s affiliates commenced patent infringement proceedings, RAI Strategic Holdings, Inc., et al. v. Philip Morris Japan, Limited, et al.,
against PMI’s Japanese subsidiary, Philip Morris Japan Limited, and a third-party distributor in the Tokyo District Court. Plaintiffs seek damages and
injunctive relief against the commercialization of the Platform 1 blade products in Japan.
In November 2020, BAT’s affiliates commenced patent infringement proceedings, RAI Strategic Holdings, Inc., et al. v. Philip Morris Romania SRL, et al.,
against PMI’s Romanian subsidiaries, Philip Morris Romania S.R.L. and Philip Morris Trading S.R.L., and a third-party distributor in the Court of Law of
Bucharest, Civil Registry. Plaintiffs seek damages and preliminary and permanent injunctive relief against the manufacture and commercialization of the
Platform 1 blade products in Romania. In February 2021, the court dismissed plaintiffs’ request for a preliminary injunction. In April 2021, the appellate
court denied plaintiffs' appeal, confirming the dismissal of plaintiffs' request for preliminary injunction. Plaintiffs' proceeding requesting damages and a
permanent injunction remains pending before the Court of Law of Bucharest, Civil Registry. In an October 14, 2021 hearing, the court stayed the
proceeding.
In March 2021, BAT’s affiliates commenced patent infringement proceedings, RAI Strategic Holdings, Inc., et al. v. Philip Morris Korea, Co., Ltd., against
PM Korea in the Seoul Central District Court. Plaintiffs seek damages and injunctive relief against the commercialization of the Platform 1 blade heated
tobacco units in South Korea.
In July, 2021, Philip Morris Products, S.A. filed a claim at the High Court of Justice of England and Wales against BAT affiliates Nicoventures Trading
Limited and British American Tobacco (Investments) Limited seeking revocation of the UK parts of two BAT European patents. In January 2022, the court
ordered that the trial of the action will be in September 2022, and the trial has subsequently been set to start on September 20, 2022. In March, the BAT
affiliates stated that they would consent to revocation of one of the patents and filed an application with the court to bring a counterclaim against Philip
Morris Products S.A. and Philip Morris Limited seeking from the court a declaration that the remaining BAT affiliate patent is infringed by Platform 1
induction products, as well as damages and injunctive relief against the commercialization of the Platform 1 induction products in the U.K.
Other patent challenges by both parties are pending in various jurisdictions.
We believe that the foregoing proceedings by the affiliates of BAT are without merit and will defend them vigorously.
We are also involved in additional litigation arising in the ordinary course of our business. While the outcomes of these proceedings are uncertain,
management does not expect that the ultimate outcomes of other litigation, including any reasonably possible losses in excess of current accruals, will have
a material adverse effect on our consolidated results of operations, cash flows or financial position.
33
-- 34 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Third-Party Guarantees
On October 17, 2020, Medicago Inc., an equity method investee of Philip Morris Investments B.V. (“PMIBV”), a PMI subsidiary, entered into a
contribution agreement with the Canadian government (the “Contribution Agreement”) whereby the Canadian government agreed to contribute up to CAD
173 million (approximately $131 million on the date of signing) to Medicago Inc., to support its on-going COVID-19 vaccine development and clinical
trials, and for the construction of its Quebec City manufacturing facility (the “Project”). On March 31, 2022, the Contribution Agreement was amended (the
“Contribution Agreement Amendment”) to reflect an additional contribution from the Canadian government up to CAD 27 million (approximately
$22 million on the date of signing) to Medicago Inc. for the construction of its Quebec City manufacturing facility. PMIBV and the majority shareholder of
Medicago Inc. are also parties to the Contribution Agreement and the Contribution Agreement Amendment as guarantors of Medicago Inc.’s obligations
thereunder on a joint and several basis (“Co-Guarantors”). The Co-Guarantors agreed to repay amounts contributed by the Canadian government plus
interest, if Medicago Inc. fails to do so, and could be responsible for the costs of other Medicago’s obligations (such as the achievement of specific
milestones of the Project). The maximum amount of these obligations is currently non-estimable. As of March 31, 2022, PMI has determined that these
guarantees did not have a material impact on its condensed consolidated financial statements.
In connection with the Contribution Agreement, PMIBV and the majority shareholder of Medicago Inc. entered into a guarantors’ agreement that
apportions Co-Guarantors’ obligations and limits those of PMIBV to its share of holdings in Medicago Inc. During 2022, Medicago Inc. initiated additional
rounds of equity funding in which PMIBV did not participate. As a result, PMIBV’s share of holdings in Medicago Inc. was reduced from approximately
23% as of December 31, 2021 to approximately 21% as of March 31, 2022. The guarantees are in effect through March 31, 2026.
Note 9. Income Taxes:
Income tax provisions for jurisdictions outside the United States of America, as well as state and local income tax provisions, were determined on a
separate company basis, and the related assets and liabilities were recorded in PMI’s condensed consolidated balance sheets.
PMI’s effective tax rates for the three months ended March 31, 2022 and 2021 were 19.7% and 21.5%, respectively. The effective tax rate for the three
months ended March 31, 2022, was favorably impacted by changes in earnings mix by taxing jurisdiction, as well as a decrease in deferred tax liabilities
related to the fair value adjustment of equity securities held by PMI ($13 million). For further details, see Note 12. Related Parties - Equity Investments and
Other. The effective tax rate for the three months ended March 31, 2021, was favorably impacted by the corporate income tax rate reduction in Indonesia
(enacted in the second quarter of 2020) and the Philippines (enacted in the first quarter of 2021), as well as changes in earnings mix by taxing jurisdiction.
PMI estimates that its full-year 2022 effective tax rate will be 21% to 22%, excluding discrete tax events. Changes in currency exchange rates, earnings
mix by taxing jurisdiction or future regulatory developments may have an impact on the effective tax rates, which PMI monitors each quarter. Significant
judgment is required in determining income tax provisions and in evaluating tax positions.
PMI is regularly examined by tax authorities around the world and is currently under examination in a number of jurisdictions. The U.S. federal statute of
limitations remains open for the years 2017 and onward. Foreign and U.S. state jurisdictions have statutes of limitations generally ranging from 3 to 5
years. In October 2021, a subsidiary of PMI in Indonesia, PT Hanjaya Mandala Sampoerna Tbk ("HMS"), received a tax assessment in the amount of
3.8 trillion Indonesian rupiah (approximately $260 million) primarily relating to corporate income taxes on domestic and other intercompany transactions
for the years 2017 to 2019. HMS paid the assessment in the fourth quarter of 2021 in order to avoid potential penalties and filed an objection letter with the
tax office in January 2022. The amount paid was included in other assets in PMI’s condensed consolidated balance sheets at March 31, 2022 and
December 31, 2021, and negatively impacted net cash provided by operating activities in the consolidated statements of cash flows in the period of
payment.
It is reasonably possible that within the next 12 months certain tax examinations will close, which could result in a change in unrecognized tax benefits
along with related interest and penalties. An estimate of any possible change cannot be made at this time.
34
-- 35 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note 10. Indebtedness:
Short-term Borrowings:
PMI's short-term borrowings, consisting of commercial paper and bank loans to certain PMI subsidiaries at March 31, 2022, and bank loans to certain PMI
subsidiaries at December 31, 2021, had a carrying value of $2,441 million and $225 million, respectively. The fair values of PMI’s short-term borrowings,
based on current market interest rates, approximate carrying value.
Long-term Debt:
At March 31, 2022 and December 31, 2021, PMI’s long-term debt consisted of the following:
(in millions) March 31, 2022 December 31, 2021
U.S. dollar notes, 0.875% to 6.375% (average interest rate 3.261%), due through 2044 $ 18,867 $ 19,397
Foreign currency obligations:
Euro notes, 0.125% to 3.125% (average interest rate 1.995%), due through 2039 7,561 7,687
Swiss franc notes, 1.625%, due 2024 270 273
Other (average interest rate 3.238%), due through 2029 218 224
Carrying value of long-term debt 26,916 27,581
Less current portion of long-term debt 2,897 2,798
$ 24,019 $ 24,783
Includes mortgage debt in Switzerland as well as $68 million and $71 million in finance leases at March 31, 2022 and December 31, 2021, respectively.
(a)
(a)
35
-- 36 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The fair value of PMI’s outstanding long-term debt, which is utilized solely for disclosure purposes, is determined using quotes and market interest rates
currently available to PMI for issuances of debt with similar terms and remaining maturities. At March 31, 2022, the fair value of PMI's outstanding long-
term debt, excluding the aforementioned finance leases, was as follows:
(in millions) March 31, 2022
Level 1 $ 26,610
Level 2 161
For a description of the fair value hierarchy and the three levels of inputs used to measure fair values, see Item 8, Note 2. Summary of Significant
Accounting Policies of PMI's Annual Report on Form 10-K for the year ended December 31, 2021.
Credit Facilities:
At March 31, 2022, PMI's total committed credit facilities were as follows:
(in billions)
Type
Committed
Credit
Facilities
364-day revolving credit, expiring January 31, 2023 $ 1.8
Multi-year revolving credit, expiring February 10, 2026 2.0
Multi-year revolving credit, expiring September 29, 2026 2.5
Total facilities $ 6.3
On January 28, 2022, PMI entered into an agreement, effective February 10, 2022, to amend and extend the term of its $2.0 billion multi-year revolving credit facility, for
an additional year covering the period February 11, 2026 to February 10, 2027, in the amount of $1.9 billion.
Includes pricing adjustments that may result in the reduction or increase in both the interest rate and commitment fee under the credit agreement if PMI achieves, or fails
to achieve, certain specified targets.
At March 31, 2022, there were no borrowings under these committed credit facilities, and the entire committed amounts were available for borrowing.
Note 11. Accumulated Other Comprehensive Losses:
PMI’s accumulated other comprehensive losses, net of taxes, consisted of the following:
(Losses) Earnings At At At
(in millions) March 31, 2022 December 31, 2021 March 31, 2021
Currency translation adjustments $ (7,039) $ (6,701) $ (6,586)
Pension and other benefits (2,826) (2,880) (4,172)
Derivatives accounted for as hedges 105 4 12
Total accumulated other comprehensive losses $ (9,760) $ (9,577) $ (10,746)
(1)
(2)
(1)
(2)
36
-- 37 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Reclassifications from Other Comprehensive Earnings
The movements in accumulated other comprehensive losses and the related tax impact, for each of the components above, that are due to current period
activity and reclassifications to the income statement, are shown on the condensed consolidated statements of comprehensive earnings for the three months
ended March 31, 2022 and 2021. For additional information, see Note 3. Benefit Plans for disclosures related to PMI's pension and other benefits, Note 5.
Financial Instruments for disclosures related to derivative financial instruments and Note 17. Acquisitions.
Note 12. Related Parties - Equity Investments and Other:
Equity Method Investments:
At March 31, 2022 and December 31, 2021, PMI had total equity method investments of $844 million and $879 million, respectively. Equity method
investments are initially recorded at cost. Under the equity method of accounting, the investment is adjusted for PMI's proportionate share of earnings or
losses, dividends, capital contributions, changes in ownership interests and movements in currency translation adjustments. The carrying value of our
equity method investments at March 31, 2022 and December 31, 2021, exceeded our share of the investees' book value by $724 million and $764 million,
respectively. The difference between the investment carrying value and the amount of underlying equity in net assets, excluding $684 million and $728
million attributable to goodwill as of March 31, 2022 and December 31, 2021, respectively, which consists primarily of definite-lived intangible assets is
being amortized on a straight-line basis. At March 31, 2022 and December 31, 2021, PMI received year-to-date dividends from equity method investees of
$8 million and $176 million, respectively.
PMI holds a 23% equity interest in Megapolis Distribution BV, the holding company of CJSC TK Megapolis, PMI's distributor in Russia (Eastern Europe
segment).
PMI holds a 49% equity interest in United Arab Emirates-based Emirati Investors-TA (FZC) (“EITA”). PMI holds an approximate 25% economic interest
in Société des Tabacs Algéro-Emiratie (“STAEM”), an Algerian joint venture that is 51% owned by EITA and 49% by the Algerian state-owned enterprise
Management et Développement des Actifs et des Ressources Holding ("MADAR Holding"), which manufactures and distributes under license some of
PMI’s brands (Middle East & Africa segment).
The initial investments in Megapolis Distribution BV and EITA were recorded at cost and are included in equity investments on the condensed
consolidated balance sheets.
Equity securities:
Following the deconsolidation of RBH on March 22, 2019, PMI recorded the continuing investment in RBH, PMI's wholly owned subsidiary in Canada, at
fair value of $3,280 million at the date of deconsolidation, within equity investments. For further details, see Item 8, Note 20. Deconsolidation of RBH, in
PMI's Annual Report on Form 10-K for the year ended December 31, 2021. Transactions between PMI and RBH are considered to be related party
transactions from the date of deconsolidation and are included in the tables below.
The fair value of PMI’s other equity securities, which have been classified within Level 1, was $221 million at March 31, 2022. Unrealized pre-tax loss of
$(60) million ($(47) million net of tax) on these equity securities was recorded in the condensed consolidated statement of earnings for the three months
ended March 31, 2022.
Other related parties:
United Arab Emirates-based Trans-Emirates Trading and Investments (FZC) ("TTI") holds a 33% non-controlling interest in Philip Morris Misr LLC
("PMM"), an entity incorporated in Egypt which is consolidated in PMI’s financial statements in the Middle East & Africa segment. PMM sells, under
license, PMI brands in Egypt through an exclusive distribution agreement with a local entity that is also controlled by TTI.
37
-- 38 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Godfrey Phillips India Ltd ("GPI") is one of the non-controlling interest holders in IPM India, which is a 56.3% owned PMI consolidated subsidiary in the
South & Southeast Asia segment. GPI also acts as contract manufacturer and distributor for IPM India. Amounts in the tables below include transactions
between these related parties.
Financial activity with the above related parties:
PMI’s net revenues and expenses with the above related parties were as follows:
For the Three Months Ended March
31,
(in millions) 2022 2021
Net revenues:
Megapolis Group $ 387 $ 483
Other 291 280
Net revenues $ 678 $ 763
Expenses:
Other $ 12 $ 17
Expenses $ 12 $ 17
Net revenues exclude excise taxes and VAT billed to customers.
PMI’s balance sheet activity with the above related parties was as follows:
(in millions) At March 31, 2022 At December 31, 2021
Receivables:
Megapolis Group $ 455 $ 319
Other 236 199
Receivables $ 691 $ 518
Payables:
Other $ 24 $ 25
Payables $ 24 $ 25
The activities with the above related parties are in the ordinary course of business, and are primarily for distribution, service fees, contract manufacturing
and license agreements. PMI eliminated its respective share of all significant intercompany transactions with the equity method investees.
Note 13. Sale of Accounts Receivable:
To mitigate risk and enhance cash and liquidity management, PMI sells trade receivables to unaffiliated financial institutions. These arrangements allow
PMI to sell, on an ongoing basis, certain trade receivables without recourse. The trade receivables sold are generally short-term in nature and are removed
from the condensed consolidated balance sheets. PMI sells trade receivables under two types of arrangements, servicing and non-servicing. For servicing
arrangements, PMI continues to service the sold trade receivables on an administrative basis and does not act on behalf of the unaffiliated financial
institutions. When applicable, a servicing liability is recorded for the estimated fair value of the servicing. The amounts associated with the servicing
liability were not material as of March 31, 2022 and March 31, 2021. Under the non-servicing arrangements, PMI does not provide any administrative
support or servicing after the trade receivables have been sold to the unaffiliated financial institutions.
Cumulative trade receivables sold, including excise taxes, for the three months ended March 31, 2022 and 2021, were $2.8 billion and $2.5 billion,
respectively. PMI’s operating cash flows were positively impacted by the amount of the trade
(a)
(a)
38
-- 39 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
receivables sold and derecognized from the condensed consolidated balance sheets, which remained outstanding with the unaffiliated financial institutions.
The trade receivables sold that remained outstanding under these arrangements as of March 31, 2022 and March 31, 2021, were $598 million, and $625
million, respectively. The net proceeds received are included in cash provided by operating activities in the condensed consolidated statements of cash
flows. The difference between the carrying amount of the trade receivables sold and the sum of the cash received is recorded as a loss on sale of trade
receivables within marketing, administration and research costs in the condensed consolidated statements of earnings. For the three months ended March
31, 2022 and 2021, the loss on sale of trade receivables was immaterial.
Note 14. Product Warranty:
PMI's heat-not-burn devices and e-vapor products are subject to standard product warranties generally for a period of 12 months from the date of purchase
or such other periods as required by law. PMI generally provides in cost of sales for the estimated cost of warranty in the period the related revenue is
recognized. PMI assesses the adequacy of its accrued product warranties and adjusts the amounts as necessary based on actual experience and changes in
future estimates. Factors that affect product warranties may vary across markets but typically include device version mix, product failure rates, logistics and
service delivery costs, and warranty policies. PMI accounts for its product warranties within other accrued liabilities. At March 31, 2022 and December 31,
2021, these amounts were as follows:
(in millions)
As of and For the Three
Months Ended March 31,
2022
As of and For the Year
Ended December 31,
2021
Balance at beginning of period $ 113 $ 137
Changes due to:
Warranties issued 46 154
Settlements (26) (177)
Currency/Other (3) (1)
Balance at end of period $ 130 $ 113
Note 15. Leases:
The components of PMI’s lease cost were as follows for the three months ended March 31, 2022 and 2021:
For the Three Months Ended March
31,
(in millions) 2022 2021
Operating lease cost $ 62 $ 60
Finance lease cost:
Amortization of right-of-use assets 16 8
Interest on lease liabilities — —
Short-term lease cost 14 10
Variable lease cost 6 7
Total lease cost $ 98 $ 85
Note 16. Asset Impairment and Exit Costs:
For the three months ended March 31, 2022, PMI did not record any pre-tax charges for asset impairment and exit costs. For the three months ended March
31, 2021, PMI recorded total pre-tax asset impairment and exit costs of $48 million. These pre-tax charges for the three months ended March 31, 2021 were
included in marketing, administration and research costs in the condensed consolidated statements of earnings.
39
-- 40 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
South Korea
In the first quarter of 2021, PM Korea commenced the implementation of a new business operating model, which required the restructuring of its current
distribution agreements. As a result, PMI recorded exit costs of $26 million in the three months ended March 31, 2021, related to contract terminations and
restructuring with certain distributors.
Organizational Design Optimization
As part of PMI’s transformation to a smoke-free future, PMI sought to optimize its organizational design, which included the elimination, relocation and
outsourcing of certain operations center and centralized activities. In January 2020, PMI commenced a multi-phase restructuring project in Switzerland.
PMI initiated the employee consultation procedures, as required under Swiss law, for the impacted employees. The consultation procedures for the first two
phases were completed in 2020 with the final phases initiated and completed in 2021. Additionally, since the commencement of this multi-phase
restructuring project in 2020, PMI launched a voluntary separation program in Switzerland for certain eligible employees and announced the outsourcing of
certain activities in Argentina, Indonesia, Poland and the United States. This multi-phase restructuring project was completed in the fourth quarter of 2021.
For the three months ended March 31, 2021, PMI recorded pre-tax charges of $22 million, related to the organizational design optimization. Since
inception of this multi-phase restructuring project in January 2020 through December 31, 2021, approximately 1,020 positions in total were impacted,
resulting in cumulative pre-tax charges of $308 million related to the organizational design optimization program. Of this cumulative pre-tax amount, $300
million related to separation program charges and $8 million related to asset impairment charges.
Asset Impairment and Exit Costs by Segment
PMI recorded the following pre-tax asset impairment and exit costs by segment:
(in millions) For the Three Months Ended March
31,
2021
Separation programs:
European Union $ 9
Eastern Europe 2
Middle East & Africa 2
South & Southeast Asia 3
East Asia & Australia 5
Americas 1
Total separation programs 22
Contract termination charges:
East Asia & Australia 26
Total contract termination charges 26
Asset impairment and exit costs $ 48
Organizational design optimization pre-tax charges in 2021 were allocated across all geographical segments.
(1)
(1)
40
-- 41 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Movement in Exit Cost Liabilities
The movement in exit cost liabilities for the three months ended March 31, 2022 was as follows:
(in millions)
Liability balance, January 1, 2022 $ 142
Charges, net —
Cash spent (28)
Currency/other (1)
Liability balance, March 31, 2022 $ 113
Future cash payments for exit costs incurred to date are anticipated to be substantially paid by the end of 2023, with approximately $72 million expected to
be paid in the remainder of 2022.
Note 17. Acquisitions:
Purchase of Noncontrolling Interests
Turkey – In the first quarter of 2022, PMI acquired the remaining 25% stake of its holding in Philip Morris Tütün Mamulleri Sanayi ve Ticaret A.Ş.
(formerly Philsa Philip Morris Sabancı Sigara ve Tütüncülük Sanayi ve Ticaret A.Ş.) and 24.75% stake in Philip Morris Pazarlama ve Satış A.Ş. (formerly
Philip Morris SA, Philip Morris Sabancı Pazarlama ve Satış A.Ş.) from its Turkish partners, Sabanci Holding for a total acquisition price including
transaction costs and remaining dividend entitlements of approximately $223 million. As a result of this acquisition, PMI now owns 100% of these Turkish
subsidiaries. The purchase of the remaining stakes in these holdings resulted in a decrease to PMI's additional paid-in capital of $30 million and an increase
to accumulated other comprehensive losses of $171 million primarily following the reclassification of accumulated currency translation losses from
noncontrolling interests to PMI’s accumulated other comprehensive losses during the first quarter of 2022.
Business Combinations
AG Snus - On May 6, 2021, PMI acquired 100% of AG Snus Aktieselskab ("AG Snus"), a company based in Denmark, and its Swedish subsidiary Tobacco
House of Sweden AB fully owned by AG Snus, which operates in the oral tobacco (i.e. snus) and modern oral (i.e. nicotine pouches) product categories.
The purchase price was $28 million in cash, net of cash acquired, with additional contingent payments of up to $10 million, primarily relating to product
development and performance targets over a less than two-year period. The operating results of AG Snus are included in the European Union segment, and
were not material.
Fertin Pharma – On September 15, 2021, PMI acquired 100% of Fertin Pharma A/S (“Fertin Pharma”), a company based in Denmark. Fertin Pharma is a
developer and manufacturer of pharmaceutical and well-being products based on oral and intra-oral delivery systems. The acquisition was funded with
existing cash. The total consideration of $821 million (DKK 5.2 billion) included cash of $580 million and the payment of $241 million related to the
settlement of Fertin Pharma’s indebtedness. The purchase price of $821 million was preliminarily allocated to cash ($24 million), current assets including
receivables and inventories ($69 million), non-current assets including property, plant and equipment ($228 million), goodwill ($378 million), and other
intangible assets ($245 million, which primarily consisted of customer relationships, developed technology, and in process research and development
("IPR&D")), partially offset by current liabilities ($44 million, which primarily consisted of accrued liabilities and accounts payable) and non-current
liabilities ($79 million, primarily deferred income tax). Goodwill is primarily attributable to future growth opportunities provided by acquired R&D
capabilities and any intangibles that did not qualify for separate recognition. The amortizable intangible assets are being amortized over their estimated
useful lives of 8 to 19 years. During the first quarter of 2022, PMI did not record any measurement period adjustments to the preliminary purchase price
allocation. The purchase price allocation is preliminary and continues to be subject to refinement. PMI is evaluating the deductibility of goodwill for
income tax purposes.
41
-- 42 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Vectura – During the third quarter and up to September 15, 2021, PMI acquired a controlling interest of 74.77% of the total issued shares in Vectura Group
plc (“Vectura”), an inhaled therapeutics company based in the United Kingdom. The shares were acquired through a series of open market purchases and
acceptances of the tender offer at a price of 165 pence per share. As a result of additional acceptances of the offer and the exercise of the right to acquire
compulsorily the Vectura shares, in accordance with the applicable English law, PMI completed the acquisition of 100% of Vectura in the fourth quarter of
2021. The acquisition was funded with existing cash from a designated account operated solely for the purpose of funding this acquisition.
The total purchase price of $1,384 million (GBP 1.0 billion) for 100% of the Vectura shares was preliminarily allocated to cash ($136 million), current
assets including receivables and inventories ($89 million), non-current assets including property, plant and equipment ($67 million), goodwill ($590
million), and other intangible assets ($719 million, which primarily consisted of developed technology, and IPR&D), partially offset by current liabilities
($100 million, primarily accrued liabilities), and non-current liabilities ($117 million, primarily deferred income tax). Goodwill is primarily attributable to
future growth opportunities provided by acquired R&D capabilities and any intangibles that did not qualify for separate recognition. The amortizable
intangible assets are being amortized over their estimated useful lives of 3 to 15 years. During the first quarter of 2022, PMI did not record any
measurement period adjustments to the preliminary purchase price allocation. The purchase price allocation is preliminary and continues to be subject to
refinement. PMI is evaluating the deductibility of goodwill for income tax purposes.
Pro forma results of operations for the above business combinations have not been presented as the aggregate impact is not material to PMI's consolidated
statements of earnings.
Asset Acquisition
On August 9, 2021, PMI acquired 100% of OtiTopic, Inc., a U.S. respiratory drug development company with a late-stage dry powder inhalation aspirin
treatment for acute myocardial infarction. The transaction price was $38 million in cash, plus transaction costs, with additional contingent payment of $13
million, primarily related to certain key milestones that PMI deemed probable. Additionally, PMI may owe up to $25 million in future additional contingent
payments dependent upon the achievement of certain milestones. PMI accounted for this transaction as an asset acquisition since the IPR&D of the dry
powder inhalation aspirin treatment represented substantially all of the fair value of the gross assets acquired. At the date of acquisition, PMI determined
that the acquired IPR&D had no alternative future use. As a result, PMI recorded a charge of $51 million to research and development costs within
marketing, administration and research costs in the third quarter of 2021.
As previously discussed in Note 1. Background and Basis of Presentation and Note 7. Segment Reporting, on March 31, 2022, PMI launched a new
Wellness and Healthcare business, Vectura Fertin Pharma, which consolidates Fertin Pharma, Vectura and OtiTopic, Inc. This business is considered one
operating segment with its operating results included in the Other category.
42
-- 43 of 139 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note 18. War in Ukraine:
In February 2022, the Russian Federation launched a military action against Ukraine. Since the onset of the war in Ukraine, PMI's main priority has been
the safety and security of its more than 1,300 employees and their families in the country.
Ukraine
PMI temporarily suspended its operations in Ukraine, including the closing of its factory in Kharkiv at the end of February 2022. While the effects of the
war are unpredictable and could trigger impairment reviews for long-lived assets, as of March 31, 2022, PMI is unable to estimate the information required
to perform impairment analyses (i.e., forecast of revenues, manufacturing and commercial plans). PMI is not aware of any major damage to its production
facilities, inventories or other assets in Ukraine. As a result, PMI has not recorded an impairment of long-lived assets. As of March 31, 2022, PMI’s
Ukrainian operations had approximately $0.4 billion in total assets, excluding intercompany balances. These total assets included $105 million, $192
million and $44 million in receivables, inventories and property, plant and equipment, respectively.
As of March 31, 2022, PMI recorded in its condensed consolidated statements of earnings a pre-tax charge related to circumstances driven by the conflict
of $27 million, primarily due to an inventory write down, additional allowance for receivables and the cost of PMI’s humanitarian efforts, which includes
salary continuation for its employees.
Russia
PMI has suspended its planned investments in the Russian Federation including all new product launches and commercial, innovation, and manufacturing
investments. PMI has also initiated plans to scale down its manufacturing operations in Russia amid ongoing supply chain disruptions and the evolving
regulatory environment and is working on options to exit the Russian market in an orderly manner. As a result of PMI continuing operations within Russia
as of March 31, 2022, it has not recorded an impairment of long-lived and other assets. PMI’s Russian operations as of March 31, 2022 had approximately
$1.4 billion in total assets, excluding intercompany balances. These total assets included $464 million, $487 million and $357 million in receivables,
inventories and property, plant and equipment, respectively.
As of March 31, 2022, PMI recorded in its condensed consolidated statements of earnings a pre-tax charge related to circumstances driven by the conflict
of $15 million, which was primarily due to an inventory write down related to the commercial decisions noted above.
The pre-tax charges, for both PMI’s Ukrainian and Russian affiliates, of $26 million and $16 million were recorded in cost of sales and marketing,
administration and research costs, respectively. PMI will continue to monitor the situation as it evolves and will determine if further charges are needed.
43
-- 44 of 139 --
Table of Contents
Item 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Description of Our Company
We are a leading international tobacco company working to deliver a smoke-free future and evolving our portfolio for the long-term to include products
outside of the tobacco and nicotine sector. Our current product portfolio primarily consists of cigarettes and reduced-risk products, including heat-not-burn,
vapor and oral nicotine products, which are sold in markets outside the United States. Since 2008, we have invested more than $9 billion to develop,
scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of
completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical
systems toxicology, clinical and behavioral research, as well as post-market studies. The U.S. Food and Drug Administration ("FDA") has authorized the
marketing of versions of our IQOS Platform 1 devices and consumables as Modified Risk Tobacco Products (MRTPs), finding that exposure modification
orders for these products are appropriate to promote the public health. We describe the MRTP orders in more detail in the "Business Environment" section
of this Item 2. With a strong foundation and significant expertise in life sciences, in February 2021, we announced our ambition to expand into wellness
and healthcare areas and deliver innovative products and solutions that aim to address unmet consumer and patient needs.
We currently manage our business in six geographical segments and an Other category:
• European Union ("EU");
• Eastern Europe ("EE");
• Middle East & Africa ("ME&A"), which includes our international duty free business;
• South & Southeast Asia ("S&SA");
• East Asia & Australia ("EA&A");
• Americas ("AMCS"); and
• Other, which includes the operating results of our new Wellness and Healthcare business. In the third quarter of 2021, we acquired Fertin Pharma
A/S, Vectura Group plc. (also known as Vectura Group Ltd.) and OtiTopic, Inc. On March 31, 2022, we launched a new Wellness and Healthcare
business consolidating these entities, Vectura Fertin Pharma. The operating results of this new business is reported in this Other category. For
further details, see Note 7. Segment Reporting and Note 17. Acquisitions.
Our cigarettes are sold in approximately 180 markets, and in many of these markets they hold the number one or number two market share position. We
have a wide range of premium, mid-price and low-price brands. Our portfolio comprises both international and local brands.
In addition to the manufacture and sale of cigarettes, we are engaged in the development and commercialization of reduced-risk products ("RRPs"). RRPs
is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these
products versus continuing smoking. IQOS is the leading brand in our smoke-free product portfolio. As of March 31, 2022, our smoke-free products were
available for sale in 71 markets in key cities or nationwide.
During 2021, we laid the foundation for our long-term growth ambitions beyond nicotine in wellness and healthcare, including the milestone acquisitions
of Vectura Group plc and Fertin Pharma A/S, as noted above, which provide essential capabilities for future product development.
We use the term net revenues to refer to our operating revenues from the sale of our products, including shipping and handling charges billed to customers,
net of sales and promotion incentives, and excise taxes. Our net revenues and operating income are affected by various factors, including the volume of
products we sell, the price of our products, changes in currency exchange rates and the mix of products we sell. Mix is a term used to refer to the
proportionate value of premium-price brands to mid-price or low-price brands in any given market (product mix). Mix can also refer to the proportion of
shipment volume in more profitable markets versus shipment volume in less profitable markets (geographic mix).
44
-- 45 of 139 --
Table of Contents
Our cost of sales consists principally of: tobacco leaf, non-tobacco raw materials, labor and manufacturing costs; shipping and handling costs; and the cost
of devices produced by third-party electronics manufacturing service providers. Estimated costs associated with device warranty programs are generally
provided for in cost of sales in the period the related revenues are recognized.
Our marketing, administration and research costs include the costs of marketing and selling our products, other costs generally not related to the
manufacture of our products (including general corporate expenses), and costs incurred to develop new products. The most significant components of our
marketing, administration and research costs are marketing and sales expenses and general and administrative expenses.
Philip Morris International Inc. is a legal entity separate and distinct from its direct and indirect subsidiaries. Accordingly, our right, and thus the right of
our creditors and stockholders, to participate in any distribution of the assets or earnings of any subsidiary is subject to the prior rights of creditors of such
subsidiary, except to the extent that claims of our company itself as a creditor may be recognized. As a holding company, our principal sources of funds,
including funds to make payment on our debt securities, are from the receipt of dividends and repayment of debt from our subsidiaries. Our principal
wholly owned and majority-owned subsidiaries currently are not limited by long-term debt or other agreements in their ability to pay cash dividends or to
make other distributions that are otherwise compliant with law.
Executive Summary
The following executive summary provides the business update and significant highlights from the "Discussion and Analysis" that follows.
War in Ukraine
Since the onset of the war in Ukraine, our main priority has been the safety and security of our more than 1,300 employees and their families in the country.
We have taken action to achieve three critical missions: (i) helping to evacuate more than 1,000 people from Ukraine and relocate over 2,700 others from
conflict zones to locations in the country away from the heaviest fighting; (ii) providing critical aid to employees who cannot leave or who decide to remain
in Ukraine; and (iii) providing those who have left the country with logistical, medical, financial, and other practical support in neighboring countries. We
are continuing to pay salaries to all our Ukrainian employees and are also providing substantial in-kind support to them and their families. In addition, we
have already contributed around $10 million in funds and donated essential items across the country, directly to humanitarian organizations and through our
own employee-led initiative, Projects With a Heart.
On February 25, 2022, we announced the temporary suspension of our operations in Ukraine, including at our factory in Kharkiv. While activities in the
east of Ukraine remain the most heavily impacted, we have seen some resumption of retail activities where safety allows, as we seek to provide product
availability and service to adult consumers, using existing finished goods inventories on hand. We are also working on future supply from other production
centers, although this may involve higher costs. We are applying increased security and safety measures for personnel.
In 2021, Ukraine accounted for around 2% of our total cigarette and heated tobacco unit shipment volume and under 2% of our total net revenues. As of
March 31, 2022, our Ukrainian operations had approximately $0.4 billion in total assets, excluding intercompany balances.
On March 24, 2022, we announced concrete steps we had taken to suspend planned investments and scale down our manufacturing operations in Russia.
This included:
• the discontinuation of a number of cigarette products offered in the market (representing approximately one-quarter of the company's domestic
cigarette SKUs, including Marlboro and Parliament SKUs) and the reduction of our manufacturing activities accordingly;
• the suspension of our marketing activities in the country;
• the cancellation of all product launches planned for 2022 in the market, including the launch of its flagship heated tobacco product IQOS ILUMA,
originally planned for March 2022; and
• the cancellation of our plans to manufacture TEREA heated tobacco units for IQOS ILUMA in Russia (with an eventual annualized capacity of more
than 20 billion units) and the related ongoing investment of $150 million.
45
-- 46 of 139 --
Table of Contents
Further, we announced that our Board of Directors and senior executives are working on options to exit the Russian market in an orderly manner, in the
context of an increasingly complex and rapidly changing regulatory and operating environment.
We employ more than 3,200 people in Russia and will continue to support our employees there, including paying their salaries, while continuing to fulfill
our legal obligations. We will continue to make decisions with their safety and security as a priority.
In 2021, Russia made up almost 10% of total shipment volumes and around 6% of our total net revenues. As of March 31, 2022, our Russian operations
had approximately $1.4 billion in total assets, excluding intercompany balances.
These developments above have and will continue to have a material adverse impact on our business, results of operations, cash flows and financial
position, and may result in impairment charges.
For further details, see Note 18. War in Ukraine to our condensed consolidated financial statements and the "Cautionary Factors That May Affect Future
Results" section of this MD&A.
Consolidated Operating Results for the Three Months Ended March 31, 2022
• Net Revenues - Net revenues of $7.7 billion for the three months ended March 31, 2022 increased by $161 million, or 2.1%, from the comparable
2021 amount. The change in our net revenues from the comparable 2021 amount was driven by the following (variances not to scale with quarterly
results):
During the quarter, net revenues, excluding currency and acquisitions, increased by 9.0%, mainly reflecting: favorable volume/mix, primarily driven
by higher heated tobacco unit volume (predominantly in the EU, particularly Germany, Italy and Poland), higher cigarette volume (mainly in
Indonesia, PMI Duty Free and the Philippines, partly offset by Germany and Russia) and higher device volume (driven by the EU and Japan), partially
offset by unfavorable cigarette mix (mainly in Japan); and a favorable pricing variance (notably driven by Germany, Russia and Turkey, partly offset
by Indonesia and the Philippines).
During the quarter, Russia and Ukraine accounted for around 6% of PMI's total net revenues.
46
-- 47 of 139 --
Table of Contents
Net revenues by product category for the three months ended March 31, 2022 and 2021, are shown below:
• Diluted Earnings Per Share - The changes in our reported diluted earnings per share ("diluted EPS") for the three months ended March 31, 2022,
from the comparable 2021 amounts, were as follows:
Diluted EPS % Change
For the three months ended March 31, 2021 $ 1.55
2021 Asset impairment and exit costs 0.02
2021 Tax items —
Subtotal of 2021 items 0.02
2022 Charges related to the war in Ukraine (0.03)
2022 Fair value adjustment for equity security investments (0.03)
2022 Tax items —
Subtotal of 2022 items (0.06)
Currency (0.23)
Interest 0.01
Change in tax rate 0.03
Operations 0.18
For the three months ended March 31, 2022 $ 1.50 (3.2)%
Asset impairment and exit costs – In the first quarter of 2021, we recorded pre-tax asset impairment and exit costs of $48 million, representing $38 million
net of income tax and a diluted EPS charge of $0.02 per share, related to product distribution restructuring in South Korea and the organizational design
optimization plan, primarily in Switzerland. The total pre-tax charge was included in marketing, administration and research costs on the condensed
consolidated statements of earnings. For further details, see Note 16. Asset Impairment and Exit Costs.
Charges related to the war in Ukraine – In the first quarter of 2022, we recorded a pre-tax charge of $42 million, representing $39 million net of income
tax and a diluted EPS charge of $0.03 per share, related to circumstances driven by the conflict, including inventory write downs, additional allowances for
receivables and the cost of PMI’s humanitarian efforts. Of this total pre-tax charge, $26 million was recorded in cost of sales and $16 million was recorded
in marketing, administration and research costs. For further details, see Note 18. War in Ukraine.
47
-- 48 of 139 --
Table of Contents
Fair value adjustment for equity security investments – In the first quarter of 2022, we recorded an unfavorable fair value adjustment for our equity security
investments in India and Sri Lanka of $47 million after tax (or $0.03 per share decrease in diluted EPS). The fair value adjustment for our equity security
investments was included in equity investments and securities (income)/loss, net ($60 million loss) and provision for income taxes ($13 million benefit) on
the condensed consolidated statements of earnings for the three months ended March 31, 2022. For further details, see Note 12. Related Parties - Equity
Investments and Other.
Income Taxes – The change in the tax rate that increased our diluted EPS by $0.03 per share in the table above was primarily due to changes in earnings
mix by taxing jurisdiction.
Currency – The unfavorable impact of $0.23 per share during the reporting period primarily results from the fluctuations of the U.S. dollar, especially
against the Euro, Japanese yen and Turkish lira. This unfavorable currency movement has impacted our profitability across our primary revenue markets
and local currency cost bases.
Operations – The increase in diluted EPS of $0.18 from our operations in the table above was due primarily to the following segments:
• Middle East & Africa: Favorable pricing, favorable volume/mix and lower marketing, administration and research costs, partially offset by higher
manufacturing costs; and
• European Union: Favorable volume/mix, partially offset by higher manufacturing costs;
partially offset by
• East Asia & Australia: Unfavorable volume/mix and higher manufacturing costs, partially offset by lower marketing, administration and research
costs and favorable pricing;
• South & Southeast Asia: Unfavorable pricing, partially offset by favorable volume/mix;
• Eastern Europe: Unfavorable volume/mix and higher marketing, administration and research costs, partially offset by favorable pricing;
• Americas: Higher manufacturing costs and unfavorable volume/mix, partially offset by favorable pricing; and
• Other: Primarily reflecting the amortization of intangibles related to the acquisitions, investments in research and development, and expenses related
to employee retention programs.
For further details, see the “Consolidated Operating Results” and “Operating Results by Business Segment” sections of the following “Discussion and
Analysis.”
48
-- 49 of 139 --
Table of Contents
Discussion and Analysis
Consolidated Operating Results
See pages 82-92 for a discussion of our "Cautionary Factors That May Affect Future Results." Our net revenues and operating income by segment are
shown in the table below:
(in millions) For the Three Months Ended March 31,
2022 2021 Change
Net revenues:
European Union $ 3,012 $ 2,909 3.5 %
Eastern Europe 726 796 (8.8)%
Middle East & Africa 991 801 23.7 %
South & Southeast Asia 1,123 1,173 (4.3)%
East Asia & Australia 1,404 1,472 (4.6)%
Americas 424 434 (2.3)%
Other 66 — — %
Net revenues $ 7,746 $ 7,585 2.1 %
Operating income (loss):
European Union $ 1,527 $ 1,490 2.5 %
Eastern Europe 144 261 (44.8)%
Middle East & Africa 521 335 55.5 %
South & Southeast Asia 445 529 (15.9)%
East Asia & Australia 571 695 (17.8)%
Americas 121 134 (9.7)%
Other (31) — — %
Operating income $ 3,298 $ 3,444 (4.2)%
Items affecting the comparability of results from operations were as follows:
• Asset impairment and exit costs – See Note 16. Asset Impairment and Exit Costs for details of the $48 million pre-tax charge and a breakdown of
these costs by segment for the three months ended March 31, 2021.
• Charges related to the war in Ukraine – See Note 18. War in Ukraine for details of the $42 million pre-tax charges in the Eastern Europe segment
for the three months ended March 31, 2022.
49
-- 50 of 139 --
Table of Contents
Our net revenues by product category are shown in the table below:
PMI Net Revenues by Product Category
(in millions) For the Three Months Ended March 31,
2022 2021 Change
Combustible Products
European Union $ 1,810 $ 1,950 (7.2)%
Eastern Europe 456 492 (7.2)%
Middle East & Africa 929 780 19.1 %
South & Southeast Asia 1,118 1,171 (4.6)%
East Asia & Australia 601 648 (7.3)%
Americas 416 422 (1.4)%
Total Combustible Products $ 5,330 $ 5,463 (2.4)%
Reduced-Risk Products
European Union $ 1,202 $ 959 25.4 %
Eastern Europe 270 304 (11.4)%
Middle East & Africa 62 21 +100%
South & Southeast Asia 5 2 +100%
East Asia & Australia 803 824 (2.5)%
Americas 8 12 (35.3)%
Total Reduced-Risk Products $ 2,350 $ 2,122 10.7 %
Other
Other 66 — — %
Total PMI Net Revenues $ 7,746 $ 7,585 2.1 %
Note: Sum of product categories or Regions might not foot to total PMI due to roundings.
Net revenues related to combustible products refer to the operating revenues generated from the sale of these products, including shipping and handling
charges billed to customers, net of sales and promotion incentives, and excise taxes. These net revenue amounts consist of the sale of our cigarettes and
other tobacco products combined. Other tobacco products primarily include roll-your-own and make-your-own cigarettes, pipe tobacco, cigars and
cigarillos, and do not include reduced-risk products.
Net revenues related to reduced-risk products refer to the operating revenues generated from the sale of these products, including shipping and handling
charges billed to customers, net of sales and promotion incentives, and excise taxes. These net revenue amounts consist of the sale of our heated tobacco
units, heat-not-burn devices and related accessories, and other nicotine-containing products, which primarily include our e-vapor and oral nicotine products.
Net revenues in the Other category primarily consist of operating revenues generated from the sale of inhaled therapeutics, and oral and intra-oral delivery
systems that are included in the operating results of our new Wellness and Healthcare business, Vectura Fertin Pharma.
PMI's heat-not-burn products include licensed KT&G heat-not-burn products.
References to "Cost/Other" in the Consolidated Financial Summary table of total PMI and the six geographical segments throughout this "Discussion and
Analysis" reflects the currency-neutral variances of: cost of sales (excluding the volume/mix cost component); marketing, administration and research costs
(including asset impairment and exit costs); and amortization of intangibles. “Cost/Other” also includes the currency-neutral net revenue variance,
unrelated to volume/mix and price components, attributable to: fees for certain distribution rights billed to customers in certain markets in the ME&A
Region.
50
-- 51 of 139 --
Table of Contents
Our shipment volume by segment for cigarettes and heated tobacco units is shown in the table below:
PMI Shipment Volume (Million Units)
For the Three Months Ended March 31,
2022 2021 Change
Cigarettes
European Union 36,444 36,769 (0.9)%
Eastern Europe 18,514 19,966 (7.3)%
Middle East & Africa 29,471 27,642 6.6 %
South & Southeast Asia 37,461 34,888 7.4 %
East Asia & Australia 11,553 11,362 1.7 %
Americas 14,795 14,885 (0.6)%
Total Cigarettes 148,238 145,512 1.9 %
Heated Tobacco Units
European Union 8,566 6,426 33.3 %
Eastern Europe 5,866 5,635 4.1 %
Middle East & Africa 897 396 +100%
South & Southeast Asia 94 33 +100%
East Asia & Australia 9,288 9,139 1.6 %
Americas 108 105 2.9 %
Total Heated Tobacco Units 24,819 21,734 14.2 %
Cigarettes and Heated Tobacco Units
European Union 45,010 43,195 4.2 %
Eastern Europe 24,380 25,601 (4.8)%
Middle East & Africa 30,368 28,038 8.3 %
South & Southeast Asia 37,555 34,921 7.5 %
East Asia & Australia 20,841 20,501 1.7 %
Americas 14,903 14,990 (0.6)%
Total Cigarettes and Heated Tobacco Units 173,057 167,246 3.5 %
Heated tobacco units ("HTU") is the term we use to refer to heated tobacco consumables, which include our HEETS, HEETS Creations, HEETS
Dimensions, HEETS Marlboro and HEETS FROM MARLBORO (defined collectively as HEETS), Marlboro Dimensions, Marlboro HeatSticks, Parliament
HeatSticks and TEREA, as well as the KT&G-licensed brands, Fiit and Miix (outside of South Korea).
Market share for HTUs is defined as the total sales volume for HTUs as a percentage of the total estimated sales volume for cigarettes and HTUs.
References to total industry, total market, our shipment volume and our market share performance reflect cigarettes and heated tobacco units, unless
otherwise stated.
As of the first quarter of 2022, total industry volume, PMI in-market sales volume and PMI market share for the following geographies include the cigarillo
category in Japan: the total international market, East Asia & Australia Region, and Japanese domestic market.
References to total international market, defined as worldwide cigarette and heated tobacco unit volume excluding the United States, total industry, total
market and market shares throughout this "Discussion and Analysis" are our estimates for tax-paid products based on the latest available data from a
number of internal and external sources and may, in defined instances, exclude the People's Republic of China and/or our duty free business.
51
-- 52 of 139 --
Table of Contents
2021 and 2022 estimates for total industry volume and market share in certain geographies reflect limitations on the availability and accuracy of industry
data during pandemic-related restrictions.
First-quarter 2022 estimates for total industry volume and market share in the Philippines reflect limitations on the availability and accuracy of industry
data.
In-market sales ("IMS") is defined as sales to the retail channel, depending on the market and distribution model.
North Africa is defined as Algeria, Egypt, Libya, Morocco and Tunisia.
The Gulf Cooperation Council ("GCC") is defined as Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and the United Arab Emirates (UAE).
Southeast Europe is defined as Albania, Bosnia & Herzegovina, Kosovo, Montenegro, North Macedonia and Serbia.
From time to time, PMI’s shipment volumes are subject to the impact of distributor inventory movements, and estimated total industry/market volumes are
subject to the impact of inventory movements in various trade channels that include estimated trade inventory movements of PMI’s competitors arising
from market-specific factors that significantly distort reported volume disclosures. Such factors may include changes to the manufacturing supply chain,
shipment methods, consumer demand, timing of excise tax increases or other influences that may affect the timing of sales to customers. In such instances,
in addition to reviewing PMI shipment volumes and certain estimated total industry/market volumes on a reported basis, management reviews these
measures on an adjusted basis that excludes the impact of distributor and/or estimated trade inventory movements. Management also believes that
disclosing PMI shipment volumes and estimated total industry/market volumes in such circumstances on a basis that excludes the impact of distributor
and/or estimated trade inventory movements improves the comparability of performance and trends for these measures over different reporting periods.
52
-- 53 of 139 --
Table of Contents
Key market data regarding total market size, our shipments and market share are shown in the tables below:
For the Three Months Ended March 31,
PMI Shipments (billion units) PMI Market Share (%)
Market Total Market
(billion units) Total Cigarette Heated Tobacco
Unit Total Heated Tobacco
Unit
2022 2021 2022 2021 2022 2021 2022 2021 2022 2021 2022 2021
Total (1) 563.0 556.6 173.1 167.2 148.2 145.5 24.8 21.7 26.7 26.0 3.5 2.9
European Union
France 7.8 8.2 3.5 3.8 3.5 3.7 0.1 0.1 45.0 43.6 0.7 0.6
Germany 16.1 17.4 6.8 7.1 5.9 6.5 0.9 0.6 42.3 40.8 5.9 3.6
Italy 16.8 15.9 9.7 9.6 7.1 7.5 2.6 2.2 54.2 52.8 14.8 11.3
Poland 12.8 10.8 4.8 4.0 3.8 3.4 1.0 0.6 37.3 36.7 7.6 5.4
Spain 10.0 9.6 3.3 2.7 3.2 2.6 0.2 0.1 30.4 31.1 1.5 1.2
Eastern Europe
Russia n/a 49.1 14.1 15.7 10.8 12.1 3.4 3.6 n/a 31.0 n/a 7.7
Middle East & Africa
Saudi Arabia 5.2 5.5 2.1 2.2 2.1 2.2 — — 41.1 42.3 0.8 0.8
Turkey 23.6 25.3 11.0 11.0 11.0 11.0 — — 46.9 43.4 — —
South & Southeast Asia
Indonesia 75.1 71.0 20.9 19.9 20.9 19.9 — — 27.8 28.0 — —
Philippines 15.6 13.1 9.7 8.2 9.6 8.1 — — 62.0 62.4 0.3 0.2
East Asia & Australia
Australia 2.2 2.4 0.8 0.8 0.8 0.8 — — 33.9 32.7 — —
Japan 34.4 35.6 14.2 13.8 6.1 5.9 8.1 7.9 37.2 36.1 22.9 21.5
South Korea 16.8 16.8 3.3 3.4 2.2 2.2 1.1 1.1 19.6 20.1 6.5 6.8
Americas
Argentina 7.7 7.7 4.9 5.3 4.9 5.3 — — 63.5 68.2 — —
Mexico 6.5 6.8 4.1 4.0 4.0 4.0 — — 62.5 59.6 0.4 0.3
(1) Total market and market share estimates exclude Russia & Ukraine
(2) Market share estimates are calculated using IMS data
(3) Total market and market share estimates include cigarillos
Consolidated Operating Results for the Three Months Ended March 31, 2022
The following discussion compares our consolidated operating results for the three months ended March 31, 2022, with the three months ended March 31,
2021.
During the first quarter, our total shipment volume increased by 3.5%, driven by:
• the EU, reflecting higher heated tobacco unit shipment volume across the Region (primarily in Germany, Italy and Poland), partly offset by lower
cigarette shipment volume (mainly in Germany and Italy, partially offset by Poland and Spain);
• Middle East & Africa, mainly reflecting higher cigarette shipment volume, primarily in Egypt and PMI Duty Free, partly offset by Algeria;
(2)
(3)
53
-- 54 of 139 --
Table of Contents
• South & Southeast Asia, primarily reflecting higher cigarette shipment volume, mainly in Indonesia and the Philippines; and
• East Asia & Australia, reflecting higher cigarette and heated tobacco unit shipment volume, primarily in Japan;
partly offset by
• Eastern Europe, reflecting lower cigarette shipment volume, primarily in Russia, partly offset by higher heated tobacco unit shipment volume, mainly
in Ukraine and Southeast Europe, partially offset by Russia; and
• Americas, primarily reflecting lower cigarette shipment volume, mainly in Argentina, partly offset by Brazil.
Excluding Russia and Ukraine, our total shipment volume increased by 4.9%, reflecting an increase of 4.5% in the Eastern Europe Region.
First-Quarter Impact of Inventory Movements
Excluding the net favorable impact of estimated distributor inventory movements of approximately 1.7 billion units, our total in-market sales increased by
2.5%, driven by a 16.7% increase in heated tobacco units and a 0.4% increase in cigarettes.
The net favorable impact of approximately 1.7 billion units reflected:
• A net favorable impact of 2.1 billion cigarettes, mainly driven by Japan, PMI Duty Free and Spain; partly offset by
• A net unfavorable impact of 0.5 billion heated tobacco units, primarily due to Russia.
Excluding Russia and Ukraine, our total in-market sales increased by 3.8%.
Our total heated tobacco unit in-market sales volume in the quarter was 24.8 billion units, or 19.5 billion units excluding Russia and Ukraine, representing
growth of 16.7% and 19.5%, respectively.
Our cigarette shipment volume by brand and heated tobacco units shipment volume are shown in the table below:
PMI Shipment Volume by Brand (Million Units)
First-Quarter
2022 2021 Change
Cigarettes
Marlboro 57,264 53,682 6.7 %
L&M 20,198 20,367 (0.8) %
Chesterfield 15,606 12,758 22.3 %
Philip Morris 9,753 10,184 (4.2) %
Sampoerna A 9,718 8,698 11.7 %
Parliament 9,152 8,957 2.2 %
Dji Sam Soe 5,772 5,704 1.2 %
Lark 3,452 3,899 (11.5) %
Others 17,323 21,263 (18.5) %
Total Cigarettes 148,238 145,512 1.9 %
Heated Tobacco Units 24,819 21,734 14.2 %
Total Cigarettes and Heated Tobacco Units 173,057 167,246 3.5 %
Note: Lark includes Lark Harmony; Philip Morris includes Philip Morris/Dubliss; and Sampoerna A includes Sampoerna.
54
-- 55 of 139 --
Table of Contents
The increase in our heated tobacco unit shipment volume was mainly driven by the EU (notably Germany, Italy and Poland), Japan and the Middle East &
Africa (notably Egypt). Excluding Russia and Ukraine, our heated tobacco unit shipment volume increased by 18.4%.
Our cigarette shipment volume of the following brands increased:
• Marlboro, mainly driven by PMI Duty Free, the Philippines, Russia, Spain and Turkey, partly offset by Algeria and Italy;
• Chesterfield, primarily driven by the Philippines and Russia;
• Sampoerna A in Indonesia, primarily driven by premium A Mild;
• Parliament, mainly driven by Turkey, partly offset by Saudi Arabia; and
• Dji Sam Soe in Indonesia, primarily driven by Dji Sam Soe Magnum Mild.
Our cigarette shipment volume of the following brands decreased:
• L&M, primarily due to Germany and Turkey, partly offset by Egypt and the GCC;
• Philip Morris, mainly due to Russia, partly offset by Japan;
• Lark, primarily due to Japan and Turkey; and
• "Others," mainly due to: mid-price Fortune (Philippines), Sampoerna Hijau (Indonesia) and Sampoerna U (Indonesia); and low-price Bond Street
(primarily due to Russia).
Excluding Russia and Ukraine, our cigarette shipment volume increased by: 5.1% for Marlboro, 0.1% for L&M, 10.8% for Chesterfield, 13.3% for Philip
Morris and 4.9% for Parliament.
First-Quarter International Share of Market
Our total international market share (excluding China and the United States, as well as Russia and Ukraine), defined as our cigarette and heated tobacco
unit sales volume as a percentage of total industry cigarette and heated tobacco unit sales volume, increased by 0.7 points to 26.7%, reflecting:
• Market share for heated tobacco units of 3.5%, up by 0.6 points; and
• Market share for cigarettes of 23.3%, up by 0.2 points.
Excluding China and the United States, as well as Russia and Ukraine, our total international cigarette sales volume as a percentage of total industry
cigarette sales volume increased by 0.4 points to 24.4%, mainly reflecting higher cigarette market share and/or a favorable geographic mix impact, notably
in Indonesia, PMI Duty Free and the Philippines, partly offset by Algeria and Germany.
Financial Summary
Financial Summary -
Quarters Ended
March 31,
Change
Fav./(Unfav.) Variance
Fav./(Unfav.)
2022 2021 Total Excl.
Curr. &
Acquis. Total Cur-
rency Acqui-
sitions Price Vol/
Mix Cost/
Other
(in millions)
Net Revenues $ 7,746 $ 7,585 2.1 % 9.0 % $ 161 $ (590) $ 70 $ 108 $ 562 $ 11
Cost of Sales (2,608) (2,274) (14.7)% (18.3)% (334) 125 (42) — (298) (119)
Marketing, Administration and
Research Costs (1,802) (1,849) 2.5 % 1.7 % 47 50 (35) — — 32
Amortization of Intangibles (38) (18) -(100)% (5.6)% (20) — (19) — — (1)
Operating Income $ 3,298 $ 3,444 (4.2)% 8.6 % $ (146) $ (415) $ (26) $ 108 $ 264 $ (77)
Cost/Other variance includes charges in 2022 of $26 million related to the war in Ukraine. For more details, see Note 18. War in Ukraine.
(1)
(2)
(1)
55
-- 56 of 139 --
Table of Contents
Cost/Other variance includes charges in 2022 of $16 million related to the war in Ukraine and charges in 2021 of $48 million related to asset impairment and exit costs.
For more details, see Note 16. Asset Impairment and Exit Costs and Note 18. War in Ukraine.
During the quarter, net revenues, excluding currency and acquisitions, increased by 9.0%, mainly reflecting: favorable volume/mix, primarily driven by
higher heated tobacco unit volume (predominantly in the EU, particularly Germany, Italy and Poland), higher cigarette volume (mainly in Indonesia, PMI
Duty Free and the Philippines, partly offset by Germany and Russia) and higher device volume (driven by the EU and Japan), partially offset by
unfavorable cigarette mix (mainly in Japan); and a favorable pricing variance (notably driven by Germany, Russia and Turkey, partly offset by Indonesia
and the Philippines).
During the quarter, Russia and Ukraine accounted for around 6% of PMI's total net revenues.
The unfavorable currency in net revenues was due primarily to the Euro, Japanese yen, Russian ruble and Turkish lira.
Net revenues include $2.3 billion in 2022 and $2.1 billion in 2021 related to the sale of RRPs. IQOS devices accounted for approximately 5% of RRP net
revenues in the first quarter of 2022, reflecting higher year-over year device volumes as supply constraints ease and ILUMA's positive performance.
Operating income, excluding currency and acquisitions, increased by 8.6%, primarily reflecting: favorable volume/mix, mainly driven by higher heated
tobacco unit volume and higher cigarette volume (each mainly reflecting the same geographies as for net revenues noted above), partly offset by
unfavorable cigarette mix (primarily in the EU and Japan) and device mix (predominantly in Japan); and a favorable pricing variance; partly offset by
higher manufacturing costs (primarily due to higher logistics costs and other inflationary impacts, partially offset by productivity).
Interest expense, net, of $154 million decreased by $13 million (7.8)%.
Our effective tax rate decreased by 1.8 percentage points to 19.7%. We estimate that our full-year 2022 effective tax rate will be 21% to 22%, excluding
discrete tax events. For further details, see Note 9. Income Taxes.
Net earnings attributable to PMI of $2.3 billion decreased by $87 million or 3.6%. This decrease was due primarily to lower operating income as discussed
above, partially offset by a lower effective tax rate. Diluted and basic EPS of $1.50 decreased by 3.2%. Excluding an unfavorable currency impact of $0.23,
diluted EPS increased by 11.6%.
Operating Results by Business Segment
Business Environment
Taxes, Legislation, Regulation and Other Matters Regarding the Manufacture, Marketing, Sale and Use of Tobacco Products
The tobacco industry and our company face a number of challenges that may adversely affect our business, volume, results of operations, cash flows and
financial position. These challenges, which are discussed below and in “Cautionary Factors That May Affect Future Results,” include:
• regulatory restrictions on our products, including restrictions on the packaging, marketing, and sale of tobacco or other nicotine-containing
products that could reduce our competitiveness, eliminate our ability to communicate with adult consumers, or even ban certain of our products;
• fiscal challenges, such as excessive excise tax increases and discriminatory tax structures;
• illicit trade in cigarettes and other tobacco and nicotine-containing products, including counterfeit, contraband and so-called “illicit whites”;
• intense competition, including from non-tax paid volume by certain local manufacturers;
• pending and threatened litigation as discussed in Note 8. Contingencies; and
• governmental investigations.
Regulatory Restrictions: The tobacco industry operates in a highly regulated environment. The well-known risks of smoking have led regulators to impose
significant restrictions and high excise taxes on cigarettes.
(2)
56
-- 57 of 139 --
Table of Contents
Much of the regulation that shapes the business environment in which we operate is driven by the Framework Convention on Tobacco Control (the
“FCTC”) of the World Health Organization (the “WHO”), which entered into force in 2005. The FCTC has as its main objective to establish a global
agenda for tobacco regulation, with the purpose of reducing tobacco use. To date, 182 countries and the European Union are Parties to the FCTC. The
treaty requires Parties to have in place various tobacco control measures and recommends others. The FCTC governing body, the Conference of the Parties
(“CoP”), has also adopted non-binding guidelines and policy recommendations related to certain articles of the FCTC that go beyond the text of the treaty.
In October 2018, the CoP recognized the need for more scientific assessment and improved reporting to define policy on heated tobacco products. Similar
to its previous policy recommendations on e-cigarettes, the CoP invited countries to regulate, restrict or prohibit heated tobacco products, as appropriate
under their national laws.
Prior to CoP 9 that took place in November 2021, the WHO and the WHO FCTC Secretariat published two reports on novel and emerging tobacco
products. The reports were noted by CoP 9 and related substantive discussions and decisions were deferred to CoP 10, currently scheduled for 2023. It is
not possible to predict whether or to what extent measures recommended by the WHO's reports will be implemented as the reports are not binding to the
WHO Member States.
We believe that when better alternatives to cigarettes exist, the discussion should not be whether these alternatives should be made available to the more
than one billion people who smoke today, but how fast, and within what regulatory framework to maximize their adoption while minimizing unintended
use. Therefore, we advocate for regulatory frameworks that recognize a significant difference on a risk continuum between combustible tobacco on the one
hand and non-combustible tobacco and other nicotine-containing products on the other. Regulation should include measures that will accelerate switching
to non-combustible products, for example, by allowing adult consumers who would not otherwise quit to receive truthful and non-misleading information
about such products to enable them to make informed decisions and by applying uniform product standards to enable manufacturers to demonstrate the
safety of these products as well as the absence of combustion. Regulation should also include specific rules for ingredients, labeling and consumer
communication, and should ensure that the public is informed about the health risks of all combustible and non-combustible tobacco and nicotine-
containing products. Importantly, regulation must include measures designed to prevent initiation by youth and non-smokers. We support mandated health
warnings, minimum age laws, restrictions on advertising, and public place smoking restrictions. We also support regulatory measures that help reduce illicit
trade.
Certain measures are discussed in more detail below and in the Reduced-Risk Products (RRPs) section.
Fiscal Challenges: Excessive and disruptive excise, sales and other tax increases and discriminatory tax structures are expected to continue to have an
adverse impact on our profitability, due to lower consumption and consumer down-trading to non-premium, discount, other low-price or low-taxed
combustible tobacco products such as fine cut tobacco and illicit cigarettes. In addition, in certain jurisdictions, some of our combustible products are
subject to tax structures that discriminate against premium-price products and manufactured cigarettes. We believe that such tax policies undermine public
health by encouraging consumers to turn to illicit trade, and ultimately undercut government revenue objectives, disrupt the competitive environment, and
encourage criminal activity. Other jurisdictions have imposed, or are seeking to impose, levies or other taxes specifically on tobacco companies, such as
taxes on revenues and/or profits.
World Customs Organization Developments: In 2020, the World Customs Organization (the “WCO”) amended the harmonized system nomenclature to
introduce dedicated custom codes for novel tobacco and nicotine products, including heated tobacco products, e-cigarettes and other nicotine-containing
products. The amendments became effective as of January 1, 2022. These amendments require WCO member states to transfer products from customs
codes in the current nomenclature to the new one. These amendments are not expected to significantly impact current customs duty rates.
EU Tobacco Products Directive: In April 2014, the EU adopted a significantly revised EU Tobacco Products Directive (the “TPD”), which entered into
force in May 2016. All member states have adopted laws transposing the TPD. The TPD sets forth a comprehensive set of regulatory requirements for
tobacco products, including:
• health warnings covering 65% of the front and back panels of cigarette packs, with an option for member states to further standardize tobacco
packaging, including the introduction of plain packaging;
• a ban on characterizing flavors in some tobacco products, with a transition period for menthol that expired in May 2020;
• security features and tracking and tracing measures that became effective in May 2019; and
57
-- 58 of 139 --
Table of Contents
• a framework for the regulation of novel tobacco products and e-cigarettes, including requirements for health warnings and information leaflets, a
prohibition on product packaging text related to reduced risk, and the introduction of notification requirements or authorization procedures in
advance of commercialization.
In May 2021, the European Commission published its first report on the application of the TPD. The report identifies significant progress made due to the
implementation of the TPD and where there is still room for improvement. Most notably, it finds that the EU legislation has enhanced tobacco control,
contributed to protecting the health of EU citizens by providing Member States with strong rules to address the use of tobacco products in the EU. The TPD
reportedly achieved the 2% reduction target of the impact assessment with decreased smoking prevalence among youth. The report also concludes that
there is scope for improvement in certain areas, such as enforcement at national level, assessment of ingredients, and a better consideration for novel and
emerging products.
In November 2021, the European Commission published the implementation roadmap to Europe's Beating Cancer Plan (the "Plan"). According to the Plan,
a revision of the TPD is planned for 2024.
EU Tobacco Excise Directive ("TED"): The EU Commission is preparing a legislative proposal for the revision of the 2011 EU Tobacco Excise Directive
that may include definitions and tax treatment for novel tobacco and nicotine-containing products, including heated tobacco products and e-cigarettes. The
proposal is expected to be published in the course of 2022 and adopted by the EU Council in 2023. Any final amendments to TED require unanimous
agreement by all EU member states, followed by transposition of TED into national legislation. The potential effective date for any changes to TED, after
the transposition period, is early 2024.
Plain Packaging and Other Packaging Restrictions: Plain packaging legislation bans the use of branding, logos and colors on packaging other than the
brand name and variant that may be printed only in specified locations and in a uniform font. To date, plain packaging laws have been adopted in certain
markets in all of our operating segments, including the key markets of Australia, France, Saudi Arabia and Turkey. Some countries, such as Canada,
Denmark and Israel adopted plain packaging regulations that apply to all tobacco products, including RRPs. Other countries are also considering plain
packaging legislation.
Some countries have adopted, or are considering adopting, packaging restrictions that could have an impact similar to plain packaging. Examples of such
restrictions include standardizing the shape and size of packages, prohibiting certain colors or the use of certain descriptive phrases on packaging, and
requiring very large graphic health warnings that leave little space for branding.
Restrictions and Bans on the Use of Ingredients: The WHO and others in the public health community have recommended restrictions or total bans on the
use of some or all ingredients in tobacco products, including menthol. Broad restrictions and ingredient bans would require us to reformulate our American
blend tobacco products and could reduce our ability to differentiate these products in the market in the long term. In many countries, menthol bans would
eliminate the entire category of mentholated tobacco products. The European Union banned cigarettes and roll-your-own tobacco products with
characterizing flavors. Other tobacco products, including heated tobacco products, are currently exempted from this characterizing flavor ban. However, the
European Union Commission has issued a draft delegated directive that would end this exemption. While the timing and final form of the directive is not
yet known, if adopted it would likely ban the use of characterizing flavors from heated tobacco products in the European Union, impacting a significant
proportion of our RRP products currently sold in the European Union. Other countries may follow the EU’s approach toward tobacco product ingredients.
Turkey banned menthol as of May 2020. Broader ingredient bans have been adopted by Brazil and Canada.
Bans on Display of Tobacco Products at Retail: In a number of our markets, including, but not limited to, Australia and Russia, governments have banned
the display of tobacco products at the point of sale. Other countries are considering similar bans.
Bans and Restrictions on Advertising, Marketing, Promotions and Sponsorships: For many years, the FCTC has called for, and countries have imposed,
partial or total bans on tobacco advertising, marketing, promotions and sponsorships, including bans and restrictions on advertising on radio and television,
in print and on the Internet. The FCTC's non-binding guidelines recommend that governments prohibit all forms of communication with adult smokers.
Restrictions on Product Design: Some members of the public health community are calling for the further standardization of tobacco products by requiring,
for example, that cigarettes have a certain minimum diameter, which would amount to a ban on slim cigarettes, or requiring the use of standardized filter
and cigarette paper designs. In addition, at its meeting in November 2016, the CoP adopted non-binding guidelines recommending that countries regulate
product design features that increase the attractiveness of tobacco products, such as the diameter of cigarettes and the use of flavor capsules.
58
-- 59 of 139 --
Table of Contents
Restrictions on Public Smoking and Use of Nicotine-Containing Products in Public: The pace and scope of restrictions on the use of our products have
increased significantly in most of our markets. Many countries around the world have adopted, or are likely to adopt, regulations that restrict or ban
smoking and use of nicotine-containing products in public and/or work places, restaurants, bars and nightclubs. Some public health groups have called for,
and some countries, regional governments and municipalities have adopted or proposed, bans on smoking in outdoor places, as well as bans on smoking in
cars (typically, when minors are present) and private homes.
Other Regulatory Issues: Some regulators are considering, or in some cases have adopted, regulatory measures designed to reduce the supply of tobacco
products. These include regulations intended to reduce the number of retailers selling tobacco products by, for example, reducing the overall number of
tobacco retail licenses available or banning the sale of tobacco products within specified distances of certain public facilities. In addition, South Africa
banned the sale of tobacco products, e-cigarettes, and electronic devices that heat tobacco for several months during the COVID-19 pandemic. The ban,
which was lifted on August 17, 2020, resulted in a significant increase of illicit trade of tobacco products.
In a limited number of markets, most notably Japan, we are dependent on governmental approvals that may limit our pricing flexibility.
The EU Single-Use Plastics Directive, which will require tobacco manufacturers and importers to cover the costs of public collection systems for tobacco
product filters, under Extended Producer Responsibility ("EPR") schemes, entered into force on July 2, 2019. To date, some member states transposed the
Directive into national legislation. We expect remaining member states to transpose the EU Single-Use Plastics Directive into national legislation including
EPR schemes by January 2023. While we cannot predict the impact of this initiative on our business at this time, we are monitoring developments in this
area.
Illicit Trade: Illicit tobacco trade creates a cheap and unregulated supply of tobacco products, undermines efforts to reduce smoking prevalence, especially
among youth, damages legitimate businesses and intellectual property rights, stimulates organized crime, increases corruption and reduces government tax
revenue. We generally estimate that, excluding China and the U.S., illicit trade may account for as much as 12% of global cigarette consumption; this
includes counterfeit, contraband and the persistent problem of “illicit whites,” which are cigarettes legally produced in one jurisdiction for the sole purpose
of being exported and illegally sold in another jurisdiction where they have no legitimate market. Currently, we estimate that illicit trade in the European
Union accounted for approximately 8% of total cigarette consumption in 2021.
A number of jurisdictions are considering actions to prevent illicit trade. In November 2012, the FCTC adopted the Protocol to Eliminate Illicit Trade in
Tobacco Products (the “Protocol”), which includes supply chain control measures, such as licensing of manufacturers and distributors, enforcement of these
control measures in free trade zones, controls on duty free and Internet channels and the implementation of tracking and tracing technologies. To date, 64
Parties, including the European Union, have ratified it. The Protocol came into force in September 2018. Parties must start implementing its provisions in
their national legislation. In November 2021, the second Meeting of the Parties to the Protocol decided, among others, to focus on the implementation of a
framework for global information sharing to combat illicit tobacco trade and enable the parties to exchange products' tracking and tracing information in a
secure manner. We welcome this decision and expect that other Parties will ratify the Protocol.
We devote substantial resources to help prevent illicit trade in combustible tobacco products and RRPs. For example, we engage with governments, our
business partners and other stakeholders to implement effective measures to combat illicit trade and, in some instances, pursue legal remedies to protect our
intellectual property rights.
The tracking and tracing regulations for cigarettes and roll-your-own products manufactured or destined for the EU became effective on May 20, 2019. The
effective date for other tobacco-containing products, including some of our RRPs such as heated tobacco units, is May 20, 2024. While we expect that this
regulation will increase our operating expenses, we do not expect this increase to be significant.
In 2009, our Colombian subsidiaries entered into an Investment and Cooperation Agreement with the national and regional governments of Colombia to
promote investment in, and cooperation on, anti-contraband and anti-counterfeit efforts. The agreement provides $200 million in funding over a 20-year
period to address issues such as combating illegal cigarette trade and increasing the quality and quantity of locally-grown tobacco.
In May 2016, PMI launched PMI IMPACT, a global initiative that supports third-party projects dedicated to fighting illegal trade and related crimes such as
corruption, organized criminal networks and money laundering. The centerpiece of PMI IMPACT is a council of external independent experts in the fields
of law, anti-corruption and law enforcement. The experts are
59
-- 60 of 139 --
Table of Contents
responsible for evaluating and approving funding proposals for PMI IMPACT grants. PMI has pledged $100 million to fund projects within PMI IMPACT
over three funding rounds.
Reduced-Risk Products (RRPs)
Our Approach to RRPs: We recognize that smoking cigarettes causes serious diseases and that the best way to avoid the harms of smoking is never to start
or to quit. Nevertheless, it is predicted that by 2025, the number of smokers will remain largely unchanged from the current estimate of 1.1 billion, despite
the considerable efforts to discourage smoking.
Cigarettes burn tobacco, which produces smoke. As a result of the combustion process, the smoker inhales various toxic substances. In contrast, RRPs do
not burn tobacco and therefore contain significantly lower levels of harmful and potentially harmful constituents ("HPHCs") than found in cigarette smoke.
For adult smokers who would otherwise continue to smoke, we believe that RRPs, while not risk-free, offer a much better consumer choice. Accordingly,
our key strategic priorities are to: (i) to develop and commercialize products that present less risk of harm to adult smokers who switch to those products
versus continued smoking; and (ii) educate and convince current adult smokers who would otherwise continue to smoke to switch to those products.
We recognize that this transformation from cigarettes to RRPs will take time and that the speed of transformation will depend in part upon factors beyond
our control, such as the willingness of governments, regulators and other policy groups to embrace RRPs as a desired alternative to continued cigarette
smoking. For as long as a significant number of adult smokers continues to smoke, responsible leadership of the category is critical. We aim to maintain our
competitive position in the cigarette market through selective investment. As a leading international cigarette manufacturer, we will continue to accelerate
this transformation by using our regulatory and commercial expertise and extensive commercial and distribution infrastructure as an effective platform for
the commercialization of our RRPs and communication with adult smokers and trade partners about the benefits of switching to our RRPs.
While seeking to remain competitive in the cigarette market, we are judiciously reallocating resources from cigarettes to RRPs and are streamlining our
cigarette portfolio.
We have a range of RRPs in various stages of development, scientific assessment and commercialization. We conduct rigorous scientific assessments of our
RRP platforms to substantiate that they reduce exposure to HPHCs and, ultimately, that these products present, are likely to present, or have the potential to
present less risk of harm to adult smokers who switch to them versus continued smoking. We draw upon a team of expert scientists and engineers from a
broad spectrum of scientific disciplines and our extensive learnings of adult consumer preferences to develop and assess our RRPs. Our efforts are guided
by the following key objectives:
• to develop RRPs that adult smokers who would otherwise continue to smoke find to be satisfying alternatives to smoking;
• for those adult smokers, our goal is to offer RRPs with a scientifically substantiated risk-reduction profile that approaches as closely as possible
that associated with smoking cessation;
• to substantiate the reduction of risk for the individual adult smoker and the reduction of harm to the population as a whole, based on scientific
evidence of the highest standard that is made available for scrutiny and review by external independent scientists and relevant regulatory bodies;
and
• to advocate for the development of science-based regulatory frameworks for the development and commercialization of RRPs, including the
communication of scientifically substantiated information to enable adult smokers to make better consumer choices.
Our RRP Platforms: Our product development is based on the elimination of combustion via tobacco heating and other innovative systems, which we
believe are the most promising path to providing a better consumer choice for those who would otherwise continue to smoke. We recognize that no single
product will appeal to all adult smokers. Therefore, we are developing a portfolio of products intended to appeal to a variety of distinct adult consumer
preferences.
Five PMI-developed or improved RRP platforms are in various stages of development and commercialization readiness:
Platform 1 uses a precisely controlled heating device incorporating our IQOS HeatControl technology, into which a specially designed and proprietary
tobacco unit is inserted and heated to generate an aerosol. We have conducted a series of
60
-- 61 of 139 --
Table of Contents
clinical studies for this platform, the results of which were included in our submission to the U.S. Food and Drug Administration (“FDA”) described below.
We completed a 6+6-month exposure response study and shared the results with the FDA in April 2020. The study showed that for the group that switched
to our Platform 1 product, the eight clinical risk endpoints that were tested as co-primary endpoints in the first six-month term moved in the same direction
as observed for smoking cessation after 12 months of use of this product. In addition, we completed an 18-month combined chronic toxicity and
carcinogenicity study in mice, which was on-going at the time of our FDA submission. We shared the results with the FDA in August 2018. In addition to
the original version of Platform 1 which relies on a heating technology using a blade, a new version of Platform 1 is now available using induction. All
studies referenced above were conducted with the blade version of Platform 1. We believe that there is full comparability between the versions, therefore
the data from these studies remain valid.
Platform 2 used a pressed carbon heat source which, when ignited, generates a nicotine-containing aerosol by heating tobacco. As a result of consumer
testing feedback, the design of our current Platform 2 technology has been discontinued. We are assessing alternative designs for this consumer segment.
Platform 3 provides an aerosol of nicotine salt. We have explored two routes for this platform, one with electronics and one without, and conducted
nicotine pharmacokinetic studies with both versions. The results of our pharmacokinetic study related to the version without electronics indicate this
product's potential as an acceptable alternative to continued cigarette smoking in terms of product satisfaction. In February 2020, we completed a one-
month product use and adaptation study in adult smokers for the product variant without electronics. The results of the study indicated that while during the
study period, the adult smokers did not fully switch from smoking cigarettes to this Platform 3 product, on average, they used this product on a daily basis
and significantly reduced their daily consumption of cigarettes. We are working on product modifications to enable switching by those adult smokers who
are looking for better alternatives to cigarettes.
Platform 4 covers e-vapor products, which are battery-powered devices that produce an aerosol by vaporizing a nicotine-containing liquid solution. In
2020, our e-vapor products comprised devices with the "coil and wick" technology as well as our e-vapor mesh technology designed to ensure the
consistency and quality of the generated aerosol compared to the products with the “coil and wick” technology. Recently, we discontinued the
commercialization of devices with the “coil and wick” technology. We conducted a nicotine pharmacokinetic study with respect to products with our e-
vapor mesh technology in 2017. The results of this study indicate that these products are an effective means of nicotine delivery while being a satisfying
alternative for e-cigarette users. In March 2019, a six-month pre-clinical study in mice evaluating the impact of e-cigarette vapor on the risks of pulmonary
and cardiovascular disease compared to cigarette smoke was completed; this study did not pertain to a specific product. The study demonstrated that e-
cigarette vapors induce significantly lower biological responses associated with cardiovascular and pulmonary diseases compared with cigarette smoke.
Recently, we designed a new consumable for our e-vapor mesh technology to deliver real tobacco taste satisfaction in an E-Vapor product liquid-using
patented technology, where flavors and nicotine are extracted directly from the tobacco leaves and captured in a liquid solution, without having to add
flavoring ingredients.
Platform 5 covers Modern Oral Nicotine Pouches, which consist of white pre-portioned pouches containing nicotine derived from tobacco. Users
place a pouch between the upper lip and gum and leave it there while the nicotine and taste are being released. At the end of the use, the user can dispose of
the pouch. Nicotine pouches are inherently smoke-free as they are consumed orally, and no combustion process occurs during use. Our nicotine pouches do
not contain tobacco. Instead, they contain primarily nicotine, flavors, and a cellulose substrate. The nicotine used in the pouches is of pharmaceutical-grade
like the nicotine used in medicinal products, such as gums and inhalers, while the flavors are approved for use in food in accordance with the product
quality standards for nicotine pouches developed by the Swedish Institute for Standards. In 2021, PMI acquired AG Snus as well as Fertin Pharma, two
companies manufacturing and/or marketing nicotine pouches.
We aim to expand our brand portfolio and market positions with additional RRPs. In addition, we are continuing to use our expertise, technology and
capabilities to explore new growth opportunities beyond our current business, including products that do not contain nicotine or tobacco.
After we receive the results of our scientific studies, including those mentioned above, in accordance with standard scientific practices, we share the
conclusions in scientific forums and submit them for inclusion in peer-reviewed publications.
Commercialization of RRPs: We are building a new product category and tailor our commercialization strategy to the characteristics of each specific
market. We focus our commercialization efforts on consumer retail experience, guided consumer trials and customer care, and increasingly, digital
communication programs and e-commerce. In order to accelerate switching to our Platform 1 products, our initial market introductions typically entail
one-to-one consumer engagement (in person or by digital means) and device discounts. These initial commercialization efforts require substantial
investment, which we believe
61
-- 62 of 139 --
Table of Contents
will moderate over time and further benefit from the increased use of digital engagement capabilities. During the COVID-19 pandemic, we accelerated our
investments in, and pivot to, digital consumer engagement.
As of March 31, 2022, PMI's smoke-free products are available for sale in 71 markets in key cities or nationwide.
In 2014, we introduced our Platform 1 product in pilot city launches in Nagoya, Japan, and in Milan, Italy. Since then, we have continuously expanded our
commercialization activities.
We believe that only a very small percentage of adult smokers who convert to our Platform 1 product switch back to cigarettes.
We have integrated the production of our heated tobacco units into a number of our existing manufacturing facilities, are progressing with our plans to
build manufacturing capacity for our other RRP platforms, and continue to optimize our manufacturing infrastructure.
An adequate supply chain for our RRP portfolio, including the supply of electronic devices, is important to our business. We work with four electronics
manufacturing service providers for the supply of our Platform 1 and Platform 4 devices, and a small number of other providers for other products in our
RRP portfolio and related accessories. Due to the COVID-19 pandemic, the operations of our two main electronic manufacturing service providers were
temporarily suspended at different times. Even though these suspensions did not materially affect our operations, if one or more of these service providers
were significantly constrained at the same time, the supply of the devices could be disrupted. Although we work closely with these service providers on
monitoring their production capability and financial health, we cannot guarantee that they will remain capable of meeting their commitments, particularly
during the COVID-19 pandemic and the armed conflict between Russia and Ukraine; if they will not, the commercialization of our RRPs could be
adversely affected. The production of our RRP portfolio requires various metals, and we believe that there is an adequate supply of such metals in the
world markets to satisfy our current and anticipated production requirements. However, some components and materials necessary for the production of our
RRPs, including those for the electronic devices, are obtained from single or limited sources, and can be subject to industry-wide shortages and price
fluctuations. While we were successful in maintaining adequate supply of such components and materials so far, we may not be able to secure such supply
going forward, particularly during the COVID-19 pandemic; this could negatively impact the commercialization of our RRPs.
In addition, we are also exposed to a world-wide shortage of semiconductors, which continues to put constraints on our device supplies for RRPs. We
believe, however, that the overall impact of this shortage remains manageable, and we have adjusted our device assortments to limit the effect on consumer
availability of our RRPs.
We discuss product warranties in more detail in Note 14. Product Warranty. The significance of warranty claims is dependent on a number of factors,
including device version mix, product failure rates, logistics and service delivery costs, and warranty policies, and may increase with the number of devices
sold.
Product quality may affect consumer acceptance of our RRPs.
Our near-term planned commercialization efforts for the other PMI-developed RRP platforms are as follows:
• We started commercializing an improved version of our IQOS MESH product in Canada, Croatia, the Czech Republic, Finland, Italy, Ukraine and
New Zealand under the IQOS VEEV or VEEV brand names. We currently plan to launch this product in additional markets.
• Following the consumer test conducted in 2020, and the results of the product use and adaptation study described above, we are incorporating our
learnings into our plans to improve our Platform 3 product.
• We launched a Platform 5 product in Sweden in January 2022, that is a reformulated version of the already commercialized nicotine pouches
bearing the Shiro brand by our newly acquired affiliate AG Snus.
Due to the COVID-19 pandemic and the armed conflict between Russia and Ukraine, certain of these commercialization efforts could be delayed.
RRP Regulation and Taxation: RRPs contain nicotine and are not risk-free. As we describe in more detail above, we support science-based regulation and
taxation of RRPs, and believe that regulation and taxation should differentiate between cigarettes and products that present, are likely to present, or have
the potential to present less risk of harm to adult smokers who switch to
62
-- 63 of 139 --
Table of Contents
these products versus continued smoking and should recognize a continuum of risk for tobacco and other nicotine-containing products. Regulation, as well
as industry practices, should reflect the fact that youth should not consume nicotine in any form.
Some governments have banned or are seeking to ban or severely restrict emerging tobacco and nicotine-containing products such as our RRPs and
communication of truthful and non-misleading information about such products.
These regulations might foreclose or unreasonably restrict adult consumer access even to products that might be shown to be a better consumer choice than
continuing to smoke. During the COVID-19 pandemic, some governments have been and may continue to be temporarily unable to focus on the
development of science-based regulatory frameworks for the development and commercialization of RRPs or on the enforcement or implementation of
regulations that are significant to our business.
We oppose blanket bans and unreasonable restrictions of products that have the potential to present less risk of harm compared to continued smoking. By
contrast, we support regulation that sets clear standards for all RRP categories and propels innovation to benefit adult smokers who would otherwise
continue to smoke.
In the United States, an established regulatory framework for assessing “Modified Risk Tobacco Products” and “New Tobacco Products” exists under the
jurisdiction of the FDA. We submitted to the FDA a Modified Risk Tobacco Product Application (“MRTPA”) for our Platform 1 product in December
2016, and a Premarket Tobacco Product Application (“PMTA”) for our Platform 1 product in March 2017.
On April 30, 2019, the FDA determined that a version of our Platform 1 product, namely, IQOS 2.4 and three related consumables, is appropriate for the
protection of public health and authorized it for sale in the United States. The FDA’s decision followed its comprehensive assessment of our PMTA. On
December 7, 2020, the FDA reached the same determination for the IQOS 3 device and authorized that version of our Platform 1 product for sale in the
United States.
On July 7, 2020, the FDA determined that the available scientific evidence demonstrates that the issuance of an exposure modification order would be
appropriate for the promotion of public health and authorized the marketing of a version of our Platform 1 product, namely IQOS 2.4 and three related
consumables, as a "modified risk tobacco product." The FDA authorized the marketing of this product in the U.S. with the following information:
"AVAILABLE EVIDENCE TO DATE:
• the IQOS system heats tobacco but does not burn it.
• this significantly reduces the production of harmful and potentially harmful chemicals.
• scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s
exposure to harmful or potentially harmful chemicals."
We must request and receive authorization from the FDA in order to continue marketing this product with the same modified exposure information after the
present order expires in four years from the date of the orders.
On March 18, 2021, we submitted to the FDA a supplemental MRTPA ("sMRTPA") for IQOS 3 requesting authorization to market this version of the
device as a Modified Risk Tobacco Product with reduced exposure information like IQOS 2.4. In June 2021, the FDA formally accepted and filed our
sMRTPA for substantive scientific review and, already in May 2021, the FDA opened the period for the public to provide comments on our application.
The public comment period, which was initially scheduled to be closed on August 2, 2021, was extended on July 20, 2021 to provide time for the public to
review application materials that were not previously posted by FDA. The FDA closed the comment period for IQOS 3's sMRTPA on December 10, 2021.
On March 11, 2022, the FDA authorized our sMRTPA for IQOS 3 by issuing a Modified Risk Granted Order – Exposure Modification.
There are two types of MRTP orders the FDA may issue: a “risk modification” order or an “exposure modification” order. We had requested both types of
orders for IQOS 2.4 and an initial selection of 3 consumables' variants. After review, the FDA determined that the evidence did not support issuing a "risk
modification" order at this time but that it did support issuing an "exposure modification" order for the product. This determination included a finding that
issuance of the exposure modification order is expected to benefit the health of the population as a whole. We requested (and received) an exposure
modification order for IQOS 3.
We look forward to working with the FDA to provide any additional information they may require in order to market this product with reduced risk claims.
63
-- 64 of 139 --
Table of Contents
The FDA’s PMTA and MRTP orders do not mean that the agency “approved” our Platform 1 product. These authorizations are subject to strict marketing,
reporting and other requirements, and are not a guarantee that the product will remain authorized, particularly if there is a significant uptake in youth or
non-smoker initiation. The FDA will monitor the marketing of the product.
Some states and municipalities in the U.S. have introduced severe restrictions for the sale of certain e-cigarettes and tobacco products, including those
authorized by the FDA. We believe that such restrictions on FDA-authorized products will not advance public health and will unreasonably limit adult
consumer access to products that are shown to be a better alternative to continued smoking.
In March 2020, we requested a clarification from the FDA regarding the applicability of its new health warning requirements to our heated tobacco units
sold in the United States. In June 2021, the FDA responded to our letter and requested additional information regarding the applicability of the cigarette
health warnings rule to the IQOS System and HeatSticks. Philip Morris Products S.A. is committed to providing adult consumers of tobacco products with
complete, accurate and non-misleading information regarding the health risks associated with the use of the IQOS System and HeatSticks. We shared our
views with the FDA on the applicability of new health warnings to our products in our submission on December 2, 2021.
In the U.S., tobacco and nicotine-containing products that were not commercially marketed as of February 15, 2007, are subject to review and authorization
by the FDA. Manufacturers of all non-authorized products currently on the market were required to file a PMTA with the FDA by September 9, 2020. The
FDA announced on September 9, 2020 that it will prioritize enforcement against any tobacco and nicotine-containing product sold without a PMTA. On
October 5, 2021, FDA published its final PMTA rule in the Federal Register, which is effective November 4, 2021. All future applications will have to
comply with the requirements in the PMTA rule, which is substantially similar to the version of the final PMTA rule which was posted on Advanced
Federal Register on January 19, 2021.
FDA actions may influence the regulatory approach of other governments.
On September 29, 2021, the International Trade Commission ("ITC") issued its Final Determination ("FD"), Limited Exclusion Order ("LEO") and Cease
and Desist Order ("CDO"). The ITC upheld the finding of infringement in the ID and found a subsequent violation. The ITC issued a LEO prohibiting the
importation of infringing tobacco heating articles and components thereof and cease and desist orders against Philip Morris USA, Inc. and Altria Client
Services, LLC, which went into effect at the end of the 60-day Presidential review period on November 28, 2021. We have appealed the patent issues.
Furthermore, lawsuits based on the same patent families have been repeatedly and universally rejected in European courts and the European Patent Office.
The decision has no bearing outside the United States.
On March 15, 2022, the Consolidated Appropriations Act, 2022 amended the definition of “tobacco product” contained in the Federal Food, Drug and
Cosmetic Act ("FD&C Act") to “any product made or derived from tobacco, or containing nicotine from any source, that is intended for human
consumption.” Under this definition, products containing synthetic nicotine, e.g., e-cigarettes, are subject to the FDA’s tobacco regulatory authority.
According to this new provision, effective April 14, 2022, manufacturers of tobacco products containing nicotine not derived from tobacco will be required
to submit a PMTA to the FDA and obtain authorization from the Agency to market their product under the FD&C Act or they will be subject to FDA
enforcement actions. This new provision does not have any impact on tobacco products developed by PMI and intended for commercialization in the U.S.
Until recently, there were no countries with specific product standards for heat-not-burn products. Currently, national standards setting minimum quality
and safety requirements for such products have been adopted in several countries with technical heat-not-burn specifications and/or methods for
demonstrating the absence of combustion. They are mandatory in Egypt, Jordan, Saudi Arabia, Tunisia, the UAE, Uzbekistan and Bahrain, and voluntary in
Armenia, Costa Rica, Indonesia, Kazakhstan, Kyrgyzstan, Russia, Tajikistan, Vietnam, the U.K. and Ukraine. In Japan, a voluntary standard sets minimum
safety requirements for tobacco heating devices. We expect other governments to consider similar product standards and encourage making them
mandatory.
All EU member states have transposed the EU Tobacco Products Directive, including the provisions on novel tobacco products, such as heated tobacco
units, and e-cigarettes. Most of the EU member states require a notification submitted six months before the intended placing on the market of such
products, while some require pre-market authorizations for the introduction of such products. To date, we have filed a comprehensive dossier summarizing
our scientific assessment of our Platform 1 product in over 20 member states.
64
-- 65 of 139 --
Table of Contents
In addition, in Italy, in April 2018, we submitted an application for HEETS, used with the IQOS device, requesting regulatory recognition of the reduction
of toxic substances and potential risk reduction resulting from switching to this product compared to continued cigarette smoking. In January 2019, our
application was not granted primarily on the grounds of insufficient data and questions of methodology. Due to the constraints of the review process, we
had been unable to supplement the application with all the data we subsequently filed with the FDA and to address methodological questions during the
review. We plan to submit a new application where we will clarify the concerns raised by the decision and further strengthen our application by submitting
additional evidence that became available since we submitted our first application, consistent with our FDA filings. We are confident that our evidence
supports our application.
On October 31, 2019, our Australian subsidiary, Philip Morris Limited (“PML”), submitted an application to the Scheduling Committee of the Therapeutic
Goods Administration of Australia (“TGA”) seeking to exempt heated tobacco products from being prohibited in Australia. In August 2020, the TGA
issued its decision denying the application and stating that it did not present compelling evidence to establish a public health benefit from greater access to
nicotine in heated tobacco products.
To date, several governmental agencies have published their scientific findings that analyze the harm-reduction potential of certain RRPs versus continuing
smoking, including:
In December 2017, at the request of the U.K. Department of Health and Public Health England, the U.K. Committee on Toxicity published its assessment
of the risk of heat-not-burn products relative to cigarette smoking. This assessment included analysis of scientific data for two heat-not-burn products, one
of which was our Platform 1 product. The assessment concluded that, while still harmful to health, compared with the known risks from cigarettes, heat-
not-burn products are probably less harmful. Subsequently, in February 2018, Public Health England published a report stating that the available evidence
suggests that heat-not-burn products may be considerably less harmful than cigarettes and more harmful than e-cigarettes.
In May 2018, the German Federal Institute for Risk Assessment (“BfR”) published a study on the Platform 1 aerosol relative to cigarette smoke using the
Health Canada Intense Smoking Regimen. BfR found reductions in selected HPHCs in a range of 80-99%. This publication indicates that significant
reductions in the levels of selected toxicants are likely to reduce toxicant exposure, which BfR stated might be regarded as a discrete benefit compared to
combustible cigarettes.
In May 2018, the Dutch National Institute for Public Health and Environment (“RIVM”) published a factsheet on novel tobacco products that heat rather
than burn tobacco, focusing on our Platform 1 product. RIVM analyzed the aerosol generated by our Platform 1 product and concluded that the use of this
product, while still harmful to health, is probably less harmful than continued smoking.
In June 2018, the Korean Food and Drug Administration (“KFDA”) issued a statement on products that heat rather than burn tobacco. The KFDA tested
three heat-not-burn products, one of which was our Platform 1 product. The KFDA confirmed that the levels of the nine HPHCs tested in the aerosol of
these products were on average approximately 90% lower compared to those measured in the cigarette smoke of the top five cigarette brands in South
Korea. However, the KFDA stated that it could not establish that the tested heat-not-burn products are less harmful than cigarettes. In October 2018, our
Korean subsidiary filed a request with a local court seeking information underlying KFDA’s analysis, conclusions and public statements. In May 2020, the
court ordered KFDA to produce certain records.
In August 2018, the Science & Technology Committee of the U.K. House of Commons published a report of its inquiry into e-cigarettes and heat-not-burn
products. The report concluded that e-cigarettes are significantly less harmful to health than smoking tobacco. The report also observed that for those
smokers who do not accept e-cigarettes, heat-not-burn products may offer a public health benefit despite their relative risk. The report called for a risk-
proportionate regulatory environment for both e-cigarettes and heat-not-burn products and noted that e-cigarettes should remain the least taxed, cigarettes
the most taxed, with heat-not-burn products falling between the two. The U.K. Committee on Advertising Practice announced the removal of a prohibition
of health claims in the advertising of e-cigarettes in the U.K. effective November 2018.
In November 2018, the Eurasian Economic Commission (regulatory body of the Eurasian Union consisting of Armenia, Belarus, Kazakhstan, Kyrgyzstan
and Russia) published the results of its commissioned study on novel nicotine-containing products, including our Platform 1 product. The study confirms
significantly lower levels of HPHCs in the aerosol generated by this product compared to cigarette smoke.
In January 2019, scientific media published the results of the study of the China National Tobacco Quality Supervision and Test Centre (“CNTQST”)
comparing the aerosol generated by our Platform 1 product with cigarette smoke. The CNTQST found that the former contained fewer, and lower levels of,
harmful constituents than the latter and concluded that the lower
65
-- 66 of 139 --
Table of Contents
temperature of heating tobacco in our Platform 1 product contributed to the difference. The CNTQST stated that the reduction in emissions of harmful
constituents cannot be interpreted as a harm/risk reduction for smokers in the same proportion.
In 2020, the Superior Health Council of Belgium (“SHC”) published results of its inquiry into heat-not-burn products. The SHC concluded that heat-not-
burn products, while not safe, have a more favorable toxicity profile than cigarettes. However, in light of the uncertainty of such products’ short and long-
term impacts, the toxic effects of the dual use with cigarettes, and the existence of approved smoking cessation tools, the SHC recommended that current
regulations for cigarettes should apply to heat-not-burn products.
The foregoing scientific findings of government agencies may not be indicative of the measures that the relevant government authorities could take in
regulating our products.
We make our scientific findings publicly available for scrutiny and peer review through several channels, including our websites. From time to time, adult
consumers, competitors, members of the scientific community, and others inquire into our scientific methodologies, challenge our scientific conclusions or
request further study of certain aspects of our RRPs and their health effects. We are committed to a robust and open scientific debate and believe that such
debate should be based on accurate and reliable scientific information. We seek to provide accurate and reliable scientific information about our RRPs;
nonetheless, we may not be able to prevent third-party dissemination of false, misleading or unsubstantiated information about these products. The
dissemination of scientifically unsubstantiated information or studies with a strong confirmation bias by third parties may cause confusion among adult
smokers and affect their decision to switch to better alternatives to continued smoking, such as our RRPs.
To date, we have been largely successful in demonstrating to regulators that our heated tobacco units are not cigarettes due to the absence of combustion,
and as such they are generally taxed either as a separate category or as other tobacco products, which typically yields more favorable tax rates than
cigarettes. Although we believe that this is sensible from the public health perspective, we cannot guarantee that regulators will continue this approach.
There can be no assurance that we will succeed in our efforts to replace cigarettes with RRPs or that regulation will allow us to commercialize RRPs in all
markets, to communicate about our RRPs, including making scientifically substantiated risk-reduction claims, or to treat RRPs differently from cigarettes.
Legal Challenges to RRPs: We face various administrative and legal challenges related to certain RRP activities, including allegations concerning product
classification, advertising restrictions, corporate communications, product coach activities, scientific substantiation, product liability, and unfair
competition. While we design our programs to comply with relevant regulations, we expect these or similar challenges to continue as we expand our
efforts to commercialize RRPs and to communicate publicly. The outcomes of these matters may affect our RRP commercialization and public
communication activities and performance in one or more markets.
Our RRP Business Development Initiatives: In December 2013, we established a strategic framework with Altria Group, Inc. (“Altria”) setting out terms on
how the parties would collaborate to develop and commercialize e-vapor products and commercialize two of our RRPs in the U.S. In late 2018, Altria
announced that it will participate in the e-vapor category only through another e-vapor company in which Altria acquired a minority interest. In September
2019, Altria's subsidiary, Philip Morris USA Inc. (“PM USA”), began commercialization of a version of our Platform 1 product in the U.S. Under the
agreement, PM USA must achieve certain milestones to maintain its exclusive distribution right and additional milestones to extend the agreement after the
initial 5-year term. PMI and Altria are currently discussing these milestones, the contractual obligations, and the impact of the United States International
Trade Commission (“ITC”) Orders (For more details please refer to Note 8. Contingencies).
In January 2020, we announced an agreement with KT&G, a leading tobacco and nicotine company in South Korea, for the commercialization of KT&G’s
smoke-free products outside of South Korea on an exclusive basis. For more information, see Acquisitions and Other Business Arrangements below.
Other Developments: In September 2017, we announced our support of the Foundation for a Smoke-Free World. In September 2020, our pledge agreement
with the Foundation was amended. We contributed $45 million in 2020, $40 million in 2021, and expect to contribute $35 million annually from 2022
through 2029, as specified in the amended pledge agreement. To date, we contributed a total of $249.5 million. The Foundation is an independent body and
is governed by its independent Board of Directors. The Foundation’s role, as set out in its corporate charter, includes funding research in the field of
tobacco harm
66
-- 67 of 139 --
Table of Contents
reduction, encouraging measures that reduce the harm caused by smoking, and assessing the effect of reduced cigarette consumption on the industry value
chain.
Governmental Investigations
From time to time, we are subject to governmental investigations on a range of matters, including tax, customs, antitrust, advertising, and labor practices.
We describe certain matters pending in Russia, South Korea and Thailand in Note 8. Contingencies.
In November 2010, a World Trade Organization ("WTO") panel issued its decision in a dispute relating to facts that arose from August 2006, between the
Philippines and Thailand, concerning a series of Thai customs and tax measures affecting cigarettes imported by PM Thailand into Thailand (see Note 8.
Contingencies for additional information). The WTO panel decision, which was upheld by the WTO Appellate Body, concluded that Thailand had no basis
to find that PM Thailand's declared customs values and taxes paid were too low, as alleged by the Department of Special Investigations of the government
of Thailand ("DSI") in 2009. The decision also created obligations for Thailand to revise its laws, regulations, or practices affecting the customs valuation
and tax treatment of future cigarette imports. Thailand agreed in September 2011 to fully comply with the decision by October 2012. The Philippines
asserts that to date Thailand has not fully complied with the WTO panel decision and commenced challenges at the WTO Appellate Body. The WTO
Appellate Body is not operational, and the appeals by Thailand are suspended indefinitely. In December 2020, the Philippines and Thailand agreed to
pursue facilitator-assisted discussions aimed at progressing and resolving outstanding issues. It is not possible to predict any future developments in these
proceedings or the outcome of these discussions.
The Public Prosecutor’s office of Rome, Italy, notified our Italian subsidiary, Philip Morris Italia S.r.l. (“PM Italia”), as well as three former or current
employees and a former external consultant of PM Italia in July 2020 and March 2020, respectively, that it concluded a preliminary investigation against
them for alleged contravention of anti-corruption laws and related disruption of trade freedom. The Public Prosecutor alleges that the individuals involved
promised certain personal favors to government officials from January to July of 2018 in exchange for favorable treatment for PM Italia, and that PM Italia
lacked appropriate organizational controls to prevent the alleged actions by the individuals. At the first trial hearing held on September 22, 2021, BAT filed
a civil claim against PM Italia claiming vicarious liability for any wrongdoing of its former or current employees. BAT claims EUR 50 million in damages.
The court admitted the claim as a matter of course and issued summons for PM Italia to appear as civil party in the case. The next trial hearing is scheduled
for June 1, 2022. PM Italia believes the charges brought against it by the Public Prosecutor are without merit and will defend them vigorously.
Vectura Fertin Pharma
Subsequent to the end of the first quarter, on April 5, 2022, the European Commission issued a proposal for a regulation on fluorinated greenhouse gases. If
accepted, the proposal also establishes quantitative limits on usage of certain propellant gases which are components of certain products sold by our
Vectura Fertin Pharma business. This may impact the related products development and market strategies, may have an adverse impact on the value of
technology and goodwill acquired in PMI’s 2021 purchase of Vectura Group plc, and may result in impairment charges.
Asset Impairment and Exit Costs
We discuss asset impairment and exit costs in Note 16. Asset Impairment and Exit Costs to our condensed consolidated financial statements.
U.S. GAAP Treatment of Turkey as a Highly Inflationary Economy
Following the categorization of Turkey by the International Practices Task Force of the Center for Audit Quality as a country with a three-year cumulative
inflation rate greater than 100%, the country is considered highly inflationary in accordance with U.S. GAAP. Consequently, PMI has begun to account for
the operations of its Turkish affiliates as highly inflationary, and treat the U.S. dollar as the functional currency of the affiliates, effective April 1, 2022.
67
-- 68 of 139 --
Table of Contents
Acquisitions and Other Business Arrangements
We discuss our acquisitions in Note 17. Acquisitions to our condensed consolidated financial statements.
Global Collaboration Agreement with KT&G
In January 2020, PMI announced a global collaboration agreement with the leading tobacco and nicotine company in South Korea, KT&G, to
commercialize KT&G’s smoke-free products outside of the country. The agreement will run for an initial period of three years. The two companies plan for
global collaboration with the intention to actively expand to cover many markets, based on commercial success. The agreement allows PMI to distribute
current KT&G smoke-free products, and their evolutions, on an exclusive basis, and does not restrict PMI from distributing its own or third-party products.
KT&G’s smoke-free product brand portfolio includes heat-not-burn tobacco products (e.g., LIL Mini and LIL Plus), hybrid technologies that combine heat-
not-burn tobacco and e-vapor technologies (e.g., LIL HYBRID), and e-vapor products (e.g., LIL Vapor). PMI will be responsible for the commercialization
of smoke-free products supplied under the agreement.
Products sold under the agreement are subject to careful assessment to ensure they meet the regulatory requirements in the markets where they are
launched, as well as our standards of quality and scientific substantiation to confirm the absence of combustion and significant reductions of emissions of
harmful chemicals compared to cigarettes. PMI and KT&G will seek any necessary regulatory approvals that may be required on a market-by-market basis.
There are no current plans to commercialize KT&G products in the United States.
Since the third quarter of 2020, we have launched commercial initiatives for licensed KT&G products in select markets.
Equity Investments
We discuss our equity investments in Note 12. Related Parties - Equity Investments and Other to our condensed consolidated financial statements.
Trade Policy
We are subject to various trade restrictions imposed by the U.S. and countries in which we do business (“Trade Sanctions”), including the trade and
economic sanctions administered by the U.S. Department of the Treasury's Office of Foreign Assets Control and the U.S. Department of State. It is our
policy to comply fully with these Trade Sanctions.
Tobacco products are agricultural products under U.S. law and are not technological or strategic in nature. From time to time we make sales in countries
subject to Trade Sanctions, either where such sanctions do not apply to our business or pursuant to exemptions or licenses. On March 11, 2022, the U.S.
introduced a ban on export, re-export, sale, or supply, directly or indirectly, from the U.S., or by a U.S. person, wherever located, of certain tobacco and
manufactured tobacco substitutes to Russia and Belarus.
From time to time, a subsidiary sells products to distributors that, in turn, sell those products to duty free customers that supply U.N. peacekeeping forces
around the world, including those in the U.N. peacekeeping mission located in Abyei, a special administrative territory in Sudan. We do not believe that
these sales, which are not subject to Trade Sanctions, and are de minimis in volume and value, present a material risk to our shareholders, our reputation or
the value of our shares. We have no employees, operations or assets in Sudan.
We do not sell products in Iran, North Korea and Syria. From time to time, we explore opportunities to sell our products in one or more of these countries,
as permitted by law.
We sell cigarettes in Cuba under a distribution agreement. These sales are permitted by U.S. law under a License Exception for Agricultural Commodities,
issued by the United States Department of Commerce (Bureau of Industry and Security), granted to our distributor.
Certain states within the U.S. have enacted legislation permitting or requiring state pension funds to divest or abstain from future investment in stocks of
companies that do business with certain countries that are sanctioned by the U.S. Because we do business in certain of these countries, these state pension
funds may have divested of our stock or may not invest in our stock. We do not believe such legislation has had a material effect on the price of our shares.
68
-- 69 of 139 --
Table of Contents
PMI is also subject to various Trade Sanctions imposed by the EU and other jurisdictions ("Trade Sanctions"). We comply fully with these Trade
Sanctions.
On June 24, 2021, the EU introduced sanctions regarding the Republic of Belarus ("Belarus") aimed at specific sectors of the Belarus economy, including
the tobacco sector. Subsequently, seven non-EU countries (Norway, Iceland, Liechtenstein, North Macedonia, Bosnia and Herzegovina, Montenegro, and
Albania) announced that they “aligned themselves” with the majority of the EU sanctions. Switzerland and the UK have also imposed sanctions similar in
scope to the EU sanctions.
On August 9, 2021, the U.S. imposed blocking sanctions on certain Belarusian individuals and entities pursuant to an Executive Order, which expanded the
bases for the imposition of sanctions, including, among others, by authorizing the imposition by OFAC of blocking sanctions on persons operating in the
tobacco sector of the Belarus economy. In 2021, the U.S., the EU, the U.K., Switzerland and several other jurisdictions supplemented their respective
sanctions lists by including additional Belarusian sanctions targets.
Following the start of the conflict in Ukraine on February 24, 2022, the U.S., the EU, the UK, Switzerland, Canada, Australia, New Zealand, Singapore,
South Korea, Japan and other countries introduced extensive economic sanctions and export controls against Russia. While the introduced sanctions
slightly vary from jurisdiction to jurisdiction, they are largely aligned. The restrictions are primarily targeted at the Russian financial, banking, oil, military,
aviation and marine sectors. Among sanctions targets are Russian political figures and military personnel, certain oligarchs and journalists, and companies
operating in the above-mentioned sectors. Export to Russia of certain luxury goods, and goods and technology which might contribute to Russia’s
technological enhancement was banned. Seven non-EU countries (Norway, Iceland, Liechtenstein, North Macedonia, Bosnia and Herzegovina,
Montenegro, and Albania) announced that they “aligned themselves” with the majority of the EU sanctions. Ukraine imposed its own sanctions against
Russia, and certain targeted Russian entities and individuals.
Russia introduced certain countermeasures aimed at reducing the effect of Western sanctions. Countermeasures include the ban on export of certain goods
from Russia, including tobacco-related production equipment, restrictions on lending to foreign borrowers and transactions with securities and real estate
involving companies from “hostile” countries (i.e., those which introduced sanctions regarding Russia).
PMI complies with all applicable laws and regulations, including sanctions, in the markets where it operates. We have taken appropriate actions in
response to the latest sanctions to ensure full compliance with the relevant restrictions.
Operating Results – Three Months Ended March 31, 2022
The following discussion compares operating results within each of our geographical segments and Other category for the three months ended March 31,
2022, with the three months ended March 31, 2021.
Unless otherwise stated, references to total industry, total market, our shipment volume and our market share performance reflect cigarettes and heated
tobacco units. Estimates for total industry volume and market share in certain geographies reflect limitations on the availability and accuracy of industry
data during pandemic-related restrictions.
European Union:
Financial Summary -
Quarters Ended
March 31,
Change
Fav./(Unfav.) Variance
Fav./(Unfav.)
2022 2021 Total
Excl.
Curr. &
Acquis. Total Cur-
rency Acqui-
sitions Price Vol/
Mix Cost/
Other (in millions)
Net Revenues $ 3,012 $ 2,909 3.5 % 10.5 % $ 103 $ (206) $ 4 $ 5 $ 300 $ —
Operating Income $ 1,527 $ 1,490 2.5 % 12.3 % $ 37 $ (145) $ (2) $ 5 $ 208 $ (29)
During the quarter, net revenues, excluding currency and acquisitions, increased by 10.5%, reflecting: favorable volume/mix, mainly driven by higher
heated tobacco unit volume (notably in Germany, Italy and Poland) and higher device volume (notably in Italy), partly offset by lower cigarette volume
(mainly in Germany, partly offset by Spain). Pricing variance was slightly
69
-- 70 of 139 --
Table of Contents
favorable, primarily reflecting higher combustible pricing (driven by Germany), largely offset by lower pricing for devices (notably in Italy).
Operating income, excluding currency and acquisitions, increased by 12.3%, primarily reflecting: favorable volume/mix, mainly driven by higher heated
tobacco unit volume (primarily reflecting the same geographies as for net revenues noted above), partly offset by lower cigarette volume (mainly in
Germany); partially offset by higher manufacturing costs (primarily due to inflationary impacts).
European Union - Total Market, PMI Shipment Volume and Market Share Commentaries
Total market and market share performance are shown in the table below:
European Union Key Data First-Quarter
Change
2022 2021 % / pp
Total Market (billion units) 109.6 106.4 3.0 %
PMI Market Share
Marlboro 16.2 % 17.0 % (0.8)
L&M 5.5 % 5.8 % (0.3)
Chesterfield 5.6 % 5.5 % 0.1
Philip Morris 2.2 % 2.2 % —
Heated Tobacco Units 7.6 % 5.6 % 2.0
Others 3.0 % 3.2 % (0.2)
Total European Union 40.1 % 39.3 % 0.8
In the quarter, the estimated total market in the EU increased by 3.0% to 109.6 billion units, primarily driven by:
• Italy, up by 5.3%, mainly reflecting the impact on adult smoker average daily consumption of the easing of pandemic-related measures; and
• Poland, up by 18.7%, primarily reflecting a lower estimated prevalence of illicit trade and higher border sales due to the easing of pandemic-related
measures;
partly offset by
• Germany, down by 7.5%, primarily reflecting the impact of excise tax-driven price increases and higher cross-border (non-domestic) purchases due to
the easing of pandemic-related measures.
70
-- 71 of 139 --
Table of Contents
Our total shipment volume increased by 4.2% to 45.0 billion units, mainly driven by:
• Poland, up by 20.7%, mainly reflecting the higher total market, as well as a higher market share driven by heated tobacco units; and
• Spain, up by 23.1%, or by 1.7% excluding the net favorable impact of estimated distributor inventory movements, reflecting a higher total market,
partly offset by a lower market share due to cigarettes.
Excluding the net unfavorable impact of estimated distributor inventory movements (notably in Italy, partly offset by Spain), our total in-market sales
volume increased by 5.2%.
Eastern Europe:
Financial Summary -
Quarters Ended March
31,
Change
Fav./(Unfav.) Variance
Fav./(Unfav.)
2022 2021 Total
Excl.
Curr. &
Acquis. Total Cur-
rency Acqui-
sitions Price Vol/
Mix Cost/
Other (in millions)
Net Revenues $ 726 $ 796 (8.8)% 0.3 % $ (70) $ (72) $ — $ 36 $ (34) $ —
Operating Income $ 144 $ 261 (44.8)% (21.8)% $ (117) $ (60) $ — $ 36 $ (26) $ (67)
During the quarter, net revenues, excluding currency and acquisitions, increased by 0.3%, reflecting: a favorable pricing variance, mainly driven by higher
combustible pricing (primarily in Russia); largely offset by unfavorable volume/mix, mainly due to unfavorable cigarette volume (mainly in Russia).
During the quarter, Russia and Ukraine accounted for around 65% of PMI's total net revenues in the Region.
Operating income, excluding currency and acquisitions, decreased by 21.8%, notably reflecting pre-tax charges in the first quarter of 2022 related to the
war in Ukraine ($42 million), as well as unfavorable volume/mix, mainly due to unfavorable cigarette volume/mix (primarily in Russia); and higher
marketing, administration and research costs; partly offset by a favorable pricing variance.
71
-- 72 of 139 --
Table of Contents
Eastern Europe - Total Market, PMI Shipment Volume and Market Share Commentaries
Given the company's intention to exit the Russian market and the impact of the war in Ukraine on business operations in the country, PMI is providing a
total market estimate for the Eastern Europe Region excluding Russia and Ukraine.
In the quarter, the estimated total market in Eastern Europe, excluding Russia and Ukraine, increased, mainly driven by:
• Kazakhstan, up by 6.2%, primarily reflecting a favorable comparison versus the prior year period due to the temporary supply chain impact of the
introduction, in January 2021, of certain mandatory requirements related to the sale of tobacco products; and
• Southeast Europe, up by 10.0%, mainly reflecting increased in-bound travel and the impact on adult smoker average daily consumption of the easing
of pandemic-related measures.
The company's reported shipment volume, presented below, includes Russia and Ukraine.
Our total shipment volume decreased by 4.8% to 24.4 billion units, primarily due to:
• Russia, down by 9.9%.
During the quarter, Russia and Ukraine accounted for around 73% of PMI's total shipment volume in the Region. Excluding Russia and Ukraine, total
shipment volume increased by 4.5%.
72
-- 73 of 139 --
Table of Contents
Middle East & Africa:
Financial Summary -
Quarters Ended
March 31,
Change
Fav./(Unfav.) Variance
Fav./(Unfav.)
2022 2021 Total
Excl.
Curr. &
Acquis. Total Cur-
rency Acqui-
sitions Price Vol/
Mix Cost/
Other (in millions)
Net Revenues $ 991 $ 801 23.7 % 42.3 % $ 190 $ (149) $ — $ 163 $ 165 $ 11
Operating Income $ 521 $ 335 55.5 % 89.9 % $ 186 $ (115) $ — $ 163 $ 125 $ 13
During the quarter, net revenues, excluding currency and acquisitions, increased by 42.3%, primarily reflecting: favorable volume/mix, mainly driven by
higher cigarette volume (primarily in Kuwait and PMI Duty Free, partly offset by Algeria) and higher heated tobacco unit volume (notably in Egypt); and a
favorable pricing variance, driven by combustible pricing (mainly in Turkey).
Operating income, excluding currency and acquisitions, increased by 89.9%, mainly reflecting: a favorable pricing variance; favorable volume/mix, mainly
driven by the same factors and geographies as for net revenues noted above; and lower marketing, administration and research costs; partly offset by higher
manufacturing costs (primarily due to inflationary impacts).
Middle East & Africa - Total Market, PMI Shipment Volume and Market Share Commentaries
In the quarter, the estimated total market in the Middle East & Africa decreased, mainly due to:
• Algeria, down by 37.5%, or by 8.2% excluding the net unfavorable impact of estimated trade inventory movements, primarily reflecting industry
supply chain disruptions; and
• Turkey, down by 6.8%, mainly reflecting a higher estimated prevalence of illicit trade, partly offset by the impact on adult smoker average daily
consumption of the easing of pandemic-related measures, coupled with increased in-bound tourism;
partly offset by
• International Duty Free, up by 40.2%, reflecting the impact of reduced government travel restrictions and increased passenger traffic in certain
geographies.
73
-- 74 of 139 --
Table of Contents
Our total shipment volume increased by 8.3% to 30.4 billion units, notably driven by:
• PMI Duty Free, up by +100%, or by 50.8% excluding the net favorable impact of estimated distributor inventory movements, reflecting the higher
total market and a higher market share; and
• Egypt, up by 10.7%, primarily reflecting a higher market share, driven by cigarettes and heated tobacco units;
partly offset by
• Algeria, down by 27.5%, mainly reflecting the lower total market, partly offset by a higher market share driven by cigarettes.
Excluding the net favorable impact of estimated distributor inventory movements, our total in-market sales volume increased by 4.3%.
South & Southeast Asia:
Financial Summary -
Quarters Ended
March 31,
Change
Fav./(Unfav.) Variance
Fav./(Unfav.)
2022 2021 Total
Excl.
Curr. &
Acquis. Total Cur-
rency Acqui-
sitions Price Vol/
Mix Cost/
Other
(in millions)
Net Revenues $ 1,123 $ 1,173 (4.3)% (0.5)% $ (50) $ (44) $ — $ (145) $ 139 $ —
Operating Income $ 445 $ 529 (15.9)% (11.2)% $ (84) $ (25) $ — $ (145) $ 87 $ (1)
During the quarter, net revenues, excluding currency and acquisitions, decreased by 0.5%, reflecting: an unfavorable pricing variance, due to combustible
pricing (mainly in Indonesia and the Philippines); largely offset by favorable volume/mix, primarily driven by higher cigarette volume (mainly in Indonesia
and the Philippines) and favorable cigarette mix (primarily in Indonesia, partly offset by the Philippines).
Operating income, excluding currency and acquisitions, decreased by 11.2%, primarily reflecting: an unfavorable pricing variance; partly offset by
favorable volume/mix, mainly driven by higher cigarette volume (primarily in Indonesia and the Philippines).
74
-- 75 of 139 --
Table of Contents
South & Southeast Asia - Total Market, PMI Shipment Volume and Market Share Commentaries
In the quarter, the estimated total market in South & Southeast Asia increased, mainly due to:
• India, up by 7.2%, primarily reflecting a favorable comparison versus the prior year period, during which pandemic-related restrictions impacted the
movement of certain products, including tobacco;
• Indonesia, up by 5.8%, mainly reflecting impact on adult smoker consumption of the easing of pandemic-related measures, which drove growth in the
tax-advantaged 'below tier one' segment; and
• the Philippines, up by 19.2%, primarily reflecting the net favorable impact of estimated trade inventory movements related to first-quarter 2022 price
increases;
partly offset by
• Bangladesh, down by 12.9%, mainly reflecting the impact of pandemic-related restrictions on mobility during February 2022; and
• Thailand, down by 13.3%, primarily reflecting the impact of excise tax-driven price increases.
Our total shipment volume increased by 7.5% to 37.6 billion units, mainly driven by:
• Indonesia, up by 5.2%, primarily reflecting the higher total market, partly offset by a lower market share (mainly due to adult smoker down-trading to
the 'below tier one' segment as a result of significantly lower retail prices, partly offset by share growth for our premium and hand-rolled portfolio);
and
• the Philippines, up by 18.4%, primarily reflecting the higher total market.
75
-- 76 of 139 --
Table of Contents
East Asia & Australia:
Financial Summary -
Quarters Ended
March 31,
Change
Fav./(Unfav.) Variance
Fav./(Unfav.)
2022 2021 Total
Excl.
Curr. &
Acquis. Total Cur-
rency Acqui-
sitions Price Vol/
Mix Cost/
Other
(in millions)
Net Revenues $ 1,404 $ 1,472 (4.6)% 2.6 % $ (68) $ (106) $ — $ 30 $ 8 $ —
Operating Income $ 571 $ 695 (17.8)% (8.1)% $ (124) $ (68) $ — $ 30 $ (121) $ 35
During the quarter, net revenues, excluding currency and acquisitions, increased by 2.6%, reflecting: a favorable pricing variance, primarily driven by
higher combustible pricing (predominantly in Japan). Volume/mix was slightly favorable, mainly reflecting higher device and heated tobacco unit volume
in Japan, largely offset by unfavorable cigarette mix (primarily in Japan) and unfavorable device mix in Japan.
Operating income, excluding currency and acquisitions, decreased by 8.1%, mainly reflecting: unfavorable volume/mix, primarily due to unfavorable mix
for cigarettes and devices in Japan; and higher manufacturing costs (mainly due to higher logistics costs); partly offset by lower marketing, administration
and research costs (notably driven by a favorable comparison related to 2021 asset impairment and exit costs of $31 million); and a favorable pricing
variance.
East Asia & Australia - Total Market, PMI Shipment Volume and Market Share Commentaries
In the quarter, the estimated total market in East Asia & Australia, excluding China, decreased, mainly due to:
• Japan, down by 3.2%, primarily reflecting the impact of the October 2021 excise tax-driven price increase.
Our total shipment volume increased by 1.7% to 20.8 billion units, mainly driven by:
• Japan, up by 3.2%. Excluding the net favorable impact of estimated distributor inventory movements, total in-market sales volume was essentially
stable.
Excluding the net favorable impact of estimated distributor inventory movements, our total in-market sales volume decreased by 1.0%.
76
-- 77 of 139 --
Table of Contents
Americas:
Financial Summary -
Quarters Ended
March 31,
Change
Fav./(Unfav.) Variance
Fav./(Unfav.)
2022 2021 Total
Excl.
Curr. &
Acquis. Total Cur-
rency Acqui-
sitions Price Vol/
Mix Cost/
Other (in millions)
Net Revenues $ 424 $ 434 (2.3)% 0.7 % $ (10) $ (13) $ — $ 19 $ (16) $ —
Operating Income $ 121 $ 134 (9.7)% (8.2)% $ (13) $ (2) $ — $ 19 $ (9) $ (21)
During the quarter, net revenues, excluding currency and acquisitions, increased by 0.7%, reflecting: a favorable pricing variance, driven by combustible
products (mainly in Argentina, Brazil and Mexico); partly offset by unfavorable volume/mix, mainly due to lower cigarette volume (primarily in
Argentina) and unfavorable cigarette mix (primarily in Brazil).
Operating income, excluding currency and acquisitions, decreased by 8.2%, mainly reflecting: higher manufacturing costs (primarily due to inflationary
impacts); and unfavorable volume/mix (mainly due to the same factors and geographies as for net revenues noted above); partly offset by a favorable
pricing variance.
Americas - Total Market, PMI Shipment Volume and Market Share Commentaries
In the quarter, the estimated total market in Americas, excluding the U.S., decreased, primarily due to:
• Canada, down by 14.3%, notably reflecting the impact of price increases and out-switching from cigarettes to e-vapor products; and
• Mexico, down by 3.8%. Excluding the net unfavorable impact of estimated trade inventory movements, the total market increased by 1.4%, mainly
driven by the impact on adult smoker average daily consumption of the easing of pandemic-related measures, coupled with the impact of increased in-
bound tourism;
partly offset by
• Brazil, up by 4.1%, primarily reflecting a lower estimated prevalence of illicit trade.
77
-- 78 of 139 --
Table of Contents
Our total shipment volume decreased by 0.6% to 14.9 billion units, mainly due to:
• Argentina, down by 7.1%, primarily reflecting a lower market share due to adult smoker down-trading to ultra-low-price brands produced by local
manufacturers;
partly offset by
• Brazil, up by 5.4%, mainly reflecting the higher total market and a higher market share driven by Chesterfield.
Other:
In the third quarter of 2021, we acquired Fertin Pharma A/S, Vectura Group plc. and OtiTopic, Inc. On March 31, 2022, we launched a new Wellness and
Healthcare business consolidating these entities, Vectura Fertin Pharma. The operating results of this new business are reported in the Other category. The
business operations of our Wellness and Healthcare business are managed and evaluated separately from the geographical segments.
Financial Summary -
Quarters Ended
March 31,
Change
Fav./(Unfav.) Variance
Fav./(Unfav.)
2022 2021 Total
Excl.
Curr. &
Acquis. Total Cur-
rency Acqui-
sitions Price Vol/
Mix Cost/
Other (in millions)
Net Revenues $ 66 $ — — % — % $ 66 $ — $ 66 $ — $ — $ —
Operating Income / (Loss) $ (31) $ — — % — % $ (31) $ — $ (24) $ — $ — $ (7)
During the quarter, we recorded net revenues of $66 million, as well as an operating loss of $31 million, primarily reflecting the amortization of intangibles
related to the acquisitions, investments in research and development, and expenses related to employee retention programs.
78
-- 79 of 139 --
Table of Contents
Financial Review
Cash Flow Highlights
For the Three Months Ended March 31,
(in millions) 2022 2021
Net cash provided by operating activities $ 1,118 $ 435
Net cash provided by (used in) investing activities (196) 55
Net cash used in financing activities (701) (3,649)
Net Cash Provided by Operating Activities
During the first quarter of 2022, net cash provided by operating activities increased by $0.7 billion compared with the first quarter of 2021. Excluding
unfavorable currency movements of $0.4 billion, net cash provided by operating activities increased by $1.1 billion, due primarily to higher currency-
neutral net earnings and lower working capital requirements of $0.7 billion.
The lower working capital requirements in the first quarter of 2022 as compared with the first quarter of 2021 were primarily due to the timing of excise
tax-paid inventory movements and excise tax payments, including the 2021 settlement of excise tax liabilities driven by the COVID-19 pandemic-related
build-up of inventory.
Net Cash Provided by (Used in) Investing Activities
During the first quarter of 2022, net cash used in investing activities was $196 million as compared to $55 million of net cash provided by investing
activities in the first quarter of 2021. This change was due primarily to unfavorable movements of $78 million in cash collateral exchanged with financial
institutions to secure derivatives designated as net investment hedges of Euro assets principally related to changes in exchange rates between the Euro and
the U.S. dollar, higher capital expenditures and other investments. For further detail on our derivatives designated as net investment hedges and other
investments, see Note 5. Financial Instruments.
Capital expenditures of $229 million during the first quarter of 2022 increased slightly as compared with the first quarter of 2021. The 2022 capital
expenditures were primarily related to our ongoing investments in RRPs. We expect total capital expenditures in 2022 to be approximately $1.0 billion.
79
-- 80 of 139 --
Table of Contents
Net Cash Used in Financing Activities
During the first quarter of 2022, net cash used in financing activities decreased by $2.9 billion compared to the first quarter of 2021. The lower cash usage
primarily reflected proceeds from short-term borrowings in 2022 (primarily commercial paper of $2.2 billion) and lower long-term debt repayments ($0.5
billion in 2022 compared with 1.6 billion in 2021), partially offset by share repurchases in the first quarter of 2022 under our share repurchase program and
the purchase of the remaining stakes in our Turkish affiliates in the first quarter of 2022. For further details on the purchase of the remaining stakes in our
Turkish affiliates, see Note 17. Acquisitions.
Debt and Liquidity
We define cash and cash equivalents as short-term, highly liquid investments, readily convertible to known amounts of cash that mature within a maximum
of three months and have an insignificant risk of change in value due to interest rate or credit risk changes. As a policy, we do not hold any investments in
structured or equity-linked products. Our cash and cash equivalents are predominantly held with institutions that have investment-grade long-term credit
rating. As part of our cash management strategy and in order to manage counterparty exposure, we also enter into reverse repurchase agreements. Such
agreements are collateralized with government or corporate securities held by a custodial bank and, at maturity, cash is paid back to PMI, and the collateral
is returned to the bank. For the three months ended March 31, 2022 and the full-year 2021, the activities for such reverse repurchase agreements were not
material.
We utilize long-term and short-term debt financing, including a commercial paper program that is regularly used to finance ongoing liquidity requirements,
as part of our overall cash management strategy. Our ability to access the capital and credit markets as well as overall dynamics of these markets may
impact borrowing costs. We expect that the combination of our long-term and short-term debt financing, the commercial paper program and the committed
credit facilities, coupled with our operating cash flows, will enable us to meet our liquidity requirements.
In August 2021, we published a business transformation-linked financing framework (“Framework”), which integrates the company’s smoke-free
transformation into its financing strategy. The Framework outlines the guidelines that we will follow in issuing business transformation-linked financing
instruments in the debt capital and loan markets, which may include public notes offerings, private placements, loans, and other relevant financing
instruments.
Credit Ratings – The cost and terms of our financing arrangements as well as our access to commercial paper markets may be affected by applicable credit
ratings. At March 31, 2022, our credit ratings and outlook by major credit rating agencies were as follows:
Short-term Long-term Outlook
Moody’s P-1 A2 Stable
Standard & Poor’s A-1 A Stable
Fitch F1 A Stable
80
-- 81 of 139 --
Table of Contents
Credit Facilities
At March 31, 2022, our committed credit facilities were as follows:
(in billions)
Type
Committed
Credit
Facilities
364-day revolving credit, expiring January 31, 2023 $ 1.8
Multi-year revolving credit, expiring February 10, 2026 2.0
Multi-year revolving credit, expiring September 29, 2026 2.5
Total facilities $ 6.3
On January 28, 2022, we entered into an agreement, effective February 10, 2022, to amend and extend the term of our $2.0 billion multi-year revolving credit facility, for
an additional year covering the period February 11, 2026 to February 10, 2027, in the amount of $1.9 billion.
Includes business transformation-linked pricing adjustments that may result in the reduction or increase in both the interest rate and commitment fee under the credit
agreement if PMI achieves, or fails to achieve, certain specified targets based on its business transformation goals.
At March 31, 2022, there were no borrowings under the committed credit facilities, and the entire committed amounts were available for borrowing.
Subject to market conditions, we currently expect to request an extension of the terms of our $2.5 billion multi-year revolving credit facility for an
additional one-year period, in accordance with and subject to the terms and conditions of the relevant revolving credit facility agreement.
All banks participating in our committed credit facilities have an investment-grade long-term credit rating from the credit rating agencies. We continuously
monitor the credit quality of our banking group, and at this time we are not aware of any potential non-performing credit provider.
These facilities do not include any credit rating triggers, material adverse change clauses or any provisions that could require us to post collateral. We
expect to continue to meet our covenants.
In addition to the committed credit facilities discussed above, certain of our subsidiaries maintain short-term credit arrangements to meet their respective
working capital needs. These credit arrangements, which amounted to approximately $2.3 billion at March 31, 2022 and December 31, 2021, are for the
sole use of our subsidiaries. Borrowings under these arrangements and other bank loans amounted to $208 million at March 31, 2022, and $225 million at
December 31, 2021.
Commercial Paper Program – We continue to have access to liquidity in the commercial paper market through programs in place in the U.S. and in Europe
having an aggregate issuance capacity of $8.0 billion. At March 31, 2022, we had $2.2 billion of commercial paper outstanding. At December 31, 2021, we
had no commercial paper outstanding. The average commercial paper balance outstanding during the first three months of 2022 was $3.7 billion. The
average commercial paper balance outstanding during 2021 was $1.1 billion.
Sale of Accounts Receivable – To mitigate credit risk and enhance cash and liquidity management, we sell trade receivables to unaffiliated financial
institutions. These arrangements allow us to sell, on an ongoing basis, certain trade receivables without recourse. The trade receivables sold are generally
short-term in nature and are removed from the condensed consolidated balance sheets. We sell trade receivables under two types of arrangements, servicing
and nonservicing.
Our operating cash flows were positively impacted by the amount of the trade receivables sold and derecognized from the condensed consolidated balance
sheets, which remained outstanding with the unaffiliated financial institutions. The trade receivables sold that remained outstanding under these
arrangements as of March 31, 2022, and March 31, 2021 were $598 million and $625 million, respectively. The net proceeds received are included in cash
provided by operating activities in the condensed consolidated statements of cash flows.
For further details, see Note 13. Sale of Accounts Receivable to our condensed consolidated financial statements.
Debt – Our total debt was $29.4 billion at March 31, 2022 and $27.8 billion at December 31, 2021.
(1)
(2)
(1)
(2)
81
-- 82 of 139 --
Table of Contents
On February 11, 2020, we filed a shelf registration statement with the U.S. Securities and Exchange Commission, under which we may from time to time
sell debt securities and/or warrants to purchase debt securities over a three-year period.
Guarantees – At March 31, 2022, we have guarantees of our own performance, which are primarily related to excise taxes on the shipment of our products.
There is no liability in the condensed consolidated financial statements associated with these guarantees. These guarantees have not had, and are not
expected to have, a significant impact on PMI’s liquidity. In October 2020, we guaranteed an obligation for an equity method investee. For further details,
see Note 8. Contingencies to our condensed consolidated financial statements.
Equity and Dividends
We discuss our stock awards as of March 31, 2022 in Note 2. Stock Plans to our condensed consolidated financial statements.
On June 11, 2021, our Board of Directors authorized a new share repurchase program of up to $7 billion, with target spending of $5 billion to $7 billion
over a three-year period. On July 22, 2021, we began repurchasing shares under this new share repurchase program. From July 22, 2021 through March 31,
2022, we repurchased 10.5 million shares of our common stock at a cost of approximately $1.0 billion. During the first quarter of 2022, we repurchased 2.0
million shares of our common stock at a cost of $199 million.
Dividends paid in the first quarter of 2022 were $2.0 billion. During the third quarter of 2021, our Board of Directors approved a 4.2% increase in the
quarterly dividend to $1.25 per common share. As a result, the present annualized dividend rate is $5.00 per common share.
Market Risk
Counterparty Risk - We predominantly work with financial institutions with strong short- and long-term credit ratings as assigned by Standard & Poor’s
and Moody’s. These banks are also part of a defined group of relationship banks. Non-investment grade institutions are only used in certain emerging
markets to the extent required by local business needs. We have a conservative approach when it comes to choosing financial counterparties and financial
instruments. As such, we do not invest or hold investments in any structured or equity-linked products. The majority of our cash and cash equivalents is
currently invested with maturities of less than 30 days.
We continuously monitor and assess the credit worthiness of all our counterparties.
Derivative Financial Instruments - We operate in markets outside of the United States of America, with manufacturing and sales facilities in various
locations throughout the world. Consequently, we use certain financial instruments to manage our foreign currency and interest rate exposure. We use
derivative financial instruments principally to reduce our exposure to market risks resulting from fluctuations in foreign exchange and interest rates by
creating offsetting exposures. We are not a party to leveraged derivatives and, by policy, do not use derivative financial instruments for speculative
purposes.
See Note 5. Financial Instruments to our condensed consolidated financial statements for further details on our derivative financial instruments and the
related collateral arrangements.
Contingencies
See Note 8. Contingencies to our condensed consolidated financial statements for a discussion of contingencies.
Cautionary Factors That May Affect Future Results
Forward-Looking and Cautionary Statements
We may from time to time make written or oral forward-looking statements, including statements contained in filings with the SEC, in reports to
stockholders and in press releases and investor webcasts. You can identify these forward-looking statements by use of words such as "strategy," "expects,"
"continues," "plans," "anticipates," "believes," "will," "aspires," "estimates," "intends," "projects," "aims," "goals," "targets," "forecasts" and other words of
similar meaning. You can also identify them by the fact that they do not relate strictly to historical or current facts.
82
-- 83 of 139 --
Table of Contents
We cannot guarantee that any forward-looking statement will be realized, although we believe we have been prudent in our plans and assumptions. Our
RRPs constitute a new product category in its early stages that is less predictable than our mature cigarette business. Achievement of future results is
subject to risks, uncertainties and inaccurate assumptions. Should known or unknown risks or uncertainties materialize, or should underlying assumptions
prove inaccurate, actual results could vary materially from those anticipated, estimated or projected. Investors should bear this in mind as they consider
forward-looking statements and whether to invest in or remain invested in our securities. In connection with the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995, we are identifying important factors that, individually or in the aggregate, could cause actual results and
outcomes to differ materially from those contained in any forward-looking statements made by us; any such statement is qualified by reference to the
following cautionary statements. We elaborate on these and other risks we face throughout this document, particularly in the "Business Environment"
section. You should understand that it is not possible to predict or identify all risk factors. Consequently, you should not consider the following to be a
complete discussion of all potential risks or uncertainties. We do not undertake to update any forward-looking statement that we may make from time to
time, except in the normal course of our public disclosure obligations.
Overall Business Risks
We may be unsuccessful in our attempts to introduce reduced-risk products, and regulators may not permit the commercialization of these products or the
communication of scientifically substantiated information and claims.
Our key strategic priorities are to: (i) develop and commercialize products that present less risk of harm to adult smokers who switch to those products
versus continued smoking; and (ii) convince and educate current adult smokers who would otherwise continue to smoke to switch to those RRPs. For our
efforts to be successful, we must:
• develop RRPs that adult smokers find acceptable alternatives to smoking;
• conduct rigorous scientific studies to substantiate that they reduce exposure to harmful and potentially harmful constituents in smoke and,
ultimately, that these products present, are likely to present, or have the potential to present less risk of harm to adult smokers who switch to
them versus continued smoking; and
• effectively advocate for a timely development of science-based regulatory frameworks for the development and commercialization of RRPs,
including communication of scientifically substantiated information to enable adult smokers to make better consumer choices.
We might not succeed in our efforts. If we do not succeed, but others do, or if heat-not-burn products are inequitably regulated compared to other RRP
categories without regard to the totality of the scientific evidence available for such products, we may be at a competitive disadvantage. In addition, actions
of some market entrants, such as the inappropriate marketing of e-vapor products to youth, as well as alleged health consequences associated with the use
of certain e-vapor products, may unfavorably impact public opinion and/or mischaracterize all e-vapor products or other RRPs to consumers, regulators and
policy makers without regard to the totality of scientific evidence available for specific products. This may impede our efforts to advocate for the
development of science-based regulatory frameworks for the development and commercialization of RRPs. We cannot predict whether regulators will
permit the sale and/or marketing of RRPs with scientifically substantiated information and claims. Such restrictions could limit the success of our RRPs.
The WHO study group on tobacco product regulation ("TobReg") published their eighth report on the scientific basis of tobacco product regulation in May
2021. The report is based on a review of scientific evidence related to novel and emerging nicotine and tobacco products, such as electronic nicotine
delivery systems ("ENDS"), electronic non-nicotine delivery systems ("ENNDS") and heated tobacco products ("HTPs") on a number of scientific topics.
The report concludes by making a number of policy recommendations on HTPs and ENDS that, if implemented, could restrict both the availability of these
products, and the access to accurate information about them. In August 2021, the WHO FCTC Secretariat published two reports to the ninth session of the
Conference of the Parties ("CoP") of the FCTC, which are not materially different from the WHO study group report.
Prior to CoP 9 that took place in November 2021, the WHO and the WHO FCTC Secretariat published two reports on novel and emerging tobacco
products. The reports were noted by CoP 9 and related substantive discussions and decisions were deferred to CoP 10, currently scheduled for 2023. It is
not possible to predict whether or to what extent measures recommended by the WHO's reports will be implemented as the reports are not binding to the
WHO Member States.
Additionally, any claims, regardless of merit, challenging our research and clinical data available to date, may impact the development of science-based
regulatory frameworks for the commercialization of the RRP category and the commercialization of the RRP category in general.
83
-- 84 of 139 --
Table of Contents
Our RRPs and commercial activities for these products are designed for, and directed toward, current adult smokers and users of nicotine-containing
products, and not for non-smokers or youth. We put significant effort in place to restrict access of our products to non-smokers or youth. Nevertheless,
technological, operational, regulatory and/or commercial setbacks might prevent us from delivering necessary infrastructure required to fulfill our
commitment of having 100% of our RRP device portfolio equipped with “Age Verification”-technology and device activation features by 2023.
If nonetheless there is a significant usage of our products or competitive products among youth or non-smokers, even in situations over which we have no
control, our credibility may suffer, and our efforts to advocate for the development of science-based regulatory frameworks for the development and
commercialization of RRPs may be significantly impacted.
Moreover, the FDA’s premarket tobacco product and modified risk tobacco product authorizations of two versions of our Platform 1 product are subject to
strict marketing, reporting and other requirements. Although we have received these products' authorizations from the FDA, there is no guarantee that the
product will remain authorized for sale in the U.S., particularly if there is a significant uptake in youth or non-smoker initiation.
The financial and business performance of our reduced-risk products is less predictable than our cigarette business.
Our RRPs are novel products in a new category, and the pace at which adult smokers adopt them may vary, depending on the competitive, regulatory, fiscal
and cultural environment, and other factors in a specific market. There may be periods of accelerated growth and periods of slower growth for these
products, the timing and drivers of which may be more difficult for us to predict versus our mature cigarette business. The impact of this lower
predictability on our projected results for a specific period may be significant, particularly during the early stages of this new product category, during the
COVID-19 pandemic as a result of unpredictability due to shortage of key components in our supply chain or due to geopolitical or macroeconomic events
that negatively impact RRP availability or adoption.
We may be unsuccessful in our efforts to differentiate reduced-risk products and cigarettes with respect to taxation.
To date, we have been largely successful in demonstrating to regulators that our RRPs are not cigarettes due to the absence of combustion, and as such they
are generally taxed either as a separate category or as other tobacco products, which typically yields more favorable tax rates than cigarettes. Nevertheless,
we are unable to predict whether regulators will be issuing new regulations where RRP will be equally taxed in line with other tobacco products such as
ordinary cigarettes. However, if we cease to be successful in these efforts, RRP unit margins may be materially adversely affected.
Consumption of tax-paid cigarettes continues to decline in many of our markets.
This decline is due to multiple factors, including increased taxes and pricing, governmental actions, the diminishing social acceptance of smoking and
health concerns, competition, continuing economic and geopolitical uncertainty, and the continuing prevalence of illicit products. These factors and their
potential consequences are discussed more fully below and in the Business Environment section. A continuous decline in the consumption of cigarettes
could have a material adverse effect on our revenue and profitability.
Cigarettes are subject to substantial taxes. Significant increases in cigarette-related taxes have been proposed or enacted and are likely to continue to be
proposed or enacted in numerous jurisdictions. These tax increases may disproportionately affect our profitability and make us less competitive versus
certain of our competitors.
Tax regimes, including excise taxes, sales taxes and import duties, can disproportionately affect the retail price of cigarettes versus other combustible
tobacco products, or disproportionately affect the relative retail price of our cigarette brands versus cigarette brands manufactured by certain of our
competitors. Because our portfolio is weighted toward the premium-price cigarette category, tax regimes based on sales price can place us at a competitive
disadvantage in certain markets. Furthermore, our volume and profitability may be adversely affected in these markets.
In addition, increases in cigarette taxes are expected to continue to have an adverse impact on our sales of cigarettes, due to resulting lower consumption
levels, a shift in sales from manufactured cigarettes to other combustible tobacco products and from the premium-price to the mid-price or low-price
cigarette categories, where we may be under-represented, from local sales to legal cross-border purchases of lower price products, or to illicit products such
as contraband, counterfeit and "illicit whites."
84
-- 85 of 139 --
Table of Contents
Our business faces significant governmental action aimed at increasing regulatory requirements with the goal of reducing or preventing the use of tobacco
products.
Governmental actions, combined with the diminishing social acceptance of smoking and private actions to restrict smoking, have resulted in reduced
industry volumes for our products in many of our markets, and we expect that such factors will continue to reduce consumption levels and will increase
down-trading and the risk of counterfeiting, contraband, "illicit whites" and legal cross-border purchases. Significant regulatory developments will continue
to take place over the next few years in most of our markets, driven principally by the World Health Organization's Framework Convention on Tobacco
Control (the "FCTC"). Since it came into force in 2005, the FCTC has led to increased efforts by tobacco control advocates and public health organizations
to promote increasingly restrictive regulatory measures on the marketing and sale of tobacco products to adult smokers. Regulatory initiatives that have
been proposed, introduced or enacted by governmental authorities in various jurisdictions include:
• restrictions on or licensing of outlets permitted to sell cigarettes;
• the levying of substantial and increasing tax and duty charges;
• restrictions or bans on advertising, marketing and sponsorship;
• the display of larger health warnings, graphic health warnings and other labeling requirements;
• restrictions on packaging design, including the use of colors, and mandating plain packaging;
• restrictions on packaging and cigarette formats and dimensions;
• restrictions or bans on the display of tobacco product packaging at the point of sale and restrictions or bans on vending machines;
• requirements regarding testing, disclosure and performance standards for tar, nicotine, carbon monoxide and other smoke constituents;
• disclosure, restrictions, or bans of tobacco product ingredients, including bans on the flavors of certain tobacco products;
• increased restrictions on smoking and use of tobacco and nicotine-containing products in public and work places and, in some instances, in
private places and outdoors;
• restrictions or prohibitions of novel tobacco or nicotine-containing products;
• elimination of duty free sales and duty free allowances for travelers;
• encouraging litigation against tobacco companies; and
• excluding tobacco companies from transparent public dialogue regarding public health and other policy matters.
Our financial results could be materially affected by regulatory initiatives resulting in a significant decrease in demand for our brands. More specifically,
requirements that lead to a commoditization of tobacco products or impede adult consumers' ability to convert to our RRPs, as well as any significant
increase in the cost of complying with new regulatory requirements could have a material adverse effect on our financial results.
Changes in the earnings mix and changes in tax laws may result in significant variability in our effective tax rates. Our ability to receive payments from
foreign subsidiaries or to repatriate royalties and dividends could be restricted by local country currency exchange controls and other regulations.
We are subject to income tax laws in the United States and numerous foreign jurisdictions. The new administration resulting from the 2020 U.S.
presidential and congressional elections could lead to changes in the U.S. tax system, including significant increases in the U.S. corporate income tax rate
and the minimum tax rate on certain earnings of foreign subsidiaries. If ultimately enacted into law, such changes could have a material adverse impact on
our effective tax rate thereby reducing our net earnings. Further changes in the tax laws of foreign jurisdictions could arise as a result of the base erosion
and profit shifting project undertaken by the Organisation for Economic Co-operation and Development, which recommended changes to numerous long-
standing tax principles. If implemented, such changes, as well as changes in taxing jurisdictions’ administrative interpretations, decisions, policies, or
positions, could also have a material adverse impact on our effective tax rate thereby reducing our net earnings. In future periods, our ability to recover
deferred tax assets could be subject to additional uncertainty
85
-- 86 of 139 --
Table of Contents
as a result of such developments. Furthermore, changes in the earnings mix or applicable foreign tax laws may result in significant variability in our
effective tax rates.
As a result of Russia’s invasion of Ukraine, certain taxing jurisdictions, including the U.S., have proposed punitive tax legislation applicable to companies
doing business in Russia. While we are working on options to exit the Russian market in an orderly manner, these punitive tax law changes, if enacted,
could also have a material adverse impact on our effective tax rate thereby reducing our net earnings. Further, in the event we are able to successfully exit
the Russian market, the sale of our Russian assets may result in U.S. tax liabilities that are material to our financial results.
Because we are a U.S. holding company, our most significant source of funds is distributions from our non-U.S. subsidiaries. Certain countries in which we
operate have adopted or could institute currency exchange controls and other regulations that limit or prohibit our local subsidiaries' ability to convert local
currency into U.S. dollars or to make payments outside the country. This could subject us to the risks of local currency devaluation and business disruption.
Risks Related to the Impact of the War in Ukraine on our Business
Our business, results of operations, cash flows and financial position may be adversely impacted by the continuation and consequences of the war in
Ukraine.
As previously disclosed in this Form 10-Q, in 2021, Russia accounted for around 10% of our total cigarette and heated tobacco unit shipment volume, and
around 6% of our total net revenues. Ukraine accounted for around 2% of our total cigarette and heated tobacco unit shipment volume, and under 2% of our
total net revenues. We also produce finished goods in Ukraine for export and manufacture products in Russia. As a result of Russia’s invasion of Ukraine,
we have suspended planned investments in Russia, including all new product launches and commercial, innovation, and manufacturing investments. We
have also initiated plans to scale down our Russian manufacturing operations and are working on options to exit the Russian market in an orderly manner.
In Ukraine, we have temporarily reduced operations, including closing our factory in the country.
The short and long-term implications of the Russian invasion of Ukraine for our operations in those countries are impossible to predict at this time. There
can be no assurance that our exit from the Russian market will be successful, orderly, or represent a fair value for our Russian assets and operations. The
likelihood of retaliatory action by the Russian government against companies, including us, as a result of actions and statements made in response to the
Russian invasion, including the possibility of legal action against us or our employees or nationalization of foreign businesses or assets, including
intangible assets such as trademarks, is impossible to predict. Further, if we are able to divest our Russian assets in an orderly manner, the nature of our
divestiture may adversely impact the value we receive for those assets. In Ukraine, there is no way to know when and to what extent we will be able to
normalize our operations or to what extent our workforce, facilities, inventory, and other assets will remain intact. These developments have and will
continue to have a material adverse impact on our business, results of operations, cash flows and financial position, and may result in impairment charges.
The conflict also elevates the likelihood of supply chain disruptions, both in the region and globally, and may inhibit our ability to timely source materials
and services needed to make and sell our products. For example, we source certain finished goods, production materials and components from both Russia
and Ukraine, including printed materials and filters, and the invasion has, and may continue to, disrupt the availability of and impact our supply chain for
these materials. These disruptions, to the extent we are unable to find alternative sources or otherwise address these supply constraints, may impact the
availability and cost of our products in other markets, which would adversely impact our business, results of operations, cash flows and financial position,
and may result in impairment charges.
The broader consequences of the invasion are also impossible to predict, but could include reputational consequences, further sanctions, financial or
currency restrictions, punitive tax law changes, embargoes, regional instability, and geopolitical shifts as well as adverse effects on macroeconomic
conditions, security conditions, currency exchange rates, and financial markets. Given the nature of our business and global operations, such geo-political
instability and uncertainty could increase the costs of our materials and operations; reduce demand for our products; have a negative impact on our supply
chains, manufacturing capabilities, or distribution capabilities; increase our exposure to currency fluctuations; constrain our liquidity or our ability to access
capital markets; create staffing or operations difficulties; or subject us to increased cyber-attacks. While we will continue to monitor this fluid situation and
develop contingency plans as necessary to address any disruptions to our business operations as they develop, the extent of the conflict’s effect on our
business and results of operations as well as the global economy, cannot be predicted.
The conflict may also have the effect of heightening many other risks disclosed in this Form 10-Q, any of which could adversely affect our business, results
of operations, cash flows or financial position. Such risks include, but are not limited to, the achievement of our strategic priorities, including achievement
of our RRP growth targets; the availability of third-party
86
-- 87 of 139 --
Table of Contents
manufacturing resources; the availability of attractive acquisition and strategic business opportunities and our ability to fully realize the benefits of these
transactions; our ability to attract, motivate, and retain the best global talent; and our loss of revenue from counterfeiting and similar illicit activities.
Risks Related to Sourcing of Materials, Products and Services
Use of third-party resources may negatively impact quality and availability of our products and services, and we may be required to replace third-party
contract manufacturers or service providers with our own resources.
We increasingly rely on third-party resources and their subcontractors/suppliers to manufacture some of our products and product parts (particularly, the
electronic devices and accessories), and to provide services, including to support our finance, commercialization and information technology processes.
While many of these arrangements improve efficiencies and decrease our operating costs, they also diminish our direct control. Such diminished control
may have a material adverse effect on the quality and availability of products or services, our supply chain, and the speed and flexibility in our response to
changing market conditions and adult consumer preferences, all of which may place us at a competitive disadvantage. In addition, we may be unable to
renew these agreements on satisfactory terms for numerous reasons, including government regulations, and our costs may increase significantly if we must
replace such third parties with our own resources.
Government mandated prices, production control programs, shifts in crops driven by economic conditions and the impact of climate change may increase
the cost or reduce the quality of the tobacco and other agricultural products used to manufacture our products.
As with other agricultural commodities, the price of tobacco leaf and cloves can be influenced by imbalances in supply and demand and the impacts of
natural disasters and pandemics such as COVID-19. Furthermore, crop quality may be influenced by variations in weather patterns, including those caused
by climate change. Tobacco production in certain countries is subject to a variety of controls, including government mandated prices and production control
programs. Changes in the patterns of demand for agricultural products could cause farmers to produce less tobacco or cloves. Any significant change in
tobacco leaf and clove prices, quality and quantity could affect our profitability and our business.
Risks Related to our International Operations
Because we have operations in numerous countries, our results may be adversely impacted by economic, regulatory and political developments, natural
disasters, pandemics or conflicts.
Some of the countries in which we operate face the threat of civil unrest and can be subject to regime changes. In others, nationalization, terrorism, conflict
and the threats of war or acts of war may have a significant impact on the business environment. Natural disasters, pandemics, economic, political,
regulatory, acts of war or threats of war, or other developments could disrupt our supply chain, manufacturing capabilities or distribution capabilities, and
our business continuity plans and other safeguards might not always be effective to fully mitigate their impact. In addition, such developments could
increase costs of our materials and operations and lead to loss of property or equipment that are critical to our business in certain markets and difficulty in
staffing and managing our operations, all of which could have a material adverse effect on our operations, volumes, revenue, net earnings and profitability.
We discuss risks associated with the invasion of Ukraine above and with the COVID-19 pandemic below.
In certain markets, we are dependent on governmental approvals of various actions such as price changes, and failure to obtain such approvals could impair
growth of our profitability.
In addition, despite our high ethical standards and rigorous controls and compliance procedures aimed at preventing and detecting unlawful conduct, given
the breadth and scope of our international operations, we may not be able to detect all potential improper or unlawful conduct by our employees and
partners. Such improper or unlawful conduct (actual or alleged) could lead to litigation and regulatory action, cause damage to our reputation and that of
our brands, and result in substantial costs.
Our reported results could be adversely affected by unfavorable currency exchange rates, and currency fluctuations could impair our competitiveness.
We conduct our business primarily in local currency and, for purposes of financial reporting, the local currency results are translated into U.S. dollars based
on average exchange rates prevailing during a reporting period. Foreign currencies may fluctuate significantly against the U.S. dollar reducing our net
revenues, operating income and EPS. Our primary local currency
87
-- 88 of 139 --
Table of Contents
cost bases may be different from our primary currency revenue markets, and U.S. dollar fluctuations against various currencies may have disproportionate
negative impact on net revenues as compared to our gross profit and operating income margins.
Risks Related to Legal Challenges and Investigations
Litigation related to tobacco use and exposure to environmental tobacco smoke could substantially reduce our profitability and could severely impair our
liquidity.
There is litigation related to tobacco products pending in certain jurisdictions in which we operate. Damages claimed in some tobacco-related litigation are
significant and, in certain cases in Brazil, Canada, and Nigeria, range into the billions of U.S. dollars. We anticipate that new cases will continue to be filed.
The FCTC encourages litigation against tobacco product manufacturers. It is possible that our consolidated results of operations, cash flows or financial
position could be materially adversely affected in a particular fiscal quarter or fiscal year by an unfavorable outcome or settlement of certain pending
litigation. We face various administrative and legal challenges related to certain RRP activities, including allegations concerning product classification,
advertising restrictions, corporate communications, product coach activities, scientific substantiation, product liability, and unfair competition. While we
design our programs to comply with relevant regulations, we expect these or similar challenges to continue as we expand our efforts to commercialize
RRPs and to communicate publicly. The outcomes of these matters may affect our RRP commercialization and public communication activities and
performance in one or more markets. Also see Note 8. Contingencies to our condensed consolidated financial statements for a discussion of pending
litigation.
From time to time, we are subject to governmental investigations on a range of matters.
Investigations include allegations of contraband shipments of cigarettes, allegations of unlawful pricing activities within certain markets, allegations of
underpayment of income taxes, customs duties and/or excise taxes, allegations of false and misleading usage of descriptors, allegations of unlawful
advertising, and allegations of unlawful labor practices. We cannot predict the outcome of those investigations or whether additional investigations may be
commenced, and it is possible that our business could be materially adversely affected by an unfavorable outcome of pending or future investigations. See
Note 8. Contingencies—Other Litigation and “Management's Discussion and Analysis of Financial Condition and Results of Operations—Operating
Results by Business Segment—Business Environment—Governmental Investigations” for a description of certain governmental investigations to which we
are subject.
We may be unable to adequately protect our intellectual property rights, and disputes relating to intellectual property rights could harm our business.
Our intellectual property rights are valuable assets, and their protection is important to our business. If the steps we take to protect our intellectual property
rights globally, including through applying for, prosecuting, maintaining and enforcing, where relevant, a combination of trademark, design, copyright,
patent, trade secrets and other intellectual property rights, are inadequate, or if others infringe or misappropriate our intellectual property rights,
notwithstanding legal protection, our business could be adversely impacted. Moreover, failing to manage our existing and/or future intellectual property
may place us at a competitive disadvantage. Intellectual property rights of third parties may limit our ability to develop, manufacture and/or commercialize
our products in one or more markets. Competitors or other third parties may claim that we infringe their intellectual property rights. Any such claims,
regardless of merit, could divert management’s attention, be costly, disruptive, time-consuming and unpredictable and expose us to significant litigation
costs and damages, and may impede our ability to develop, manufacture and/or commercialize new RRPs and improve our products, and thus have a
material adverse effect on our revenue and our profitability. In addition, if, as a result, we are unable to manufacture or sell our RRPs or improve their
quality in one or more markets, our ability to convert adult smokers to our RRPs in such markets would be adversely affected. See Note 8. Contingencies—
Other Litigation to our condensed consolidated financial statements for a description of certain intellectual property proceedings.
Risks Related to our Competitive Environment
We face intense competition, and our failure to compete effectively could have a material adverse effect on our profitability and results of operations.
We are subject to highly competitive conditions in all aspects of our business. We compete primarily on the basis of product quality, brand recognition,
brand loyalty, taste, R&D, innovation, packaging, customer service, marketing, advertising and retail price and, increasingly, adult smoker willingness to
convert to our RRPs. The competitive environment and our competitive
88
-- 89 of 139 --
Table of Contents
position can be significantly influenced by weak economic conditions, erosion of consumer confidence, competitors' introduction of lower-price products
or innovative products, higher tobacco product taxes, higher absolute prices and larger gaps between retail price categories, and product regulation that
diminishes the ability to differentiate tobacco products and restricts adult consumer access to truthful and non-misleading information about our RRPs.
Competitors in our industry include three large international tobacco companies, new market entrants, particularly with respect to innovative products,
several regional and local tobacco companies and, in some instances, state-owned tobacco enterprises, principally in Algeria, Egypt, the PRC, Taiwan,
Thailand and Vietnam. Some competitors have different profit, volume and regulatory objectives, and some international competitors are susceptible to
changes in different currency exchange rates. Certain new market entrants in the non-combustible product category may alienate consumers from
innovative products through inappropriate marketing campaigns, messaging and inferior product satisfaction, while not relying on scientific substantiation
based on appropriate R&D protocols and standards. The growing use of digital media could increase the speed and extent of the dissemination of inaccurate
and misleading information about our RRPs, all of which could have a mutual adverse effect on our profitability and results of operations.
We may be unable to anticipate changes in adult consumer preferences.
Our business is subject to changes in adult consumer preferences, which may be influenced by local economic conditions, accessibility to our products and
availability of accurate information related to our products.
To be successful, we must:
• promote brand equity successfully;
• anticipate and respond to new adult consumer trends;
• ensure that our products meet our quality standards;
• develop new products and markets and broaden brand portfolios;
• improve productivity;
• educate and convince adult smokers to convert to our RRPs;
• ensure effective adult consumer engagement, including communication about product characteristics and usage of RRPs;
• provide excellent customer care;
• ensure adequate production capacity to meet demand for our products; and
• be able to protect or enhance margins through price increases.
In periods of economic uncertainty, adult consumers may tend to purchase lower-price brands, and the volume of our premium-price and mid-price brands
and our profitability could be materially adversely impacted as a result. Such down-trading trends may be reinforced by regulation that limits branding,
communication and product differentiation.
Our ability to grow profitability may be limited by our inability to introduce new products, enter new markets or improve our margins through higher
pricing and improvements in our brand and geographic mix.
Our profit growth may be materially adversely impacted if we are unable to introduce new products or enter new markets successfully, to raise prices or to
improve the proportion of our sales of higher margin products and in higher margin geographies.
We may be unable to expand our brand portfolio through successful acquisitions or the development of strategic business relationships, and the intended
benefits from our investments may not materialize.
One element of our growth strategy is to expand our brand portfolio and market positions through selective acquisitions and the development of strategic
business relationships. Acquisition and strategic business development opportunities are limited and present risks of failing to achieve efficient and
effective integration, strategic objectives and/or anticipated revenue improvements and cost savings. There is no assurance that we will be able to acquire
attractive businesses or enter into strategic business relationships on favorable terms ahead of our competitors, or that such acquisitions or strategic
business development relationships will be accretive to earnings or improve our competitive position. In addition, we may not have a controlling position in
certain strategic investments or relationships, which could impact the extent to which the intended financial growth and other benefits from these
investments or relationships may ultimately materialize.
89
-- 90 of 139 --
Table of Contents
Our ability to achieve our strategic goals may be impaired if we fail to attract, motivate and retain the best global talent and effectively align our
organizational design with the goals of our transformation.
To be successful, we must continue transforming our culture and ways of working, align our talent and organizational design with our increasingly complex
business needs, and innovate and transform to a consumer-centric business. We compete for talent, including in areas that are new to us, such as digital,
information technology, life sciences, with companies in the consumer products, technology, pharmaceutical and other sectors that enjoy greater societal
acceptance. As a result, we may be unable to attract, motivate and retain the best global talent with the right degree of diversity, experience and skills to
achieve our strategic goals.
Risks Related to the Impact of COVID-19 on our Business
Our business, results of operations, cash flows and financial position may be adversely impacted during the continuation of the COVID-19 pandemic.
The ongoing COVID-19 pandemic has created significant societal and economic disruption, and resulted in closures of stores, factories and offices, and
restrictions on manufacturing, distribution and travel, all of which have and will continue to adversely impact our business, results of operations, cash flows
and financial position. Our business continuity plans and other safeguards may not be effective to mitigate the impact of the pandemic.
An adequate supply chain for our cigarettes and RRP portfolio, including the supply of electronic devices, is important to our business. We work with four
electronics manufacturing service providers for the supply of our Platform 1 and Platform 4 devices, and a small number of other providers for other
products in our RRP portfolio and related accessories. Due to the COVID-19 pandemic, the operations of our two main electronic manufacturing service
providers were temporarily suspended at different times. Even though these suspensions did not materially affect our operations, if one or more of these
service providers were significantly constrained at the same time, the supply of the devices could be disrupted. Although we work closely with these
service providers on monitoring their production capability and financial health, we cannot guarantee that they will remain capable of meeting their
commitments, particularly during the ongoing COVID-19 pandemic; if they will not, the commercialization of our RRPs could be adversely affected. The
production of our RRP portfolio requires various metals, and we believe that there is an adequate supply of such metals in the world markets to satisfy our
current and anticipated production requirements. However, some components and materials necessary for the production of our RRPs, including those for
the electronic devices, are obtained from single or limited sources, and can be subject to industry-wide shortages and price fluctuations. While we were
successful in maintaining adequate supply of such components and materials so far, we may not be able to secure such supply going forward, particularly
during the COVID-19 pandemic; this could negatively impact the commercialization of our RRPs.
Significant risks to our business during the ongoing COVID-19 pandemic also include our diminished ability to convert adult smokers to our RRPs,
significant volume declines in our duty-free business and certain other key markets, disruptions or delays in our manufacturing and supply chain, including
delays and increased costs in the shipment of parts to manufacture our products or for the products themselves, increased currency volatility, and delays in
certain cost saving, transformation and restructuring initiatives. Our business could also be adversely impacted if key personnel or a significant number of
employees or business partners become unavailable due to the COVID-19 outbreak. The significant adverse impact of COVID-19 on the economic or
political conditions in markets in which we operate could result in changes to the preferences of our adult consumers and lower demand for our products,
particularly for our mid-price or premium-price brands.
Continuation of the pandemic could disrupt our access to the credit markets or increase our borrowing costs. Governments may temporarily be unable to
focus on the development of science-based regulatory frameworks for the development and commercialization of RRPs or on the enforcement or
implementation of regulations that are significant to our business. In addition, messaging about the potential negative impacts of the use of our products on
COVID-19 risks may lead to increasingly restrictive regulatory measures on the sale and use of our products, negatively impact demand for our products
and the willingness of adult consumers to switch to our RRPs, and adversely impact our efforts to advocate for the development of science-based regulatory
frameworks for the development and commercialization of RRPs. All of the aforementioned impacts of the ongoing COVID-19 pandemic could have a
material adverse effect on our business, operations, results of operations, revenues, cash flow and profitability.
The impact of these risks also depends on factors beyond our knowledge or control, including the duration and severity of the COVID-19 pandemic in
general and specifically in the jurisdictions in which we operate, its recurrence in our key markets, actions taken to contain its spread and to mitigate its
public health effects, and the ultimate economic consequences thereof.
90
-- 91 of 139 --
Table of Contents
Risks Related to Illicit Trade
We lose revenues as a result of counterfeiting, contraband, cross-border purchases, "illicit whites," non-tax-paid volume produced by local manufacturers,
and counterfeiting of our Platform 1 device and heated tobacco units.
Large quantities of counterfeit cigarettes are sold in the international market. We believe that Marlboro is the most heavily counterfeited international
cigarette brand, although we cannot quantify the revenues we lose as a result of this activity. In addition, our revenues are reduced by contraband, legal
cross-border purchases, "illicit whites" and non-tax-paid volume produced by local manufacturers. Our revenues and consumer satisfaction with our
Platform 1 device and heated tobacco units may be adversely affected by counterfeit products that do not meet our product quality standards and scientific
validation procedures.
Risks Related to Cybersecurity and Data Governance
The failure of our information systems and systems owned and operated by our business partners to function as intended, or their penetration with the intent
to corrupt them or to extract data from them, or our and our business partners failure to adhere to strict data governance and cybersecurity protocols, and to
comply with privacy laws and regulations, could result in business disruption, loss of reputation, litigation and regulatory action, and loss of revenue, assets
or personal or other confidential data.
We as well as our business partners use information systems to help manage business processes, collect and interpret data and communicate internally and
externally with employees, suppliers, consumers, customers and others. Some of these information systems are managed by third-party service providers.
Our business continuity plans and other safeguards may not be effective to mitigate the impact of service interruptions, connectivity outages, and other
failures of these systems to function as intended, or to mitigate the penetration of these systems or systems owned and operated by our business partners by
parties intent on extracting or corrupting information or otherwise disrupting business processes. These events could place us at a competitive
disadvantage, result in a loss of revenue, assets, including our intellectual property, personal or other sensitive data, result in litigation and regulatory
action, impact our operations, cause damage to our reputation and that of our brands and result in significant remediation and other costs. Failure to protect
personal data, respect the rights of data subjects, and adhere to strict data governance and cybersecurity protocols could subject us to substantial fines and
other legal challenges under regulations such as the EU General Data Protection Regulation. As we are increasingly relying on digital platforms in our
business, and as privacy, data and cyber laws in the jurisdictions in which we do business are introduced or become more stringent, the magnitude of these
risks is likely to increase.
Risks Related to the Acquisitions of OtiTopic, Inc. ("OtiTopic"), Fertin Pharma A/G ("Fertin Pharma") and Vectura Group Ltd. ("Vectura")
As previously disclosed in this Form 10-Q, we have acquired Fertin Pharma and Vectura, and have since launched a new Wellness and Healthcare business
consolidating these entities, Vectura Fertin Pharma (with the Fertin Pharma acquisition and the Vectura acquisition being collectively referred to in these
Risk Factors as the “Acquisitions”).
We may be unable to successfully integrate and realize the expected benefits from the Acquisitions.
The successful integration of the acquired businesses and their operations into those of our own and our ability to realize the benefits of the Acquisitions,
are subject to a number of risks and uncertainties, many of which are not in our control. The risks and uncertainties relating to integrating the businesses
acquired include, among other things: (i) the challenge of integrating complex organizations, systems, operating procedures, industry specific compliance
programs, technology, networks and other assets of the businesses that we acquire, and the costs related to such integration efforts; (ii) the possibility that
we are unable to gain access to differentiated proprietary technology and pharmaceutical development expertise as anticipated by these Acquisitions, and
thus fail to realize our desired entry into additional smoke-free, wellness, therapeutic and healthcare platforms; (iii) the challenge of integrating the cultures
and business practices of each of Fertin Pharma and Vectura to our culture and business practices, which if not managed correctly, could lead to difficulties
in retaining key management and other key employees; and (iv) the challenge of achieving a successful integration as a result of our affiliation to our
combustible product portfolio. In addition, even if we are able to successfully integrate, the anticipated benefits of the Acquisitions may not be realized
fully, or at all, or may take longer to realize than expected. Furthermore, the success of the Acquisition also depends on the success of the research and
development efforts of Vectura Fertin Pharma, including the ability to obtain regulatory approval for new products, and the ability to commercialize or
license these new products developed by them. Moreover, our affiliation to its combustible product portfolio may stand in the way of introducing and
growing new product categories, and
91
-- 92 of 139 --
Table of Contents
may prevent us in being successful in developing a long-term sustainable ecosystem of products in the wellness, therapeutic and healthcare categories.
The businesses that we acquire in the Acquisitions may have liabilities that are not known to us.
The businesses that we have acquired in the Acquisitions may have liabilities that we were unable to identify, or were unable to discover, in the course of
performing our due diligence investigations during the Acquisitions thereof. We cannot assure you that the indemnification available to us under the
respective acquisition agreements that we have negotiated, will be sufficient in amount, scope or duration to fully offset the possible liabilities associated
with the respective business or property that we will assume upon consummation of each acquisition. Any such liabilities, individually or in the aggregate,
could have a material adverse effect on our business, financial condition and results of operations.
Accounting adjustments related to the Acquisitions could adversely affect our financial results.
We have accounted for the completion of the Acquisitions using the acquisition method of accounting. Differences between preliminary estimates and the
final acquisition accounting may occur, and these differences could have a material impact on the consolidated financial statements and our future results of
operations and financial position in combination with the businesses acquired. Furthermore, given the nature of the assets being acquired in the
Acquisitions, we may not be able to avoid future impairments of those assets, which may also have a material impact on our future results of operation and
financial position.
PMI and Vectura Fertin Pharma may be subject to uncertainties that could adversely affect our respective businesses, and adversely affect the financial
results of our combined businesses.
Our success following these Acquisitions will depend in part upon our ability, and the ability of Vectura Fertin Pharma, to maintain business relationships.
Uncertainty about the effect of the Acquisitions on customers, suppliers, employees and other constituencies of each of Fertin Pharma and Vectura, may
have a material adverse effect on us and/or the businesses that we have acquired with the proposed Acquisitions. Customers, suppliers and others who do
business with Vectura Fertin Pharma may delay or defer business decisions, decide to terminate, modify or renegotiate their relationships, or take other
actions as a result of the Acquisitions, which could negatively affect the revenues, earnings and cash flows of our company or the businesses that we have
acquired with these Acquisitions. If we are unable to maintain the business and operational relationships of Vectura Fertin Pharma, our financial position,
results of operations or cash flows upon combining with these companies could be adversely affected.
92
-- 93 of 139 --
Table of Contents
Item 4. Controls and Procedures.
PMI carried out an evaluation, with the participation of PMI’s management, including PMI’s Chief Executive Officer and Chief Financial Officer, of the
effectiveness of PMI’s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) as of the
end of the period covered by this report. Based upon that evaluation, PMI’s Chief Executive Officer and Chief Financial Officer concluded that PMI’s
disclosure controls and procedures are effective. There have been no changes in PMI’s internal control over financial reporting during the most recent fiscal
quarter that have materially affected, or are reasonably likely to materially affect, PMI’s internal control over financial reporting.
93
-- 94 of 139 --
Table of Contents
Part II - OTHER INFORMATION
Item 1. Legal Proceedings.
See Note 8. Contingencies of the Notes to the Condensed Consolidated Financial Statements included in Part I – Item 1 of this report for a discussion of
legal proceedings pending against Philip Morris International Inc. and its subsidiaries.
Item 1A. Risk Factors.
Information regarding Risk Factors appears in “MD&A – Cautionary Factors That May Affect Future Results,” in Part I – Item 2 of this Form 10-Q and in
Part I – Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2021.
94
-- 95 of 139 --
Table of Contents
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Our share repurchase activity for each of the three months in the quarter ended March 31, 2022, was as follows:
Period
Total Number
of Shares
Repurchased
Average
Price Paid
Per Share
Total Number of
Shares Purchased as
Part of Publicly
Announced Plans or
Programs
Approximate Dollar
Value of Shares that
May Yet be Purchased
Under the Plans or
Programs
January 1, 2022 –
January 31, 2022 (1) 377,393 $ 97.65 8,892,022 $ 6,178,541,816
February 1, 2022 –
February 28, 2022 (1) 668,911 $ 107.16 9,560,933 $ 6,106,858,356
March 1, 2022 –
March 31, 2022 (1) 920,426 $ 97.79 10,481,359 $ 6,016,847,275
Pursuant to Publicly
Announced Plans
or Programs 1,966,730 $ 100.95
January 1, 2022 –
January 31, 2022 (2) 14,393 $ 96.86
February 1, 2022 –
February 28, 2022 (2) 218,668 $ 110.52
March 1, 2022 –
March 31, 2022 (2) 2,884 $ 100.55
For the Quarter Ended March
31, 2022 2,202,675 $ 101.88
(1) On June 11, 2021, our Board of Directors authorized a new share repurchase program of up to $7 billion, with target spending of $5 billion to $7
billion over a three-year period that commenced in July 2021. These share repurchases have been made pursuant to the $7 billion program.
(2) Shares repurchased represent shares tendered to us by employees who vested in restricted and performance share unit awards and used shares to
pay all, or a portion of, the related taxes.
95
-- 96 of 139 --
Table of Contents
Item 6. Exhibits.
10.1 Amendment and Extension Agreement, effective February 1, 2022, among PMI, the lenders named therein and Citibank Europe PLC,
UK Branch (legal successor to Citibank International Limited), as administrative agent (incorporated by reference to Exhibit 10.1 to
the Current Report on Form 8-K filed February 1, 2022).
10.2 Amendment and Extension Agreement, effective February 10, 2022, among PMI, the lenders named therein, Citibank Europe PLC,
UK Branch, as facility agent, and Citibank, N.A., as swingline agent (incorporated by reference to Exhibit 10.2 to the Current Report
on Form 8-K filed February 1, 2022).
10.3 Supplemental Letter to the Offer Letter with Drago Azinovic, dated December 7, 2008.
10.4 Employment Agreement with Drago Azinovic, effective August 1, 2012.
10.5 Supplemental Letter to the Employment Agreement with Drago Azinovic, effective April 1, 2017.
10.6 Supplemental Letter to the Employment Agreement with Drago Azinovic, effective January 1, 2018.
10.7 Employment Agreement with Jorge Insuasty, effective January 1, 2021.
10.8 Supplemental Letter to the Employment Agreement with Jacek Olczak, effective March 1, 2022.
10.9 Form of Restricted Stock Unit Agreement (2022 Grant).
10.10 Form of Performance Stock Unit Agreement (2022 Grant).
10.11 Restricted Stock Unit Agreement (2022 Grant) (Emmanuel Babeau).
10.12 Performance Stock Unit Agreement (2022 Grant) (Emmanuel Babeau).
31.1 Certification of the Registrant's Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934,
as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 Certification of the Registrant's Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934,
as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 Certification of the Registrant's Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.
32.2 Certification of the Registrant's Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.
101.INS XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded
within the Inline XBRL document.
101.SCH XBRL Taxonomy Extension Schema.
101.CAL XBRL Taxonomy Extension Calculation Linkbase.
101.DEF XBRL Taxonomy Extension Definition Linkbase.
101.LAB XBRL Taxonomy Extension Label Linkbase.
101.PRE XBRL Taxonomy Extension Presentation Linkbase.
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
96
-- 97 of 139 --
Table of Contents
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
PHILIP MORRIS INTERNATIONAL INC.
/s/ EMMANUEL BABEAU
Emmanuel Babeau
Chief Financial Officer
April 28, 2022
97
-- 98 of 139 --
Exhibit 10.3
PHILIP MORRIS
INTERNATIONAL
PRIVATE & CONFIDENTIAL
Mr. Drago Azinovic
HAND DELIVERED
December 4, 2008
Dear Mr. Azinovic,
We refer to our letter today confirming, subject to your acceptance, the terms of your employment by Philip Morris International Management
S.A. (the "Company") (the "Offer Letter").
This letter sets out additional terms and conditions applicable to your employment by the Company.
Termination of employment
Should the Company give you notice of termination of your contract of employment, for any reason, at any time before the third anniversary
of the Effective Date (as defined in the Offer Letter), the value of the termination package shall be no less than the equivalent of EUR 2.2
millions net of taxes. This is also applicable should you, over the same period of time - but not before the eighteenth month of employment
after the Effective Date (as defined in the Offer Letter) - decide not to pursue your employment with the Company on the basis of material
reasons and / or causes such as - but not limited to - lack of material changes in terms of employment (grade and compensation) before the
end of the assignment or failing lo reach an agreement on your next position, if this is outside the European Union - pre 2004 accession - or
Switzerland, before the end of the assignment.
Should the Company give you notice of termination of your contract of employment at any time after the third anniversary of the Effective
Date (as defined in the Offer Letter), the value of the termination package shall be no less than the equivalent of EUR 1.32 millions net of
taxes.
Restricted Stock Grant
On the effective date, you will be granted Restricted Stock of Philip Morris International, Inc. with a value of on the effective date of US
Dollars 300'000.-. The terms of the Philip Morris International Inc., 2008 Performance Incentive Plan shall apply to such grant, including the
vesting period of 3 years.
To the extent that the terms of this letter are inconsistent with the terms of the Offer Letter, the terms of this letter shall prevail. Please
indicate your acceptance hereof by signing and returning one copy of this letter to us.
Yours sincerely,
PHILIP MORRIS INTERNATIONAL
MANAGEMENT S.A.
/s/ GÉRALD HÉRITIER /s/ DANIELE REGORDA
Gérald Héritier Daniele Regorda
Vice President CoE Reward & Retain & Mobility Senior Vice President Human Resources PMI
Read and approved: /s/ DRAGO AZINOVIC Date: 7-12-2008
(Drago Azinovic)
Philip Morris International Management S.A.
AVENUE DE RHODANIE 50 CASE POSTALE 1171 1001 LAUSANNE SWITZERLAND TELEPHONE: +41 21 618 61 11 TELEFAX: +41 21 618 46 18
-- 99 of 139 --
Exhibit 10.4
PRIVATE & CONFIDENTIAL
Mr Drago Azinovic
c/o Philip Morris Japan Kabushiki Kaisha
Lausanne, June 4, 2012
Dear Drago,
We are pleased to confirm your employment by Philip Morris International Management SA (hereafter referred to as the
"Company") as President European Union, reporting to Mr Andre Calantzopoulos, Chief Operating Officer, and based in
Lausanne, Switzerland.
This contract supersedes and replaces any previous employment contracts.
The terms and conditions of your employment will be as follows:
Effective date
This contract will be effective as of August 1, 2012 (the “Effective Date”), provided that you are in possession of a valid work
permit by then.
For the purpose of benefits which are linked to seniority in the Company, your initial entry date into Philip Morris International
Inc. or its subsidiaries will be taken into account, i.e. March 1, 2009.
Annual base salary
Your gross annual base salary, to be paid in 13 installments, will be Swiss Francs (CHF) 800’007.--, corresponding to your band,
which is C.
Incentive Compensation Award Program
As a band C employee, you will be eligible to participate in the Incentive Compensation (“IC”) Award Program, which is
administered at the sole discretion of the Compensation and Leadership Development Committee of the Board of Directors
pursuant and subject to the terms of the 2012 Performance Incentive Plan (or any similar plan in the future). Each eligible
employee has an annual IC award target that assumes a PMI company performance rating of 100 and an "Optimal" individual
performance. As a band C employee, this target is currently 120% of annual base salary.
Philip Morris International Management S.A.
AVENUE DE RHODANIE 50 1007 LAUSANNE SWITZERLAND TELEPHONE : +41 58 242 00 00 TELEFAX : +41 58 242 01 01
www.philipmorrisinternational.com
-- 100 of 139 --
Equity Award Program
As a band C employee, you will be eligible to participate in the Equity Award Program, which is administered at the sole
discretion of the Compensation and Leadership Development Committee of the Board of Directors pursuant and subject to the
terms of the 2012 Performance Incentive Plan (or any similar plan in the future). Each eligible employee has an annual equity
award target that assumes a PMI company performance rating of 100 and an "Optimal" individual performance. As a band C
employee, this target is currently 180% of annual base salary.
The Incentive Compensation and Equity Award Programs are discretionary and do not obligate the Company to make an award
nor entitle employees to receive an award. Eligibility to participate in the Programs does not guarantee receipt of an award and
receiving an annual award does not guarantee receipt of an award in the future. Any awards that are made may be higher or
lower than the targets mentioned above.
Fidelity premium
For each completed year of service, the Company pays a cumulative bonus of CHF 150.-- on each anniversary of the Effective
Date, up to a maximum of CHF 3'000.-- for 20 years of service.
Pension Fund
In accordance with the Swiss Federal Pension Law (“LPP”), you will remain a member of the “Caisse de pensions Philip Morris
en Suisse” (the “Pension Fund”), providing old age, disability, and survivor’s benefits. For further details, please refer to the
Pension Fund regulations.
According to the current Pension Fund regulations, you will pay a contribution equivalent to 6% of your pensionable salary. This
contribution will be deducted each month from your salary.
Swiss social security schemes (AVS/AI/APG/AC)
Contributions to the various Swiss Federal insurance schemes will be deducted from your compensation each month in
accordance with the applicable Swiss laws.
Accident insurance
In accordance with Swiss Federal Insurance Law (LAA), you are automatically covered for accident in the event of occupational
or non-occupational accidents. This cover is paid for by the Company.
Health insurance
If you wish, you may join the Company group health insurance contract. Employees and their eligible dependents (spouse and
dependent children up to age 18 or up to age 25 if full-time students or apprentices) can enroll into this group health insurance
scheme. The Company bears a substantial portion of the insurance premium cost. No Company contributions will be paid if you
choose to arrange an individual cover outside the group scheme.
Salary continuation in the event of sickness
In accordance with the regulations of the Company’s insurer, 100% of the annual base salary is paid for up to 2 years from the
first day you are unable to work. This cover is paid for by the Company.
Philip Morris International Management S.A.
AVENUE DE RHODANIE 50 1007 LAUSANNE SWITZERLAND TELEPHONE : +41 58 242 00 00 TELEFAX : +41 58 242 01 01
www.philipmorrisinternational.com
-- 101 of 139 --
Life insurance
In accordance with the regulations of the Company’s insurer and in coordination with the Pension Fund, you are provided with
an insurance cover in case of death and permanent disability paid for by the Company.
Office working hours
The weekly basic work schedule is 40 hours spread over 5 days, from Monday to Friday based on a full occupational rate. You
understand and agree that your annual base salary includes all compensation for time worked in excess of the basic work
schedule, and that there will be no extra compensation for such work. For further details, please refer to the Human Resources
Department.
Tax assistance
The Company will pay the fees of tax advisers approved by the Company on the occasions you are required to complete a tax
declaration in Switzerland.
Company Car
You will be entitled to a company car in accordance with Company policy.
Vacation days
Your vacation entitlement is 25 working days per calendar year. For the current year your entitlement will be calculated pro rata
temporis.
Relocation expenses
In accordance with Company policy, you will receive a relocation allowance amounting to CHF 71’364.-- to help defray the
miscellaneous non-reimbursable costs associated with your relocation from Tokyo, Japan to Lausanne, Switzerland. This
amount is derived by taking 1/12 of your annual base salary (capped at the midpoint of Band F) and grossing it up at a fixed
standard rate to take account of tax liability on this allowance. This relocation allowance will be paid to you with your first salary
and consequently be subject to social security and tax deductions.
The Company will also pay for the travel costs associated with your relocation from Tokyo, Japan to Lausanne, Switzerland, in
accordance with the Company’s Business Travel policy.
With prior approval of the Human Resources Department, the Company will pay a remover selected by the Company to pack,
transport, store if necessary, and unpack your household goods from Tokyo, Japan to Lausanne, Switzerland, in accordance
with Company Policy. The Relocation Services Department will coordinate this with you. Your move should take place within one
year from the Effective Date.
Temporary accommodation
In accordance with Company policy, temporary accommodation will be provided to you for up to 60 days.
th
Philip Morris International Management S.A.
AVENUE DE RHODANIE 50 1007 LAUSANNE SWITZERLAND TELEPHONE : +41 58 242 00 00 TELEFAX : +41 58 242 01 01
www.philipmorrisinternational.com
-- 102 of 139 --
Taxability of benefits
Certain benefits described above are subject to income tax and social security deductions. Please also take into account that
the tax and social security treatment of all benefits may change in the future according to Swiss law or Company policy. Details
may be obtained from the HR Department.
Privacy policy and data protection
The Company is part of a multinational group of companies, which is active in developing the skills and careers of its
employees. As part of the Company’s career and skills development program, information about your employee status,
personnel profile and similar matters may be transmitted to the Company's affiliates, whether in Switzerland or elsewhere. This
information is treated confidentially and in accordance with Philip Morris International’s Policy on the Collection, Use and
Protection of Personal Data. By signing this contract you will express your consent to such transmittal. You retain the right at any
time to withdraw your consent related to the transmittal of any such data as described above, provided that such withdrawal is
addressed in writing to the Human Resources Department. For the purposes of this contract an “affiliate” of the Company means
any company or other entity which controls or is controlled by or under common control with the Company.
Confidential Information
Consistent with your obligations under Swiss law, you undertake not to disclose any Confidential Information, whether during or
after your employment by the Company, and upon termination of your employment to return any Confidential Information in
tangible or electronic form in your possession. For these purposes “Confidential Information” means any trade secrets and other
proprietary information pertaining to the Company or its affiliates, which has not been made available to the general public by an
authorized representative of the Company or its affiliates, whether patentable or not, including for example any idea, formula,
technique, invention, process, program, business, marketing and sales plans, financial, organizational and sales data, and
similar information in line with all Company Records & Information Management (RIM) policies, procedures, and guidelines.
Company Property
Furthermore upon termination of your employment, you should return to the Company and/or its affiliates all paper and
electronic files and documents, tapes, CD’s, and copies thereof and other items belonging to the Company and its affiliates,
irrespective of their source and origin, including Company corporate cards, telephone cards, keys, access and identification
cards, computers, and, if requested, will certify that this has been done to the best of your belief and that you also comply with
all Company Records & Information Management (RIM) policies, procedures, and guidelines before your departure.
The settlement of any outstanding expenses due to the Company, including, but not limited to any outstanding balance on the
account of the corporate card issued in your name will be set-off with any payable sums.
Termination of employment
This contract shall be terminated in accordance with Swiss law.
Governing law, applicable policies and Jurisdiction
The validity, construction and performance of this Employment Agreement shall be governed by the laws of Switzerland without
regard to its conflict of law provisions and shall be subject to the exclusive jurisdiction of the competent courts of the Canton de
Vaud, Switzerland. The Policies and Procedures of the Company, Philip Morris International, as amended or newly issued from
time to time, shall also apply.
Philip Morris International Management S.A.
AVENUE DE RHODANIE 50 1007 LAUSANNE SWITZERLAND TELEPHONE : +41 58 242 00 00 TELEFAX : +41 58 242 01 01
www.philipmorrisinternational.com
-- 103 of 139 --
Miscellaneous
The foregoing represents the basis of your employment with the Company. Please indicate your acceptance thereof by signing
and returning one copy of this contract to us.
Should you have any questions, feel free to contact Ms Ulrike Kubala, Vice President Human Resources European Union & PMI
Labour Relations.
We look forward to your joining Philip Morris International Management SA in Lausanne, and remain,
Yours sincerely,
PHILIP MORRIS INTERNATIONAL MANAGEMENT S.A.
/s/ KEVIN DOUGLAS CLICK /s/ RALF ZYSK
Kevin Douglas Click Ralf Zysk
Senior Vice President Human Resources PMI Vice President Compensation & Benefits and
International Assignments PMI
Read and approved: /s/ DRAGO AZINOVIC Date: 20/6/2012
(Drago Azinovic)
Philip Morris International Management S.A.
AVENUE DE RHODANIE 50 1007 LAUSANNE SWITZERLAND TELEPHONE : +41 58 242 00 00 TELEFAX : +41 58 242 01 01
www.philipmorrisinternational.com
-- 104 of 139 --
Exhibit 10.5
PERSONAL AND CONFIDENTIAL
To: Mr. Drago AZINOVIC Lausanne, February 27, 2017
Subject: Merit Increase
Dear Drago,
Further to your annual performance assessment we confirm that your 2017 merit increase amounts to 2.42%.
As a result of this increase, effective April 1, 2017, the following conditions of your employment have been modified
according to the information detailed below:
Gross Base Salary: CHF 845’000.-- annually, CHF 65’000.-- monthly
Comparatio: 94%
All other conditions relating to your employment with Philip Morris International Management SA remain as stated in
your employment contract and in any subsequent amendments.
We would like to take this opportunity to wish you continued success and satisfaction.
Yours sincerely,
/s/ RALF ZYSK
Ralf Zysk
Vice President Compensation & Benefits
and International Assignments PMI
Avenue de Rhodanie 50, 1007 Lausanne, Switzerland T:+41 (58) 242 00 00, F: +41 (58) 242 01 11
-- 105 of 139 --
Exhibit 10.6
PERSONAL AND CONFIDENTIAL
To: Mr. Drago AZINOVIC Lausanne, December 14, 2017
Subject: New Appointment
Dear Drago,
We confirm that effective January 1, 2018, the following conditions of your employment will be modified according to the
information detailed below:
Position: President Middle East, Africa & PMI Duty Free Region
Reporting to: Mr. Jacek Olczak, Chief Operating Officer
All other conditions relating to your employment with Philip Morris International Management SA remain as stated in your
employment contract and in any subsequent amendments.
We would like to take this opportunity to wish you continued success and satisfaction.
Yours sincerely,
PHILIP MORRIS INTERNATIONAL
MANAGEMENT SA
/s/ RALF ZYSK
Ralf Zysk
Vice President Compensation & Benefits
and International Assignments PMI
Philip Morris International Management SA, Avenue de Rhodanie 50, 1007 Lausanne, Switzerland
T:+41 (58) 242 00 00, F: +41 (58) 242 01 01
-- 106 of 139 --
Exhibit 10.7
PRIVATE & CONFIDENTIAL
Mr. Jorge Insuasty
Email delivery
Neuchâtel, October 8, 2020
Dear Mr. Insuasty,
Following our discussions and subject to the approval of the Board of Directors of Philip Morris International Inc. and the
Compensation and Leadership Development Committee (the "Committee") of the Board of Directors of Philip Morris
International Inc., the terms and conditions of your employment with Philip Morris Products S.A. (hereafter referred to as the
"Company") will be as follows:
Position
You will be appointed Chief Life Sciences Officer, reporting to Mr. André Calantzopoulos, Chief Executive Officer PMI, and
based in Neuchâtel, Switzerland.
Effective Date
This contract will be effective as of January 1, 2021 (the “Effective Date”), with a physical start date on January 4, 2021, for an
indefinite period of time.
Annual Base Salary
Your gross annual base salary, to be paid in 13 installments, will be Swiss Francs (CHF) 700’011.--, corresponding to your
grade, which is 22.
The 13th installment will be pro-rated for the number of months worked in a given year, and paid to you in November.
Page 1 of 11
Philip Morris Products S.A., Quai Jeanrenaud 3, 2000 Neuchâtel, Switzerland
T:+41 (58) 242 11 11 F: +41 (58) 242 81 11
-- 107 of 139 --
(58) , (58) 8
-- 108 of 139 --
Sign-On Cash Award
You will receive a sign-on bonus amount of CHF 600'000.-- gross, payable in two equal installments. The first installment (CHF
300'000.--) will be paid with your first salary payment, subject to social security deductions and taxes, and the second
installment (CHF 300'000.--), subject to your still being an employee of the Company or an affiliate of the Company on July 1,
2021, with your salary payment for July 2021, also subject to social security deductions and taxes.
Should you voluntarily cease to be employed by the Company or an affiliate of the Company for any reason or should the
Company terminate your employment for a reason which constitutes a “Cause” (as defined in this contract) the following will
apply:
• within 6 months of the Effective Date, you will be liable to repay the full amount of the first installment to the Company.
• between 7 and 12 months of the Effective Date, you will be liable to repay the full amount of the first installment and the
second installment.
• between 13 and 24 months of the Effective Date, you will be liable to repay the full amount of the second installment.
Sign-On Stock Awards
You will be granted Restricted Stock Units (“RSUs”) with a fair market value of CHF 1’400’000.--. on the later of (1) the date you
start employment or (2) the date the Committee approves the stock award.This stock grant is scheduled to vest in two equal
installments, in January 2022 and in January 2023, respectively.
On February 4, 2021 (provided you are still employed by the Company at this time), you will be granted a stock award with a fair
market value of CHF 840’000 as follows:
(a) 45% in the form of RSUs and
(b) 55% in the form of Performance Share Units (“PSUs”). The performance measures and targets for the PSUs will be
reflected in the respective award statement.
(c) Both RSUs and PSUs are scheduled to vest in February 2024.
You will be entitled to receive dividend equivalents during the vesting periods for the RSUs. You will receive dividend equivalents
on your vested PSUs after the end of the performance period when the company performance is certified and the final number
of vested PSUs is determined.
The stock awards will be subject to the terms of the 2017 Performance Incentive Plan and the applicable stock agreements.
Page 2 of 11
Philip Morris Products S.A., Quai Jeanrenaud 3, 2000 Neuchâtel, Switzerland
T:+41 (58) 242 11 11, F: +41 (58) 242 81 11
-- 109 of 139 --
Incentive Compensation Award Program
As a grade 22 employee, you will be eligible to participate in the Incentive Compensation (“IC”) Award Program, which is
administered at the sole discretion of the Committee pursuant and subject to the terms of the 2017 Performance Incentive Plan
(or any similar plan adopted from time to time). Each eligible employee has an annual IC award target that assumes a PMI
company performance rating and an individual performance rating of 100.
For a grade 22 employee, the current target is 90% of annual base salary. Targets are reviewed annually and are made
available to employees under the PMI 23-G4 Guidelines Global Variable Compensation Programs Annex 1.
Stock Award Program
As a grade 22 employee, you will be eligible to participate in the Stock Award Program, which is administered at the sole
discretion of the Committee pursuant and subject to the terms of the 2017 Performance Incentive Plan (or any similar plan
adopted from time to time). Each eligible employee has an annual stock award target that assumes an individual performance
rating of 100.
For a grade 22 employee, the current target is 120% of annual base salary. Targets are reviewed annually and are made
available to employees under the PMI 23-G4 Guidelines Global Variable Compensation Programs Annex 2.
The Incentive Compensation and Stock Award Programs are discretionary and do not obligate the Company to make an award
nor entitle employees to receive an award. Eligibility to participate in the Programs does not guarantee receipt of an award and
receiving an annual award does not guarantee receipt of an award in the future. Any awards that are made may be higher or
lower than the targets mentioned above. Targets may be amended at the discretion of the Company at any time without prior
notice.
Vacation Days
Your vacation entitlement will be a minimum of 25 working days per calendar year or more according to the Company
guidelines. For every incomplete calendar year your entitlement will be calculated pro rata temporis.
In addition, the Company grants (i) two Floating Days per calendar year, that may be taken at any time during the year (these
two days cannot be carried over to the following year), and (ii) two fixed days as company holidays in addition to the public
holidays of the Canton de Neuchâtel. This corresponds to the current Company practice, which the Company has the right to
change at any time without notice or compensation.
Fidelity Premium
For each completed year of service, the Company pays a cumulative bonus of CHF 150.-- on each anniversary of the Effective
Date, up to a maximum of CHF 3'000.-- for 20 years of service.
Page 3 of 11
Philip Morris Products S.A., Quai Jeanrenaud 3, 2000 Neuchâtel, Switzerland
T:+41 (58) 242 11 11, F: +41 (58) 242 81 11
-- 110 of 139 --
Trial Period
No trial period will apply.
Termination of Employment
This contract shall be terminable in accordance with Swiss law. Each party may terminate the agreement for the end of a month
by giving one month notice within the first year of employment, two months notice from the second to ninth year of employment
or three months notice as of the tenth year of employment.
Should the Company unilaterally terminate your employment within 12 (twelve) months of the Effective Date (reference: end of
employment date as notified by the employer) for a reason which does not constitute a “Cause” as defined in this section, the
Company shall offer you a lump sum severance payment covering (a) the base salary you would have received from the end of
employment date until the end of the 12 month period following the Effective Date and (b) an amount in lieu of the prorated
Incentive Compensation that you would have received through the end of the 12 month period, provided you shall execute the
separation agreement proposed by the Company. In such a case, the period between the end of employment date and the end
of the 12 month period following the Effective Date will serve as a worldwide non-compete period, compensated through the
severance payment.
Should the Company unilaterally terminate your employment within 24 (twenty-four) months of the Effective Date (reference:
end of employment date as notified by the employer) for a reason which does not constitute a “Cause” as defined in this section,
the Company shall offer you a lump sum severance payment covering (a) the base salary you would have received from the end
of employment date until the end of the 24 month period following the Effective Date and (b) an amount in lieu of the Incentive
Compensation that you would have received through the end of the 24 month period, provided you shall execute the separation
agreement proposed by the Company. In such a case, the period between the end of employment date and the end of the 24
month period following the Effective Date will serve as a worldwide non-compete period, compensated through the severance
payment.
The PMI policy regarding the adjustment or recovery of compensation shall also apply to the severance conditions stipulated
under this section.
The treatment of compensation granted under the PMI performance incentive plans upon a change of control shall be governed
by the applicable performance incentive plan.
Any individual tax and social security obligations that may arise under the severance conditions stipulated under this section in
any jurisdiction are solely the employee's. The Company will have no responsibility, directly or indirectly, with respect to such
obligations, including any obligation to pay, reimburse or gross up any payments to the employee.
For the purposes of this contract, “Cause” means termination because of:
(i) continued failure to substantially perform the employee’s job duties (other than resulting from incapacity due to disability) after
a written demand by the Company (or any of its subsidiaries or affiliates, as the case may be) that identifies the manner in which
the Company (or any of its subsidiaries or affiliates, as the case may be) has reasonably determined that the employee has not
performed his or her duties; or
Page 4 of 11
Philip Morris Products S.A., Quai Jeanrenaud 3, 2000 Neuchâtel, Switzerland
T:+41 (58) 242 11 11, F: +41 (58) 242 81 11
-- 111 of 139 --
Termination of Employment (cont’d)
(ii) gross negligence in the performance of the employee’s job duties, willful misconduct, or a material violation of Company
policy (including the PMI Guidebook for Success), that the Company has reasonably determined has resulted in, or is likely to
result in, a material and demonstrable detriment to the business, operations, properties, financial condition or reputation of the
Company (or any of its subsidiaries or affiliates); or
(iii) the employee’s conviction of a felony or a plea of nolo contendere by the employee with respect to a felony.
Pension Fund
In accordance with the Swiss Federal Pension Law (“LPP”), you will become a member of the “Caisse de pension Philip Morris
en Suisse” (the “Pension Fund”), providing old age, disability, and survivor’s benefits. For further details, please refer to the
Pension Fund regulations.
Your contribution to the Pension Fund will be deducted each month from your salary according to the current Pension Fund
regulations.
Swiss Social Security Schemes (AVS/AI/APG/AC)
Contributions to the various Swiss Federal insurance schemes will be deducted from your compensation each month in
accordance with the applicable Swiss laws.
Accident Insurance
In accordance with Swiss Federal Insurance Law (LAA), you are automatically covered for accident in the event of occupational
or non-occupational accidents. This cover is paid for by the Company.
Health Insurance
If you wish, you may join the Company group health insurance contract. All permanent employees can enroll into this group
health insurance scheme. The Company bears a portion of the insurance premium cost. You can enroll your immediate family
members in the ‘family’ group insurance schemes at your own cost. No Company contributions will be paid if you choose to
arrange an individual cover outside the group scheme.
Page 5 of 11
Philip Morris Products S.A., Quai Jeanrenaud 3, 2000 Neuchâtel, Switzerland
T:+41 (58) 242 11 11, F: +41 (58) 242 81 11
-- 112 of 139 --
Salary Continuation in the Event of Sickness
In accordance with the regulations of the Company’s insurer, 100% of the annual base salary is paid for up to 2 years from the
first day you are unable to work. This cover is paid for by the Company without affecting the right of each party to end the
contract.
Life Insurance
In accordance with the regulations of the Company’s insurer and in coordination with the Pension Fund, you are provided with
an insurance cover in case of death paid for by the Company.
Office Working Hours
The weekly basic work schedule is 40 hours spread over 5 days, from Monday to Friday, based on a full time occupational rate.
You understand and agree that your annual base salary includes all compensation for time worked in excess of the basic work
schedule, and that there will be no extra compensation for such work. For further details, please refer to the People & Culture
Department.
Protective Clothing and Equipment
Depending on the location and type of work, protective wear is compulsory. Such protective clothing and equipment (safety
shoes, safety glasses and ear plugs) shall be provided to the Employee free of charge.
Relocation Expenses
With prior approval of the People & Culture Department, the Company will pay a remover selected by the Company to pack,
transport, store if necessary, and unpack your household goods from your current home location to Switzerland, in accordance
with Company Policy. The Relocation Services Department will coordinate this with you. Your move should take place within
eighteen months from the Effective Date.
The Company will also pay you a relocation allowance amounting to CHF 34'014.-- with the first feasible payroll upon your
physical relocation to Switzerland. This amount will be subject to social security deductions and will be taxable.
The Company will also pay for the travel costs associated with your relocation from your current home location to Switzerland, in
accordance with the Company’s Business Travel policy.
Temporary Accommodation
Temporary accommodation will be provided to you until August 31, 2021. As of September 1, 2021 this provision will no longer
apply.
Page 6 of 11
Philip Morris Products S.A., Quai Jeanrenaud 3, 2000 Neuchâtel, Switzerland
T:+41 (58) 242 11 11, F: +41 (58) 242 81 11
-- 113 of 139 --
Tax Assistance
The Company will pay the fees of tax advisers chosen by the Company on the first and second occasions you are required to
complete a tax declaration in Switzerland (provided you are still employed by the Company at this time). Should you not opt for
this benefit, please send a note at YOURHR@pmi.com within three months from the Effective Date of the contract. This
entitlement may be subject to income tax and/or social security deductions if applicable, which the Company does not
compensate.
After this initial period, the Company will either (i) pay the fees of tax advisers chosen by the Company on the occasions you are
required to complete a tax declaration in Switzerland subject to you contributing for CHF 3’500.-- per year (amount to be
deducted from your salary) or (ii) pay you an allowance of CHF 1’500.-- per year in lieu of tax assistance. This entitlement may
be subject to income tax and/or social security deductions, if applicable. You must indicate your preference by sending a note at
YOURHR@pmi.com. Should no preference be indicated, the Company will automatically opt for the second (ii) option.
Company Car (or Cash Allowance / Yearly Travel Pass)
You will be entitled to a company car in accordance with Company policy.
If you choose not to receive a company car, you may opt for a cash allowance or a travelcard in Switzerland for you and your
partner in accordance with Company policy.
Taxability of Benefits
Certain benefits described in this contract are subject to income tax and social security deductions. Please also take into
account that the tax and social security treatment of all benefits may change in the future according to Swiss law or Company
policy. Details may be obtained from the People & Culture Department.
Data Protection
The Company will, in the course of its business, process personal data relating to you (for example, personal details, bank
account information, or automated records of your use of information systems, or information required for building access control
systems).
The Company may also in the course of its business, process personal information relating to other persons whose personal
information you provide, such as your relative(s) or partner(s) (“Your Contacts”) (for example contact details or information in
connection with employee benefits).
You give your consent to the Company to:
Page 7 of 11
Philip Morris Products S.A., Quai Jeanrenaud 3, 2000 Neuchâtel, Switzerland
T:+41 (58) 242 11 11, F: +41 (58) 242 81 11
-- 114 of 139 --
Data Protection (cont’d)
(a) process your personal information for its, and its Affiliates’, business purposes. Those purposes include legal, personnel,
administrative and management purposes (including, for example: payroll administration; correspondence; IT systems
development, operation and maintenance; building access controls; performance review, and talent management);
(b) process your sensitive personal data (for example data relating to health), where this is necessary for the administration of
the employment relationship, and is permitted by law (for example, to administer health benefits);
(c) make your personal information available to its Affiliates for them to process for their own benefit, for the same purposes as
described above;
(d) make your personal information available, and to permit the Company’s Affiliates also to make your personal information
available:
(i) to third parties who provide products or services to the Company or its Affiliates (such as advisers, payroll
administrators, and information services providers) for the same purposes as described above; and
(ii) to other third parties, where required or permitted by law, including: regulatory authorities; potential or future employers;
and governmental or quasi-governmental organisations.
You also confirm that, before providing us with personal information of Your Contacts, you will obtain their consent to the
Company processing their data as above.
As a multi-national organisation, PMI transfers personal information globally. You consent to the transfer of your personal
information, as outlined above, either within or outside Switzerland and including where the country or territory in question does
not maintain data protection standards that are equivalent to those of Switzerland. In all cases, PMI will implement adequate
measures for the treatment of the data in accordance with PMI 03-C.
You may request access to the personal information that we hold about you, or request the correction or deletion of your
personal information, by contacting your People & Culture Department.
Confidential Information
Consistent with your obligations under Swiss law, you undertake not to disclose any Confidential Information (written or oral),
whether before, during or after your employment by the Company, and upon termination of your employment to return any
Confidential Information in tangible or electronic form in your possession. For these purposes “Confidential Information” means
any trade secrets and other proprietary information pertaining to the Company or its affiliates, which has not been made
available to the general public by an authorized representative of the Company or its affiliates, whether patentable or not,
including for example any intellectual property, idea, formula, method, technique, invention, process, program, algorithm, know-
how, equipment, business, marketing and sales plans, security protocols, legal strategies, status of regulatory submissions and
approvals, financial, organizational and sales data, and similar information in line with all Company Records & Information
Management (RIM) policies, procedures, and guidelines.
Page 8 of 11
Philip Morris Products S.A., Quai Jeanrenaud 3, 2000 Neuchâtel, Switzerland
T:+41 (58) 242 11 11, F: +41 (58) 242 81 11
-- 115 of 139 --
Confidential Information (cont’d)
The Company may provide you with information and/or documents with respect to your future position before the Effective Date,
and some of them may be of confidential nature. You expressly agree that this section "Confidential Information" applies to any
confidential information and/or documents you may have access to before the beginning of your employment.
Intellectual Property Rights
You hereby assign to the Company to the fullest extent permitted by law, throughout the world and for the entire term of
protection, all copyrights (including all rights in software and databases) and neighboring rights in the works created by you,
alone or with others, within and outside your contractual duties, while performing your activity for the Company. If and to the
extent that an assignment of any of such rights is not permitted under applicable law, you agree not to assert them and authorize
the Company to exercise such rights on your behalf. In particular, the Company shall have the unrestricted right to exercise the
author's moral rights in the works, including without limitation the right to alter the works, create derivative works and to
determine whether, when, how and under what name the works shall be published.
Concerning the inventions, patents and designs generated by you alone or with others while performing your employment
activity for the Company:
a) If they have been generated within your contractual duties, they belong to the Company, regardless of whether they
are protectable or not, and no specific compensation is due to you by the Company;
b) If they have been generated outside the performance of your contractual duties, the Company is entitled to acquire
them. In this case, if you make such invention/patent/design, you shall promptly inform the Company thereof in writing. If
the Company declares that it wishes to acquire such invention/patent/design, you shall be entitled to an appropriate
special compensation, which shall be determined by taking into account all circumstances, such as the business value of
the invention, patent or design, the contribution of the Company or its auxiliary persons, the utilization of the Company's
installations, as well as your expenses and your position within the Company.
All tangible and/or intangible work result (including without limitation all documents, drawings, samples, know-how, trade
secrets, concepts and ideas) and any intellectual property rights therein, which are generated by you, alone or with others,
within and outside your contractual duties while performing your employment activity for the Company, shall belong to the
Company.
Save for the special compensation according to the subsection b) above, you shall not be entitled to any compensation for the
rights granted to the Company under this Section "Intellectual Property Rights" in addition to the salary agreed between the
parties.
Insofar as a transfer of Intellectual Property Rights would be required, you shall at the Company's first request, co-operate and
perform all actions that the Company may deem desirable or necessary to effectuate or formalize such transfer.
The provisions of this Section "Intellectual Property Rights" shall survive the termination or expiration of the employment
relationship.
Page 9 of 11
Philip Morris Products S.A., Quai Jeanrenaud 3, 2000 Neuchâtel, Switzerland
T:+41 (58) 242 11 11, F: +41 (58) 242 81 11
-- 116 of 139 --
Company Property
Furthermore upon termination of your employment, you should return to the Company and/or its affiliates all paper and
electronic files and documents, tapes, CD’s, and copies thereof and other items belonging to the Company and its affiliates,
irrespective of their source and origin, including Company corporate cards, telephone cards, keys, access and identification
cards, computers, and, if requested, will certify that this has been done to the best of your belief and that you also comply with
all Company Records & Information Management (RIM) policies, procedures, and guidelines before your departure.
The settlement of any outstanding expenses due to the Company, including, but not limited to any outstanding balance on the
account of the corporate card issued in your name could be set-off with any payable sums.
Duties of the Employee
You shall complete your tasks and promote the affairs of the Company diligently and carefully, and shall safeguard the interests
of the Company.You have to exercise your responsibilities, functions, duties and powers in compliance with applicable laws and
regulations and with the strategies and guidelines of the
Company, and will comply with the codes, principles, practices and procedures that are applicable within the Company, as
issued or amended during the employment relationship.
Governing Law, Applicable Policies and Jurisdiction
The validity, construction and performance of this Employment Agreement shall be governed by the laws of Switzerland without
regard to its conflict of law provisions and shall be subject to the exclusive jurisdiction of the competent courts of the Canton de
Neuchâtel, Switzerland. The Policies and Procedures of the Company, Philip Morris International, as amended or newly issued
from time to time, shall also apply.
Miscellaneous
The foregoing represents the basis of your employment with the Company. Please indicate your acceptance thereof by signing
and returning one copy of this contract to us by October 19, 2020 the latest. After this date this contract will become null and
void.
Should you have any questions, feel free to contact Mr. Constantin Romanov, Global Head of Total Rewards.
Page 10 of 11
Philip Morris Products S.A., Quai Jeanrenaud 3, 2000 Neuchâtel, Switzerland
T:+41 (58) 242 11 11, F: +41 (58) 242 81 11
-- 117 of 139 --
Miscellaneous (cont’d)
Regarding administrative matters, the People & Culture Department will contact you during your first weeks of employment.
We look forward to your joining PHILIP MORRIS PRODUCTS S.A. and remain,
Yours sincerely,
PHILIP MORRIS PRODUCTS S.A.
/s/ CONSTANTIN ROMANOV /s/ RALF ZYSK
Constantin Romanov Ralf Zysk
Global Head of Total Rewards Global Head of People Sustainability, Employee
Relations
Read and approved: /s/ JORGE INSUASTY Date: 16/10/2020
(Jorge Insuasty)
Page 11 of 11
Philip Morris Products S.A., Quai Jeanrenaud 3, 2000 Neuchâtel, Switzerland
T:+41 (58) 242 11 11, F: +41 (58) 242 81 11
-- 118 of 139 --
Exhibit 10.8
PERSONAL AND CONFIDENTIAL
To: Mr. Jacek Olczak
Lausanne, March 1, 2022
Dear Jacek,
We are pleased to confirm that effective March 1, 2022, your base salary is increased to CHF 1’400’000.-- annually,
CHF 107’692.-- monthly. This represents a 3.7% increase.
All other conditions relating to your employment with Philip Morris Products S.A., formerly Philip Morris International
Management SA, remain as stated in your employment contract and in any subsequent amendments.
Yours sincerely,
PHILIP MORRIS PRODUCTS S.A.
/s/ CHARLES BENDOTTI
Charles Bendotti
Global Head of People & Culture
Philip Morris Products S.A., Avenue de Rhodanie 50, 1007 Lausanne, Switzerland
T:+41 (58) 242 00 00, F: +41 (58) 242 01 01
-- 119 of 139 --
Exhibit 10.9
PHILIP MORRIS INTERNATIONAL INC.
2017 PERFORMANCE INCENTIVE PLAN
RESTRICTED STOCK UNIT AGREEMENT
FOR PHILIP MORRIS INTERNATIONAL INC. COMMON STOCK
(February 10, 2022)
PHILIP MORRIS INTERNATIONAL INC. (the “Company”), a Virginia corporation, hereby grants to the employee identified in the
Award Statement (the “Employee”) under the Philip Morris International Inc. 2017 Performance Incentive Plan (the “Plan”), a Restricted
Stock Unit Award (the “Award”) dated February 10, 2022 (the “Award Date”) with respect to the number of shares of the Common Stock
of the Company (the “Common Stock”) set forth in the Award Statement (the “RSUs”), all in accordance with and subject to the
following terms and conditions:
1. Normal Vesting. Subject to Section 2 of this Agreement below, the RSUs shall become fully vested on the Vesting Date set forth in
the Award Statement (the “Vesting Date”), provided that the Employee remains an employee of the PMI Group during the entire period
commencing on the Award Date and ending on the Vesting Date, and provided further that the Employee has complied with all applicable
provisions of HSR.
2. Termination of Employment Before Vesting Date. (a) In the event of the termination of the Employee’s employment with the PMI
Group prior to the Vesting Date due to (i) death, Disability or (ii) Normal Retirement, or (iii) early retirement or termination of employment
(other than for Cause), in either case by mutual agreement and after the Employee has attained age 58, then the RSUs shall become fully
vested on the date of death, Disability, Normal Retirement, or such early retirement or termination of employment or the date specified in
such mutual agreement.
(b) Subject to the provisions of section 6(a) of the Plan, if the Employee’s employment with the PMI Group is terminated prior to the
Vesting Date in circumstances not specified in items (i), (ii) or (iii) of the preceding paragraph, the Employee shall forfeit all rights to the
RSUs. Notwithstanding the foregoing and except as provided in section 6(a) of the Plan, upon the termination of an Employee’s
employment with the PMI Group, the Compensation Committee may, in its sole discretion, vest some or all of the RSUs.
(c) If within the period of 12 months prior to the date of termination of employment, the Employee was an Executive Officer (as
designated by the Board of Directors of the Company within the meaning of Section 16 of the Securities Exchange Act of 1934, as
amended) and the termination of employment of such Employee is due to a reason other than death or Disability, any shares of Common
Stock that are received by such Employee as a result of accelerated vesting provisions of Section 2(a) or (b), shall be automatically
subject to a holding period that expires 12 consecutive months from the date of termination of employment.
3. Voting and Dividend Rights; Withholding Tax on Dividend Equivalents. The Employee does not have the right to vote the RSUs
or receive dividends prior to the date, if any, such RSUs are paid to the Employee in the form of Common Stock pursuant to the terms
hereof. However, unless otherwise determined by the Compensation Committee, the Employee shall receive cash amounts (less
applicable withholding taxes) equal to the dividends paid from the date the Award is granted through the date of payment under Section 7
of this Agreement
-- 120 of 139 --
with respect to shares of Common Stock issuable with respect to the Award, as such dividends are paid.
4. Transfer Restrictions. This Award and the RSUs are non-transferable and may not be transferred, assigned, hypothecated, pledged
or otherwise encumbered and shall not be subject to execution, attachment or similar process. Upon any attempt to effect any such
disposition, or upon the levy of any such process, the Award shall immediately become null and void and the RSUs shall be forfeited.
These restrictions shall not apply, however, to any payments received pursuant to Section 7 of this Agreement below. In addition, shares
of Common Stock subject to the holding period described in Section 2 (c) of this Agreement may not be transferred, assigned,
hypothecated, pledged or otherwise encumbered for the duration of the applicable holding period.
5. Withholding Taxes on Common Stock upon Vesting. With respect to Common Stock issuable upon vesting, the Company is
authorized to satisfy the actual statutory withholding taxes, or hypothetical withholding tax amounts if applicable, arising from this
Award by (a) deducting the number of shares of Common Stock payable under the RSUs having an aggregate value equal to the amount
of withholding taxes due from the total number of shares of Common Stock payable under the RSUs becoming subject to current taxation
or (b) the remittance of the required amounts from any proceeds realized upon the open-market sale of the Common Stock received in
payment of vested RSUs by the Employee. Shares of Common Stock payable under the RSUs deducted from this Award in satisfaction
of tax withholding shall be valued at the Fair Market Value of the Common Stock on the date as of which the amount giving rise to the
withholding requirement first became includible in the gross income of the Employee under applicable tax laws. If the Employee is on an
international assignment, the Company will calculate the amount of hypothetical tax which will be imposed on the Employee’s RSUs, in
accordance with the Company’s guidelines in force at the time the withholding obligation arises.
6. Death of Employee. If any of the RSUs shall vest upon the death of the Employee, any Common Stock received in payment of the
vested RSUs shall be registered in the name of the estate of the Employee.
7. Settlement of RSUs. Each RSU granted pursuant to this Award represents an unfunded and unsecured promise of the Company,
subject to the vesting and other terms of this Agreement, to issue to the Employee one share of the Common Stock. Except as otherwise
expressly provided in the Award Statement and subject to the terms of this Agreement, such issuance shall be made to the Employee (or,
in the event of his or her death to the Employee’s estate as provided above) as soon as reasonably practicable following the vesting of the
RSU pursuant to Section 1 or 2 of this Agreement (and, if the Employee is subject to US Federal income tax, in no event later than
March 15 of the calendar year following such Employee’s separation from service, except as otherwise provided in Section 8 below),
provided, however, that if the Company determines that settlement in the form of Common Stock is impractical or impermissible under
the laws of the Employee’s country of residence, the RSUs will be settled in the form of cash, and provided further that any applicable
waiting period under HSR has expired or been terminated.
8. Special Payment Provisions. Notwithstanding anything in this Agreement to the contrary, if the Employee is subject to US Federal
income tax on any part of the payment of the RSUs and this Award is subject to Code section 409A, then the RSUs shall be subject to the
following provisions of this Section 8. If the Employee is a “specified employee” within the meaning of Code section 409A, any payment
of RSUs under Section 7 of this Agreement
-- 121 of 139 --
above that is on account of his separation from service and is scheduled to be paid within six months after such separation from service
shall accrue without interest and shall be paid as soon as reasonably practicable after the first day of the seventh month beginning after
the date of the Employee’s separation from service or, if earlier, as soon as reasonably practicable following the Employee’s death.
During such delayed distribution period, the Employee shall continue to receive cash amounts equal to dividends on Common Stock
pursuant to Section 3 of this Agreement, and such amounts shall be paid to the Employee as such dividends are paid. In the event of a
“Change in Control” under section 6(b) of the Plan that is not also a “change in control event” with the meaning of Treas. Reg. §1.409A-
3(i)(5)(i), the RSUs shall vest as set forth in section 6(a) of the Plan, but shall not be paid upon such Change in Control as provided by
section 6(a) of the Plan, and shall instead be paid at the time the RSUs would otherwise be paid pursuant to this Agreement. References
to termination of employment and separation from service shall be interpreted to mean a separation from service, within the meaning of
Code section 409A, with the Company and all of its affiliates treated as a single employer under Code section 409A. This Agreement
shall be construed in a manner consistent with Code section 409A.
9. Board Authorization in the Event of Restatement. Notwithstanding anything in this Agreement to the contrary, if the Board of
Directors of the Company or an appropriate Committee of the Board determines that, as a result of fraud, misconduct, a restatement of
the Company’s financial statements, or a significant write-off not in the ordinary course affecting the Company’s financial statements, an
Employee has received more compensation in connection with this Award than would have been paid absent the fraud, misconduct,
write-off or incorrect financial statement, the Board or Committee, in its discretion, shall take such action with respect to this Award as it
deems necessary or appropriate to address the events that gave rise to the fraud, misconduct, write-off or restatement and to prevent its
recurrence. Such action may include, to the extent permitted by applicable law, causing the partial or full cancellation of this Award and,
with respect to RSUs that have vested, requiring the Employee to repay to the Company the partial or full Fair Market Value of the
Award determined at the time of vesting. The Employee agrees by accepting this Award that the Board or Committee may make such a
cancellation, impose such a repayment obligation, or take other necessary or appropriate action in such circumstances.
10. Other Terms and Definitions. The terms and provisions of the Plan (a copy of which will be furnished to the Employee upon
written request to the Office of the Secretary, Avenue de Rhodanie 50, 1007 Lausanne, Switzerland) are incorporated herein by reference.
To the extent any provision of this Award is inconsistent or in conflict with any term or provision of the Plan, the Plan shall govern.
Capitalized terms not otherwise defined herein have the meaning set forth in the Plan.
For purposes of this Agreement, (a) the term “Disability” means permanent and total disability as determined under procedures
established by the Company for purposes of the Plan, and (b) the term “Normal Retirement” means retirement from active employment
under a pension plan of any member of the PMI Group or under an employment contract with any member of the PMI Group on or after
the date specified as the normal retirement age in the pension plan or employment contract, if any, under which the Employee is at that
time accruing pension benefits for his or her current service (or, in the absence of a specified normal retirement age, the age at which
pension benefits under such plan or contract become payable without reduction for early commencement and without any requirement of
a particular period of prior service). In any case in which (i) the meaning of “Normal Retirement” is uncertain under the definition
contained in the prior sentence or (ii) a termination of employment at or after age 65 would not otherwise constitute “Normal
Retirement,” an Employee’s termination
-- 122 of 139 --
of employment shall be treated as a “Normal Retirement” under such circumstances as the Compensation Committee, in its sole
discretion, deems equivalent to retirement. “PMI Group” means the Company and each of its subsidiaries and affiliates. Generally, for
purposes of this Agreement, (x) a “subsidiary” includes only any company in which the Company, directly or indirectly, has a beneficial
ownership interest of greater than 50 percent and (y) an “affiliate” includes only any company that (A) has a beneficial ownership
interest, directly or indirectly, in the Company of greater than 50 percent or (B) is under common control with the Company through a
parent company that, directly or indirectly, has a beneficial ownership interest of greater than 50 percent in both the Company and the
affiliate. “Compensation Committee” means the Compensation and Leadership Development Committee of the Board of Directors of the
Company. “HSR” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. “Code section 409A” means section
409A of the Internal Revenue Code and the regulations thereunder.
IN WITNESS WHEREOF, this Restricted Stock Unit Agreement has been duly executed as of February 10, 2022.
PHILIP MORRIS INTERNATIONAL INC.
By: /s/ DARLENE QUASHIE HENRY
Name: Darlene Quashie Henry
Title: Vice President, Associate General Counsel & Corporate Secretary
-- 123 of 139 --
Exhibit 10.10
PHILIP MORRIS INTERNATIONAL INC.
2017 PERFORMANCE INCENTIVE PLAN
PERFORMANCE SHARE UNIT AGREEMENT
FOR PHILIP MORRIS INTERNATIONAL INC. COMMON STOCK
(February 10, 2022)
Performance Period: January 1, 2022 to December 31, 2024
PHILIP MORRIS INTERNATIONAL INC. (the “Company”), a Virginia corporation, hereby grants to the employee identified in the
Award Statement (the “Employee”) under the Philip Morris International Inc. 2017 Performance Incentive Plan (the “Plan”), a
Performance Share Unit Award (the “Award”) dated February 10, 2022 (the “Award Date”) representing a right to receive shares of the
Common Stock of the Company (the “Common Stock”) set forth in the Award Statement (the “PSUs”), all in accordance with and
subject to the following terms and conditions:
1. Normal Vesting.
(a) Subject to Section 1(b) of this Agreement below, a number of PSUs shall become vested on the Vesting Date set
forth in the Award Statement (the “Vesting Date”), provided that the Employee remains an employee of the PMI Group during the entire
period commencing on the Award Date and ending on the Vesting Date, and that the Employee has complied with all applicable
provisions of HSR.
(b) The actual number of PSUs that become vested on the Vesting Date is equal to a percentage of the target number
of PSUs (the “Performance Percentage”), which percentage is determined based on the performance achieved during the applicable
performance period, as shown on the Award Statement and as determined by the Compensation Committee. The minimum percentage of
PSUs that can vest is zero, while the maximum is twice the targeted number, subject to the limitations of the Plan. Notwithstanding the
foregoing, if the date on which the Compensation Committee certifies the Performance Percentage is after the Vesting Date, then the
actual number of PSUs that become vested shall not be determined until such later date of certification, and such later date of
certification shall be treated as the Vesting Date for purposes of cash payments with respect to dividends and the timing of payment of the
PSUs pursuant to Sections 3 and 7 of this Agreement. The Compensation Committee shall certify the Performance Percentage no later
than December 1 of the year in which the Vesting Date occurs.
2. Termination of Employment Before Vesting Date. In the event of the termination of the Employee’s employment with the PMI
Group prior to the Vesting Date due to (a) Normal Retirement, or (b) early retirement or termination of employment (other than for
Cause), in either case by mutual agreement and after the Employee has attained age 58, then the requirement that the Employee remain
an employee of the PMI Group through the Vesting Date shall be deemed satisfied, and the number of PSUs that become vested shall be
determined based on the Performance Percentage as certified by the Compensation Committee in accordance with Section 1 of this
Agreement. In the event of the termination of the Employee’s employment with the PMI Group prior to the Vesting Date due to death or
Disability, then the requirement that the Employee remain an employee of the PMI Group through the Vesting Date shall be deemed
satisfied, and the number of PSUs that become vested shall be equal to the target number of PSUs set forth on the Award Statement.
Subject to the provisions of section 6(a) of the Plan, if the Employee’s employment with the PMI Group is terminated prior to the
Vesting Date for any reason not specified in the preceding paragraph, the Employee shall forfeit all rights to the PSUs. Notwithstanding
the foregoing and except as provided in section 6(a) of the Plan, upon the termination of an Employee’s employment with the PMI
Group, the Compensation Committee
-- 124 of 139 --
may, in its sole discretion, treat the requirement that the Employee remain an employee of the PMI Group through the Vesting Date as
deemed satisfied with respect to some or all of the PSUs, and in such case the number of PSUs that become vested shall be determined
based on the Performance Percentage as certified by the Compensation Committee in accordance with Section 1 of this Agreement
multiplied by the target number of PSUs for which the Compensation Committee treats the continued employment requirement as
deemed satisfied.
If the requirement that the Employee remain an employee of the PMI Group through the Vesting Date is deemed satisfied under this
Section 2 for any reason other than the Employee’s death or Disability, but the Employee dies before the Compensation Committee’s
certification of the Performance Percentage, then the number of PSUs that become vested shall be equal to the target number of PSUs for
which the continued employment requirement is deemed satisfied under this Section 2.
3. Voting and Dividend Rights; Withholding Taxes on Dividend Equivalents. The Employee does not have the right to vote the PSUs
or receive dividends prior to the date, if any, PSUs become vested and Common Stock becomes issuable to the Employee pursuant to the
terms hereof. However, unless otherwise determined by the Compensation Committee, the Employee shall be credited with cash amounts
equal to the dividends paid from the date the Award is granted through the date of payment under Section 7 of this Agreement with
respect to shares of Common Stock that become issuable as of the Vesting Date, with such cash credits calculated without interest and
paid, less applicable tax withholdings, in accordance with this Agreement.
4. Transfer Restrictions. The Award and the PSUs are non-transferable and may not be assigned, hypothecated or otherwise pledged
and shall not be subject to execution, attachment or similar process. Upon any attempt to effect any such disposition, or upon the levy of
any such process, the Award shall immediately become null and void and the PSUs shall be forfeited. These restrictions shall not apply,
however, to any payments received pursuant to Section 7 of this Agreement below.
5. Withholding Taxes on Common Stock upon Vesting. With respect to Common Stock issuable upon vesting, the Company is
authorized to satisfy the actual statutory withholding taxes, or hypothetical withholding tax amounts if applicable, arising from this
Award by (a) deducting the number of shares of Common Stock payable under the PSUs having an aggregate value equal to the amount
of withholding taxes due from the total number of shares of Common Stock payable under the PSUs becoming subject to current taxation
or (b) the remittance of the required amounts from any proceeds realized upon the open-market sale of the Common Stock received in
payment of vested PSUs by the Employee. Shares of Common Stock payable under the PSUs deducted from this Award in satisfaction of
tax withholding shall be valued at the Fair Market Value of the Common Stock on the date as of which the amount giving rise to the
withholding requirement first became includible in the gross income of the Employee under applicable tax laws. If the Employee is on an
international assignment, the Company will calculate the amount of hypothetical tax which will be imposed on the Employee’s PSUs, in
accordance with the Company’s guidelines in force at the time the withholding obligation arises.
6. Death of Employee. If any of the PSUs shall vest upon the death of the Employee, any Common Stock received in payment of the
vested PSUs shall be registered in the name of the estate of the Employee, and any cash amounts credited with respect to dividends shall
be paid to the estate of the Employee.
7. Settlement of PSUs. The grant pursuant to this Award represents an unfunded and unsecured promise of the Company, subject to
the vesting, achievement of performance targets and other conditions of this Agreement, to issue to the Employee for each vested PSU
one share of the Common Stock and to pay to the Employee in a single lump sum any cash amounts credited on such vested PSU with
respect to dividends. Except as otherwise expressly provided in the Award Statement and subject to the terms of this Agreement,
2
-- 125 of 139 --
such issuance and lump sum payment shall be made to the Employee (or, in the event of his or her death to the Employee’s estate as
provided above) (a) in all cases other than those set forth in clause (b), as soon as reasonably practicable following the Vesting Date and
no later than December 31 of the year in which the Vesting Date occurs, and (b) in the case of termination of employment by reason of
death or Disability or the Employee’s death after a termination of employment in the circumstances specified in Section 2, as soon as
reasonably practicable following such termination of employment or death. Notwithstanding the foregoing, if the Company determines
that settlement in the form of Common Stock is impractical or impermissible under the laws of the Employee’s country of residence, the
PSUs will be settled in the form of cash, and further notwithstanding the foregoing, payment will not occur until any applicable waiting
period under HSR has expired or been terminated.
8. Special Payment Provisions. Notwithstanding anything in this Agreement to the contrary, if the Employee is subject to US Federal
income tax on any part of the payment of the PSUs and this Award is subject to Code section 409A, then the PSUs shall be subject to the
following provisions of this Section 8. If the Employee is a “specified employee” within the meaning of Code section 409A, any issuance
or payment in respect of the PSUs under Section 7 of this Agreement above that is on account of his separation from service and is
scheduled to be paid within six months after such separation from service shall accrue without interest and shall be paid as soon as
reasonably practicable after the first day of the seventh month beginning after the date of the Employee’s separation from service or, if
earlier, as soon as reasonably practicable following the Employee’s death. During such delayed distribution period, the Employee shall
continue to be credited with cash amounts equal to dividends on Common Stock for the applicable Award pursuant to Section 3 of this
Agreement, and such amounts shall accrue without interest and shall be paid in a lump sum at the time specified in the preceding
sentence. In the event of a “Change in Control” under section 6(b) of the Plan that is not also a “change in control event” with the
meaning of Treas. Reg. §1.409A-3(i)(5)(i), the PSUs shall vest as set forth in section 6(a) of the Plan, but shall not be paid upon such
Change in Control or termination of employment as provided by section 6(a) of the Plan, and shall instead be paid at the time the PSUs
would otherwise be paid pursuant to this Agreement. References to termination of employment and separation from service shall be
interpreted to mean a separation from service, within the meaning of Code section 409A, with the Company and all of its affiliates treated
as a single employer under Code section 409A. This Agreement shall be construed in a manner consistent with Code section 409A.
9. Board Authorization in the Event of Restatement. Notwithstanding anything in this Agreement to the contrary, if the Board of
Directors of the Company or an appropriate Committee of the Board determines that, as a result of fraud, misconduct, a restatement of
the Company’s financial statements, or a significant write-off not in the ordinary course affecting the Company’s financial statements, an
Employee has received more compensation in connection with this Award than would have been paid absent the fraud, misconduct,
write-off or incorrect financial statement, the Board or Committee, in its discretion, shall take such action with respect to this Award as it
deems necessary or appropriate to address the events that gave rise to the fraud, misconduct, write-off or restatement and to prevent its
recurrence. Such action may include, to the extent permitted by applicable law, causing the partial or full cancellation of this Award and,
with respect to PSUs that have vested, requiring the Employee to repay to the Company the partial or full Fair Market Value of the Award
determined at the time of vesting. The Employee agrees by accepting this Award that the Board or Committee may make such a
cancellation, impose such a repayment obligation, or take other necessary or appropriate action in such circumstances.
10. Other Terms and Definitions. The terms and provisions of the Plan (a copy of which will be furnished to the Employee upon
written request to the Office of the Secretary, Avenue de Rhodanie 50, 1007 Lausanne, Switzerland) are incorporated herein by reference.
To the extent any provision of this Award is inconsistent or in conflict with any term or provision of the Plan, the Plan shall govern.
Capitalized terms not
3
-- 126 of 139 --
otherwise defined herein have the meaning set forth in the Plan. This Award shall be treated as an Incentive Award for purposes of the
Plan.
For purposes of this Agreement, (a) the term “Disability” means permanent and total disability as determined under procedures
established by the Company for purposes of the Plan, and (b) the term “Normal Retirement” means retirement from active employment
under a pension plan of any member of the PMI Group or under an employment contract with any member of the PMI Group on or after
the date specified as the normal retirement age in the pension plan or employment contract, if any, under which the Employee is at that
time accruing pension benefits for his or her current service (or, in the absence of a specified normal retirement age, the age at which
pension benefits under such plan or contract become payable without reduction for early commencement and without any requirement of
a particular period of prior service). In any case in which (i) the meaning of “Normal Retirement” is uncertain under the definition
contained in the prior sentence or (ii) a termination of employment at or after age 65 would not otherwise constitute “Normal
Retirement,” an Employee’s termination of employment shall be treated as a “Normal Retirement” under such circumstances as the
Compensation Committee, in its sole discretion, deems equivalent to retirement. “PMI Group” means the Company and each of its
subsidiaries and affiliates. Generally, for purposes of this Agreement, (x) a “subsidiary” includes only any company in which the
Company, directly or indirectly, has a beneficial ownership interest of greater than 50 percent and (y) an “affiliate” includes only any
company that (A) has a beneficial ownership interest, directly or indirectly, in the Company of greater than 50 percent or (B) is under
common control with the Company through a parent company that, directly or indirectly, has a beneficial ownership interest of greater
than 50 percent in both the Company and the affiliate. “Compensation Committee” means the Compensation and Leadership
Development Committee of the Board of Directors of the Company. “HSR” means the Hart-Scott-Rodino Antitrust Improvements Act of
1976, as amended. “Code section 409A” means section 409A of the Internal Revenue Code and the regulations thereunder.
IN WITNESS WHEREOF, this Performance Share Unit Agreement has been duly executed as of February 10, 2022.
PHILIP MORRIS INTERNATIONAL INC.
By: /s/ DARLENE QUASHIE HENRY
Name: Darlene Quashie Henry
Title: Vice President, Associate General Counsel & Corporate Secretary
4
-- 127 of 139 --
Exhibit 10.11
PHILIP MORRIS INTERNATIONAL INC.
2017 PERFORMANCE INCENTIVE PLAN
RESTRICTED STOCK UNIT AGREEMENT
FOR PHILIP MORRIS INTERNATIONAL INC. COMMON STOCK
(February 10, 2022)
PHILIP MORRIS INTERNATIONAL INC. (the “Company”), a Virginia corporation, hereby grants to the employee identified in the
Award Statement (the “Employee”) under the Philip Morris International Inc. 2017 Performance Incentive Plan (the “Plan”), a Restricted
Stock Unit Award (the “Award”) dated February 10, 2022 (the “Award Date”) with respect to the number of shares of the Common Stock
of the Company (the “Common Stock”) set forth in the Award Statement (the “RSUs”), all in accordance with and subject to the
following terms and conditions:
1. Normal Vesting. Subject to Section 2 of this Agreement below, the RSUs shall become fully vested on the Vesting Date set forth in
the Award Statement (the “Vesting Date”), provided that the Employee remains an employee of the PMI Group during the entire period
commencing on the Award Date and ending on the Vesting Date, and provided further that the Employee has complied with all applicable
provisions of HSR.
2. Termination of Employment Before Vesting Date.
(a) In the event of the termination of the Employee’s employment with the PMI Group prior to the Vesting Date due to (i) death,
Disability, (ii) Normal Retirement,(iii) termination of employment unilaterally by the Company (other than for Cause), as set forth in the
agreement with the Employee effective as of May 1, 2020 (the “Employment Agreement”), or (iv) early retirement or termination of
employment (other than for Cause) in either case by mutual agreement and after the Employee has attained age 58, then the RSUs shall
become fully vested on the date of death, Disability, Normal Retirement, or such early retirement or termination of employment or the
date specified in such mutual agreement; provided, however, that the event of the termination set forth in item (iii) of this Section 2(a),
the vesting would be further subject to the terms of the Employment Agreement.
(b) Subject to the provisions of section 6(a) of the Plan, if the Employee’s employment with the PMI Group is terminated prior to the
Vesting Date in circumstances not specified in items (i), (ii), (iii) or (iv) of the preceding paragraph, the Employee shall forfeit all rights
to the RSUs. Notwithstanding the foregoing and except as provided in section 6(a) of the Plan, upon the termination of an Employee’s
employment with the PMI Group, the Compensation Committee may, in its sole discretion, vest some or all of the RSUs.
(c) If within the period of 12 months prior to the date of termination of employment, the Employee was an Executive Officer (as
designated by the Board of Directors of the Company within the meaning of Section 16 of the Securities Exchange Act of 1934, as
amended) and the termination of employment of such Employee is due to a reason other than death or Disability, any shares of Common
Stock that are received by such Employee as a result of accelerated vesting provisions of Section 2(a) or (b), shall be automatically
subject to a holding period that expires 12 consecutive months from the date of termination of employment.
3. Voting and Dividend Rights; Withholding Tax on Dividend Equivalents. The Employee does not have the right to vote the RSUs
or receive dividends prior to the date, if any, such RSUs are paid to the Employee in the form of Common Stock pursuant to the terms
-- 128 of 139 --
hereof. However, unless otherwise determined by the Compensation Committee, the Employee shall receive cash amounts (less
applicable withholding taxes) equal to the dividends paid from the date the Award is granted through the date of payment under Section 7
of this Agreement with respect to shares of Common Stock issuable with respect to the Award, as such dividends are paid.
4. Transfer Restrictions. This Award and the RSUs are non-transferable and may not be transferred, assigned, hypothecated, pledged
or otherwise encumbered and shall not be subject to execution, attachment or similar process. Upon any attempt to effect any such
disposition, or upon the levy of any such process, the Award shall immediately become null and void and the RSUs shall be forfeited.
These restrictions shall not apply, however, to any payments received pursuant to Section 7 of this Agreement below. In addition, shares
of Common Stock subject to the holding period described in Section 2(c) of this Agreement may not be transferred, assigned,
hypothecated, pledged or otherwise encumbered for the duration of the applicable holding period.
5. Withholding Taxes on Common Stock upon Vesting. With respect to Common Stock issuable upon vesting, the Company is
authorized to satisfy the actual statutory withholding taxes, or hypothetical withholding tax amounts if applicable, arising from this
Award by (a) deducting the number of shares of Common Stock payable under the RSUs having an aggregate value equal to the amount
of withholding taxes due from the total number of shares of Common Stock payable under the RSUs becoming subject to current taxation
or (b) the remittance of the required amounts from any proceeds realized upon the open-market sale of the Common Stock received in
payment of vested RSUs by the Employee. Shares of Common Stock payable under the RSUs deducted from this Award in satisfaction
of tax withholding shall be valued at the Fair Market Value of the Common Stock on the date as of which the amount giving rise to the
withholding requirement first became includible in the gross income of the Employee under applicable tax laws. If the Employee is on an
international assignment, the Company will calculate the amount of hypothetical tax which will be imposed on the Employee’s RSUs, in
accordance with the Company’s guidelines in force at the time the withholding obligation arises.
6. Death of Employee. If any of the RSUs shall vest upon the death of the Employee, any Common Stock received in payment of the
vested RSUs shall be registered in the name of the estate of the Employee.
7. Settlement of RSUs. Each RSU granted pursuant to this Award represents an unfunded and unsecured promise of the Company,
subject to the vesting and other terms of this Agreement, to issue to the Employee one share of the Common Stock. Except as otherwise
expressly provided in the Award Statement and subject to the terms of this Agreement, such issuance shall be made to the Employee (or,
in the event of his or her death to the Employee’s estate as provided above) as soon as reasonably practicable following the vesting of the
RSU pursuant to Section 1 or 2 of this Agreement (and, if the Employee is subject to US Federal income tax, in no event later than
March 15 of the calendar year following such Employee’s separation from service, except as otherwise provided in Section 8 below),
provided, however, that if the Company determines that settlement in the form of Common Stock is impractical or impermissible under
the laws of the Employee’s country of residence, the RSUs will be settled in the form of cash, and provided further that any applicable
waiting period under HSR has expired or been terminated.
8. Special Payment Provisions. Notwithstanding anything in this Agreement to the contrary, if the Employee is subject to US Federal
income tax on any part of the payment of
2
-- 129 of 139 --
the RSUs and this Award is subject to Code section 409A, then the RSUs shall be subject to the following provisions of this Section 8. If
the Employee is a “specified employee” within the meaning of Code section 409A, any payment of RSUs under Section 7 of this
Agreement above that is on account of his separation from service and is scheduled to be paid within six months after such separation
from service shall accrue without interest and shall be paid as soon as reasonably practicable after the first day of the seventh month
beginning after the date of the Employee’s separation from service or, if earlier, as soon as reasonably practicable following the
Employee’s death. During such delayed distribution period, the Employee shall continue to receive cash amounts equal to dividends on
Common Stock pursuant to Section 3 of this Agreement, and such amounts shall be paid to the Employee as such dividends are paid. In
the event of a “Change in Control” under section 6(b) of the Plan that is not also a “change in control event” with the meaning of Treas.
Reg. §1.409A-3(i)(5)(i), the RSUs shall vest as set forth in section 6(a) of the Plan, but shall not be paid upon such Change in Control as
provided by section 6(a) of the Plan, and shall instead be paid at the time the RSUs would otherwise be paid pursuant to this Agreement.
References to termination of employment and separation from service shall be interpreted to mean a separation from service, within the
meaning of Code section 409A, with the Company and all of its affiliates treated as a single employer under Code section 409A. This
Agreement shall be construed in a manner consistent with Code section 409A.
9. Board Authorization in the Event of Restatement. Notwithstanding anything in this Agreement to the contrary, if the Board of
Directors of the Company or an appropriate Committee of the Board determines that, as a result of fraud, misconduct, a restatement of
the Company’s financial statements, or a significant write-off not in the ordinary course affecting the Company’s financial statements, an
Employee has received more compensation in connection with this Award than would have been paid absent the fraud, misconduct,
write-off or incorrect financial statement, the Board or Committee, in its discretion, shall take such action with respect to this Award as it
deems necessary or appropriate to address the events that gave rise to the fraud, misconduct, write-off or restatement and to prevent its
recurrence. Such action may include, to the extent permitted by applicable law, causing the partial or full cancellation of this Award and,
with respect to RSUs that have vested, requiring the Employee to repay to the Company the partial or full Fair Market Value of the
Award determined at the time of vesting. The Employee agrees by accepting this Award that the Board or Committee may make such a
cancellation, impose such a repayment obligation, or take other necessary or appropriate action in such circumstances.
10. Other Terms and Definitions. The terms and provisions of the Plan (a copy of which will be furnished to the Employee upon
written request to the Office of the Secretary, Avenue de Rhodanie 50, 1007 Lausanne, Switzerland) are incorporated herein by reference.
To the extent any provision of this Award is inconsistent or in conflict with any term or provision of the Plan, the Plan shall govern.
Capitalized terms not otherwise defined herein have the meaning set forth in the Plan.
For purposes of this Agreement, (a) the term “Disability” means permanent and total disability as determined under procedures
established by the Company for purposes of the Plan, and (b) the term “Normal Retirement” means retirement from active employment
under a pension plan of any member of the PMI Group or under an employment contract with any member of the PMI Group on or after
the date specified as the normal retirement age in the pension plan or employment contract, if any, under which the Employee is at that
time accruing pension benefits for his or her current service (or, in the absence of a specified normal retirement age, the age at which
pension benefits under such plan or contract become payable without reduction for early commencement and without any requirement of
a particular period
3
-- 130 of 139 --
of prior service). In any case in which (i) the meaning of “Normal Retirement” is uncertain under the definition contained in the prior
sentence or (ii) a termination of employment at or after age 65 would not otherwise constitute “Normal Retirement,” an Employee’s
termination of employment shall be treated as a “Normal Retirement” under such circumstances as the Compensation Committee, in its
sole discretion, deems equivalent to retirement. “PMI Group” means the Company and each of its subsidiaries and affiliates. Generally,
for purposes of this Agreement, (x) a “subsidiary” includes only any company in which the Company, directly or indirectly, has a
beneficial ownership interest of greater than 50 percent and (y) an “affiliate” includes only any company that (A) has a beneficial
ownership interest, directly or indirectly, in the Company of greater than 50 percent or (B) is under common control with the Company
through a parent company that, directly or indirectly, has a beneficial ownership interest of greater than 50 percent in both the Company
and the affiliate. “Compensation Committee” means the Compensation and Leadership Development Committee of the Board of
Directors of the Company. “HSR” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. “Code section 409A”
means section 409A of the Internal Revenue Code and the regulations thereunder.
IN WITNESS WHEREOF, this Restricted Stock Unit Agreement has been duly executed as of February 10, 2022.
PHILIP MORRIS INTERNATIONAL INC.
By: /s/ DARLENE QUASHIE HENRY
Name: Darlene Quashie Henry
Title: Vice President, Associate General Counsel & Corporate Secretary
4
-- 131 of 139 --
Exhibit 10.12
PHILIP MORRIS INTERNATIONAL INC.
2017 PERFORMANCE INCENTIVE PLAN
PERFORMANCE SHARE UNIT AGREEMENT
FOR PHILIP MORRIS INTERNATIONAL INC. COMMON STOCK
(February 10, 2022)
Performance Period: January 1, 2022 to December 31, 2024
PHILIP MORRIS INTERNATIONAL INC. (the “Company”), a Virginia corporation, hereby grants to the employee identified in the
Award Statement (the “Employee”) under the Philip Morris International Inc. 2017 Performance Incentive Plan (the “Plan”), a
Performance Share Unit Award (the “Award”) dated February 10, 2022 (the “Award Date”) representing a right to receive shares of the
Common Stock of the Company (the “Common Stock”) set forth in the Award Statement (the “PSUs”), all in accordance with and
subject to the following terms and conditions:
1. Normal Vesting.
(a) Subject to Section 1(b) of this Agreement below, a number of PSUs shall become vested on the Vesting Date set
forth in the Award Statement (the “Vesting Date”), provided that the Employee remains an employee of the PMI Group during the entire
period commencing on the Award Date and ending on the Vesting Date, and that the Employee has complied with all applicable
provisions of HSR.
(b) The actual number of PSUs that become vested on the Vesting Date is equal to a percentage of the target number
of PSUs (the “Performance Percentage”), which percentage is determined based on the performance achieved during the applicable
performance period, as shown on the Award Statement and as determined by the Compensation Committee. The minimum percentage of
PSUs that can vest is zero, while the maximum is twice the targeted number, subject to the limitations of the Plan. Notwithstanding the
foregoing, if the date on which the Compensation Committee certifies the Performance Percentage is after the Vesting Date, then the
actual number of PSUs that become vested shall not be determined until such later date of certification, and such later date of
certification shall be treated as the Vesting Date for purposes of cash payments with respect to dividends and the timing of payment of the
PSUs pursuant to Sections 3 and 7 of this Agreement. The Compensation Committee shall certify the Performance Percentage no later
than December 1 of the year in which the Vesting Date occurs.
2. Termination of Employment Before Vesting Date.
i. In the event of the termination of the Employee’s employment with the PMI Group prior to the Vesting Date due to (a)
Normal Retirement, or (b) early retirement or termination of employment (other than for Cause), in either case by mutual
agreement and after the Employee has attained age 58, then the requirement that the Employee remain an employee of the
PMI Group through the Vesting Date shall be deemed satisfied, and the number of PSUs that become vested shall be
determined based on the Performance Percentage as certified by the Compensation Committee in accordance with Section
1 of this Agreement.
ii. In the event that the termination of the Employee’s employment with the PMI Group prior to the Vesting Date by the
Company (other than for Cause), as set forth in the agreement with the Employee effective as of May 1, 2020 (the
“Employment Agreement”), then the requirement that the Employee remain an employee of the PMI Group through the
Vesting Date shall be deemed satisfied, and the number of PSUs that become vested shall be determined based on the
Performance Percentage as certified by the Compensation Committee in accordance with Section 1 of this Agreement and
shall be prorated based on the number of months of employment between the award date and the vesting date of the award;
provided, however, that the event of the termination set forth in this Section 2(ii), the vesting would be further subject to
the terms of the Employment Agreement.
iii. In the event of the termination of the Employee’s employment with the PMI Group prior to the Vesting Date due to death
or Disability, then the requirement that the Employee remain an employee of the PMI
-- 132 of 139 --
Group through the Vesting Date shall be deemed satisfied, and the number of PSUs that become vested shall be equal to
the target number of PSUs set forth on the Award Statement.
Subject to the provisions of section 6(a) of the Plan, if the Employee’s employment with the PMI Group is terminated prior to the
Vesting Date for any reason not specified in the preceding paragraphs, the Employee shall forfeit all rights to the PSUs. Notwithstanding
the foregoing and except as provided in section 6(a) of the Plan, upon the termination of an Employee’s employment with the PMI
Group, the Compensation Committee may, in its sole discretion, treat the requirement that the Employee remain an employee of the PMI
Group through the Vesting Date as deemed satisfied with respect to some or all of the PSUs, and in such case the number of PSUs that
become vested shall be determined based on the Performance Percentage as certified by the Compensation Committee in accordance
with Section 1 of this Agreement multiplied by the target number of PSUs for which the Compensation Committee treats the continued
employment requirement as deemed satisfied.
If the requirement that the Employee remain an employee of the PMI Group through the Vesting Date is deemed satisfied under this
Section 2 for any reason other than the Employee’s death or Disability, but the Employee dies before the Compensation Committee’s
certification of the Performance Percentage, then the number of PSUs that become vested shall be equal to the target number of PSUs for
which the continued employment requirement is deemed satisfied under this Section 2.
3. Voting and Dividend Rights; Withholding Taxes on Dividend Equivalents. The Employee does not have the right to vote the PSUs
or receive dividends prior to the date, if any, PSUs become vested and Common Stock becomes issuable to the Employee pursuant to the
terms hereof. However, unless otherwise determined by the Compensation Committee, the Employee shall be credited with cash amounts
equal to the dividends paid from the date the Award is granted through the date of payment under Section 7 of this Agreement with
respect to shares of Common Stock that become issuable as of the Vesting Date, with such cash credits calculated without interest and
paid, less applicable tax withholdings, in accordance with this Agreement.
4. Transfer Restrictions. The Award and the PSUs are non-transferable and may not be assigned, hypothecated or otherwise pledged
and shall not be subject to execution, attachment or similar process. Upon any attempt to effect any such disposition, or upon the levy of
any such process, the Award shall immediately become null and void and the PSUs shall be forfeited. These restrictions shall not apply,
however, to any payments received pursuant to Section 7 of this Agreement below.
5. Withholding Taxes on Common Stock upon Vesting. With respect to Common Stock issuable upon vesting, the Company is
authorized to satisfy the actual statutory withholding taxes, or hypothetical withholding tax amounts if applicable, arising from this
Award by (a) deducting the number of shares of Common Stock payable under the PSUs having an aggregate value equal to the amount
of withholding taxes due from the total number of shares of Common Stock payable under the PSUs becoming subject to current taxation
or (b) the remittance of the required amounts from any proceeds realized upon the open-market sale of the Common Stock received in
payment of vested PSUs by the Employee. Shares of Common Stock payable under the PSUs deducted from this Award in satisfaction of
tax withholding shall be valued at the Fair Market Value of the Common Stock on the date as of which the amount giving rise to the
withholding requirement first became includible in the gross income of the Employee under applicable tax laws. If the Employee is on an
international assignment, the Company will calculate the amount of hypothetical tax which will be imposed on the Employee’s PSUs, in
accordance with the Company’s guidelines in force at the time the withholding obligation arises.
6. Death of Employee. If any of the PSUs shall vest upon the death of the Employee, any Common Stock received in payment of the
vested PSUs shall be registered in the name of the estate of the Employee, and any cash amounts credited with respect to dividends shall
be paid to the estate of the Employee.
7. Settlement of PSUs. The grant pursuant to this Award represents an unfunded and unsecured promise of the Company, subject to
the vesting, achievement of performance targets and other conditions of this Agreement, to issue to the Employee for each vested PSU
one share of the Common Stock and to pay to the Employee in a single lump sum any cash amounts credited on such vested PSU with
respect to dividends. Except as otherwise expressly provided in the Award Statement and subject to the terms of this Agreement, such
issuance and lump sum payment shall be made
2
-- 133 of 139 --
to the Employee (or, in the event of his or her death to the Employee’s estate as provided above) (a) in all cases other than those set forth
in clause (b), as soon as reasonably practicable following the Vesting Date and no later than December 31 of the year in which the
Vesting Date occurs, and (b) in the case of termination of employment by reason of death or Disability or the Employee’s death after a
termination of employment in the circumstances specified in Section 2, as soon as reasonably practicable following such termination of
employment or death. Notwithstanding the foregoing, if the Company determines that settlement in the form of Common Stock is
impractical or impermissible under the laws of the Employee’s country of residence, the PSUs will be settled in the form of cash, and
further notwithstanding the foregoing, payment will not occur until any applicable waiting period under HSR has expired or been
terminated.
8. Special Payment Provisions. Notwithstanding anything in this Agreement to the contrary, if the Employee is subject to US Federal
income tax on any part of the payment of the PSUs and this Award is subject to Code section 409A, then the PSUs shall be subject to the
following provisions of this Section 8. If the Employee is a “specified employee” within the meaning of Code section 409A, any issuance
or payment in respect of the PSUs under Section 7 of this Agreement above that is on account of his separation from service and is
scheduled to be paid within six months after such separation from service shall accrue without interest and shall be paid as soon as
reasonably practicable after the first day of the seventh month beginning after the date of the Employee’s separation from service or, if
earlier, as soon as reasonably practicable following the Employee’s death. During such delayed distribution period, the Employee shall
continue to be credited with cash amounts equal to dividends on Common Stock for the applicable Award pursuant to Section 3 of this
Agreement, and such amounts shall accrue without interest and shall be paid in a lump sum at the time specified in the preceding
sentence. In the event of a “Change in Control” under section 6(b) of the Plan that is not also a “change in control event” with the
meaning of Treas. Reg. §1.409A-3(i)(5)(i), the PSUs shall vest as set forth in section 6(a) of the Plan, but shall not be paid upon such
Change in Control or termination of employment as provided by section 6(a) of the Plan, and shall instead be paid at the time the PSUs
would otherwise be paid pursuant to this Agreement. References to termination of employment and separation from service shall be
interpreted to mean a separation from service, within the meaning of Code section 409A, with the Company and all of its affiliates treated
as a single employer under Code section 409A. This Agreement shall be construed in a manner consistent with Code section 409A.
9. Board Authorization in the Event of Restatement. Notwithstanding anything in this Agreement to the contrary, if the Board of
Directors of the Company or an appropriate Committee of the Board determines that, as a result of fraud, misconduct, a restatement of
the Company’s financial statements, or a significant write-off not in the ordinary course affecting the Company’s financial statements, an
Employee has received more compensation in connection with this Award than would have been paid absent the fraud, misconduct,
write-off or incorrect financial statement, the Board or Committee, in its discretion, shall take such action with respect to this Award as it
deems necessary or appropriate to address the events that gave rise to the fraud, misconduct, write-off or restatement and to prevent its
recurrence. Such action may include, to the extent permitted by applicable law, causing the partial or full cancellation of this Award and,
with respect to PSUs that have vested, requiring the Employee to repay to the Company the partial or full Fair Market Value of the Award
determined at the time of vesting. The Employee agrees by accepting this Award that the Board or Committee may make such a
cancellation, impose such a repayment obligation, or take other necessary or appropriate action in such circumstances.
10. Other Terms and Definitions. The terms and provisions of the Plan (a copy of which will be furnished to the Employee upon
written request to the Office of the Secretary, Avenue de Rhodanie 50, 1007 Lausanne, Switzerland) are incorporated herein by reference.
To the extent any provision of this Award is inconsistent or in conflict with any term or provision of the Plan, the Plan shall govern.
Capitalized terms not otherwise defined herein have the meaning set forth in the Plan. This Award shall be treated as an Incentive Award
for purposes of the Plan.
For purposes of this Agreement, (a) the term “Disability” means permanent and total disability as determined under procedures
established by the Company for purposes of the Plan, and (b) the term “Normal Retirement” means retirement from active employment
under a pension plan of any member of the PMI Group or under an employment contract with any member of the PMI Group on or after
the date specified as the normal retirement age in the pension plan or employment contract, if any, under which the Employee is at that
time accruing pension benefits for his or her current service (or, in the absence of a specified normal retirement age, the age at which
pension benefits under such plan or contract become payable without reduction for early commencement and without any requirement of
a particular
3
-- 134 of 139 --
period of prior service). In any case in which (i) the meaning of “Normal Retirement” is uncertain under the definition contained in the
prior sentence or (ii) a termination of employment at or after age 65 would not otherwise constitute “Normal Retirement,” an Employee’s
termination of employment shall be treated as a “Normal Retirement” under such circumstances as the Compensation Committee, in its
sole discretion, deems equivalent to retirement. “PMI Group” means the Company and each of its subsidiaries and affiliates. Generally,
for purposes of this Agreement, (x) a “subsidiary” includes only any company in which the Company, directly or indirectly, has a
beneficial ownership interest of greater than 50 percent and (y) an “affiliate” includes only any company that (A) has a beneficial
ownership interest, directly or indirectly, in the Company of greater than 50 percent or (B) is under common control with the Company
through a parent company that, directly or indirectly, has a beneficial ownership interest of greater than 50 percent in both the Company
and the affiliate. “Compensation Committee” means the Compensation and Leadership Development Committee of the Board of
Directors of the Company. “HSR” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. “Code section 409A”
means section 409A of the Internal Revenue Code and the regulations thereunder.
IN WITNESS WHEREOF, this Performance Share Unit Agreement has been duly executed as of February 10, 2022.
PHILIP MORRIS INTERNATIONAL INC.
By: /s/ DARLENE QUASHIE HENRY
Name: Darlene Quashie Henry
Title: Vice President, Associate General Counsel & Corporate Secretary
4
-- 135 of 139 --
Exhibit 31.1
Certifications
I, Jacek Olczak, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Philip Morris International Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:
a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;
c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent
fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially
affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control
over financial reporting.
Date: April 28, 2022
/s/ JACEK OLCZAK
Jacek Olczak
Chief Executive Officer
-1-
-- 136 of 139 --
Exhibit 31.2
Certifications
I, Emmanuel Babeau, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Philip Morris International Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:
a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;
c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent
fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially
affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control
over financial reporting.
Date: April 28, 2022
/s/ EMMANUEL BABEAU
Emmanuel Babeau
Chief Financial Officer
- 1 -
-- 137 of 139 --
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Philip Morris International Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2022 as filed
with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jacek Olczak, Chief Executive Officer of the Company, certify, pursuant
to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the
Company.
/s/ JACEK OLCZAK
Jacek Olczak
Chief Executive Officer
April 28, 2022
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature
that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Philip Morris International
Inc. and will be retained by Philip Morris International Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
-1-
-- 138 of 139 --
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Philip Morris International Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2022 as filed
with the Securities and Exchange Commission on the date hereof (the “Report”), I, Emmanuel Babeau, Chief Financial Officer of the Company, certify,
pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the
Company.
/s/ EMMANUEL BABEAU
Emmanuel Babeau
Chief Financial Officer
April 28, 2022
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature
that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Philip Morris International
Inc. and will be retained by Philip Morris International Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
-1-
-- 139 of 139 --